<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology - Al‐Inany, HG - 2016 | Cochrane Library</title> <meta content="Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology - Al‐Inany, HG - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001750.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology - Al‐Inany, HG - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001750.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001750.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology" name="citation_title"/> <meta content="Hesham G Al‐Inany" name="citation_author"/> <meta content="Faculty of Medicine, Cairo University" name="citation_author_institution"/> <meta content="kaainih@yahoo.com" name="citation_author_email"/> <meta content="Mohamed A Youssef" name="citation_author"/> <meta content="Faculty of Medicine, Cairo University" name="citation_author_institution"/> <meta content="Reuben Olugbenga Ayeleke" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Julie Brown" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="Wai Sun Lam" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Frank J Broekmans" name="citation_author"/> <meta content="University Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD001750.pub4" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/04/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001750.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001750.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001750.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Reproductive Techniques, Assisted; Gonadotropin‐Releasing Hormone [agonists, *antagonists &amp; inhibitors]; Live Birth; Ovarian Hyperstimulation Syndrome [prevention &amp; control]; Ovulation Induction [methods]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001750.pub4&amp;doi=10.1002/14651858.CD001750.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="mV7VuqgF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001750\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001750\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001750.pub4",title:"Gonadotrophin\\u2010releasing hormone antagonists for assisted reproductive technology",firstPublishedDate:"Apr 29, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001750.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001750.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001750.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001750.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001750.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001750.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001750.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001750.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001750.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001750.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>17566 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001750.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-sec-0098"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-sec-0092"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/appendices#CD001750-sec-0103"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/table_n/CD001750StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/table_n/CD001750StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/information#CD001750-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Hesham G Al‐Inany</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/information#CD001750-cr-0003">Mohamed A Youssef</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/information#CD001750-cr-0004">Reuben Olugbenga Ayeleke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/information#CD001750-cr-0005">Julie Brown</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/information#CD001750-cr-0006">Wai Sun Lam</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001750.pub4/information#CD001750-cr-0007">Frank J Broekmans</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/information/en#CD001750-sec-0113">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 April 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001750.pub4">https://doi.org/10.1002/14651858.CD001750.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001750-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001750-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001750-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001750-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001750-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001750-abs-0001" lang="en"> <section id="CD001750-sec-0001"> <h3 class="title" id="CD001750-sec-0001">Background</h3> <p>Gonadotrophin‐releasing hormone (GnRH) antagonists can be used to prevent a luteinizing hormone (LH) surge during controlled ovarian hyperstimulation (COH) without the hypo‐oestrogenic side‐effects, flare‐up, or long down‐regulation period associated with agonists. The antagonists directly and rapidly inhibit gonadotrophin release within several hours through competitive binding to pituitary GnRH receptors. This property allows their use at any time during the follicular phase. Several different regimens have been described including multiple‐dose fixed (0.25 mg daily from day six to seven of stimulation), multiple‐dose flexible (0.25 mg daily when leading follicle is 14 to 15 mm), and single‐dose (single administration of 3 mg on day 7 to 8 of stimulation) protocols, with or without the addition of an oral contraceptive pill. Further, women receiving antagonists have been shown to have a lower incidence of ovarian hyperstimulation syndrome (OHSS). Assuming comparable clinical outcomes for the antagonist and agonist protocols, these benefits would justify a change from the standard long agonist protocol to antagonist regimens. This is an update of a Cochrane review first published in 2001, and previously updated in 2006 and 2011. </p> </section> <section id="CD001750-sec-0002"> <h3 class="title" id="CD001750-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and safety of gonadotrophin‐releasing hormone (GnRH) antagonists compared with the standard long protocol of GnRH agonists for controlled ovarian hyperstimulation in assisted conception cycles. </p> </section> <section id="CD001750-sec-0003"> <h3 class="title" id="CD001750-sec-0003">Search methods</h3> <p>We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register (searched from inception to May 2015), the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i>, inception to 28 April 2015), Ovid MEDLINE (1966 to 28 April 2015), EMBASE (1980 to 28 April 2015), PsycINFO (1806 to 28 April 2015), CINAHL (to 28 April 2015) and trial registers to 28 April 2015, and handsearched bibliographies of relevant publications and reviews, and abstracts of major scientific meetings, for example the European Society of Human Reproduction and Embryology (ESHRE) and American Society for Reproductive Medicine (ASRM). We contacted the authors of eligible studies for missing or unpublished data. The evidence is current to 28 April 2015. </p> </section> <section id="CD001750-sec-0004"> <h3 class="title" id="CD001750-sec-0004">Selection criteria</h3> <p>Two review authors independently screened the relevant citations for randomised controlled trials (RCTs) comparing different GnRH agonist versus GnRH antagonist protocols in women undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI). </p> </section> <section id="CD001750-sec-0005"> <h3 class="title" id="CD001750-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial eligibility and risk of bias, and extracted the data. The primary review outcomes were live birth and ovarian hyperstimulation syndrome (OHSS). Other adverse effects (miscarriage and cycle cancellation) were secondary outcomes. We combined data to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs). Statistical heterogeneity was assessed using the I<sup>2</sup> statistic. We assessed the overall quality of the evidence for each comparison using GRADE methods. </p> </section> <section id="CD001750-sec-0006"> <h3 class="title" id="CD001750-sec-0006">Main results</h3> <p>We included 73 RCTs, with 12,212 participants, comparing GnRH antagonist to long‐course GnRH agonist protocols. The quality of the evidence was moderate: limitations were poor reporting of study methods. </p> <p>Live birth</p> <p>There was no evidence of a difference in live birth rate between GnRH antagonist and long course GnRH agonist (OR 1.02, 95% CI 0.85 to 1.23; 12 RCTs, n = 2303, I<sup>2</sup>= 27%, moderate quality evidence). The evidence suggested that if the chance of live birth following GnRH agonist is assumed to be 29%, the chance following GnRH antagonist would be between 25% and 33%. </p> <p>OHSS</p> <p>GnRH antagonist was associated with lower incidence of any grade of OHSS than GnRH agonist (OR 0.61, 95% C 0.51 to 0.72; 36 RCTs, n = 7944, I<sup>2</sup> = 31%, moderate quality evidence). The evidence suggested that if the risk of OHSS following GnRH agonist is assumed to be 11%, the risk following GnRH antagonist would be between 6% and 9%. </p> <p>Other adverse effects</p> <p>There was no evidence of a difference in miscarriage rate per woman randomised between GnRH antagonist group and GnRH agonist group (OR 1.03, 95% CI 0.82 to 1.29; 34 RCTs, n = 7082, I<sup>2</sup> = 0%, moderate quality evidence). </p> <p>With respect to cycle cancellation, GnRH antagonist was associated with a lower incidence of cycle cancellation due to high risk of OHSS (OR 0.47, 95% CI 0.32 to 0.69; 19 RCTs, n = 4256, I<sup>2</sup> = 0%). However cycle cancellation due to poor ovarian response was higher in women who received GnRH antagonist than those who were treated with GnRH agonist (OR 1.32, 95% CI 1.06 to 1.65; 25 RCTs, n = 5230, I<sup>2</sup> = 68%; moderate quality evidence). </p> </section> <section id="CD001750-sec-0007"> <h3 class="title" id="CD001750-sec-0007">Authors' conclusions</h3> <p>There is moderate quality evidence that the use of GnRH antagonist compared with long‐course GnRH agonist protocols is associated with a substantial reduction in OHSS without reducing the likelihood of achieving live birth. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001750-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001750-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001750-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001750-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001750-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001750-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001750-abs-0003">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001750-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001750-abs-0002" lang="en"> <h3>Gonadotrophin‐releasing hormone antagonists versus GnRH agonist in subfertile couples undergoing assisted reproductive technology </h3> <p><b>Review question</b> </p> <p>This updated Cochrane review evaluated the efficacy and safety of GnRH antagonists compared to the more widely‐used GnRH agonists (long‐course protocol). </p> <p><b>Background:</b> </p> <p>Gonadotrophin‐releasing hormone (GnRH) agonist is commonly used to prevent cycle cancellation secondary to a premature luteinizing hormone (LH) surge, and thereby increase the chance of live birth in women undergoing assisted reproductive technology (ART), while reducing the risk of complications such as ovarian hyperstimulation syndrome (OHSS). Gonadotrophin‐releasing hormone (GnRH) antagonists are now being seriously considered as a potential means of achieving better treatment outcomes because the protocol is more flexible and antagonists may reduce OHSS more effectively than agonists. However, there is the need to evaluate the benefits as well as the safety of these GnRH antagonist regimens in comparison with the existing GnRH agonist regimens. </p> <p><b>Study characteristics</b> </p> <p>We found 73 randomised controlled trials comparing GnRH antagonist with GnRH agonist in a total of 12,212 women undergoing ART. The evidence is current to May 2015 </p> <p><b>Key results</b> </p> <p>There was no evidence of a difference between the groups in live birth rates (i.e. rates at conclusion of a course of treatment). The evidence suggested that if the chance of live birth following GnRH agonist is assumed to be 29%, the chance following GnRH antagonist would be between 25% and 33%. However, the OHSS rates were much higher after GnRH agonist. The evidence suggested that if the risk of OHSS following GnRH agonist is assumed to be 11%, the risk following GnRH antagonist would be between 6% and 9%. </p> <p><b>Quality of the evidence</b> </p> <p>The evidence was of moderate quality for both live birth and OHSS. The main limitations of the evidence were the possibility of publication bias for live birth (with small studies likely to report favourable outcomes for GnRH antagonist) and poor reporting of study methods for OHSS. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001750-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001750-sec-0098"></div> <h3 class="title" id="CD001750-sec-0099">Implications for practice</h3> <section id="CD001750-sec-0099"> <p>The GnRH antagonist protocol is a short and simple protocol with evidence suggesting a comparable live birth rate and a substantial reduction in the incidence of ovarian hyperstimulation syndrome when compared to GnRH agonist long protocol in women undergoing ART. </p> </section> <h3 class="title" id="CD001750-sec-0100">Implications for research</h3> <section id="CD001750-sec-0100"> <p>In view of the shortcomings noted in the included studies, especially with regard to the methods of reporting of trial procedures, more properly designed studies in accordance with the CONSORT statement are need to further evaluate the effectiveness and safety of the GnRH antagonist protocol (<a href="./references#CD001750-bbs2-0155" title="SchulzKF , AltmanDG , MoherD , for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Annals of Internal Medicine2010;152:Epub 24 March. ">Schulz 2010</a>). For example, it would be desirable to have trials with low risk of bias with primary outcomes of live birth and OHSS. In addition, further studies are needed to assess this treatment regimen in poor and high responders. We attempted to subgroup treatment regimens by the ovulation triggering agent but no data were available for a proper analysis, as the majority of the included studies either used hCG or did not specify their triggering agents. This is a potential area to be explored by future research. It is also important to understand why pregnancy outcomes have become progressively more favourable with the use of GnRH antagonists. One possible explanation for this could be a decrease in LH instability. This area should be further investigated. Although not a focus of the current update, the potential effects of OCP pretreatment should be further investigated. </p> <p>Patient satisfaction surveys should also be undertaken to evaluate their impression about GnRH antagonist treatment regimens. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001750-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001750-sec-0022"></div> <div class="table" id="CD001750-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">GnRH antagonist compared to long‐course GnRH agonist for assisted reproductive technology (ART)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GnRH antagonist compared to long‐course GnRH agonist for assisted reproductive technology (ART)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women undergoing assisted reproductive technology (ART)<br/> <b>Settings:</b> clinic for ART<br/> <b>Intervention:</b> GnRH antagonist<br/> <b>Comparison:</b> long‐course GnRH agonist </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Long course GnRH agonist</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> GnRH antagonist</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman randomised</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>290 per 1000</b> <br/> (254 to 330) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.02</b> <br/> (0.85 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2303<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OHSS per woman randomised (any grade)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b> <br/> (62 to 85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.61</b> <br/> (0.51 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7944<br/> (36 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ongoing pregnancy rate per woman randomised</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>293 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>276 per 1000</b> <br/> (256 to 295) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.92</b> <br/> (0.83 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8311<br/> (37 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman randomised</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>303 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>283 per 1000</b> <br/> (267 to 303) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.91</b> <br/> (0.83 to 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9959<br/> (54 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman randomised</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> <br/> (40 to 61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.03</b> <br/> (0.82 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7082<br/> (34 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cycle cancellation due to poor ovarian response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> <br/> (68 to 101) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.32</b> <br/> (1.06 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5230<br/> (25 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>moderate</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Asymmetry of the funnel plot with small study effects in favour of GnRH antagonist<br/> <sup>2</sup> Most domains of the risk of bias were assessed as either 'unclear' or 'high'<br/> <sup>3</sup> Presence of significant heterogeneity among studies with inconsistency in the directions of effect estimates<br/> <sup>4</sup> Effect estimate with wide confidence interval </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001750-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001750-sec-0023"></div> <section id="CD001750-sec-0024"> <h3 class="title" id="CD001750-sec-0024">Description of the condition</h3> <p>Controlled ovarian hyperstimulation (COH) coupled with in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) was one of the major advances in the treatment of subfertility in the second half of the 20th century. One aspect of COH‐IVF or ICSI that requires attention is the occurrence of a luteinizing hormone (LH) surge which may occur prematurely, before the leading follicle reaches the optimum diameter for triggering ovulation. Such premature LH surges prevent effective induction of multiple follicular maturation patterns for a significant number of women. </p> <p>Gonadotrophin‐releasing hormone agonists (GnRH agonists) have played an important role in reducing the incidence of premature LH surges by reversibly blocking pituitary gonadotrophin secretion. As a result, the rates of cancellation of assisted conception cycles are decreased and pregnancy rates increased (<a href="./references#CD001750-bbs2-0123" title="AlbanoC , SmitzJ , CamusM , Riethmuller‐WinzenH , Siebert‐WeigerM , DiedrichK , et al. Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin‐releasing hormone antagonist (cetrorelix). Human Reproduction (Oxford, England)1996;11(10):2114‐8. ">Albano 1996</a>; <a href="./references#CD001750-bbs2-0139" title="HughesEG , FedorkowDM , DayaS , SagleMA , Van deKoppelP , CollinsJA . The routine use of gonadotropin‐releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta‐analysis of randomized trials. Fertility and Sterility1992;58:888‐96. ">Hughes 1992</a>). However, the use of GnRH agonists is not without disadvantages. Even though the standard long‐course GnRH agonist protocol proved to be the most efficacious protocol (<a href="./references#CD001750-bbs2-0126" title="DayaS . Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database of Systematic Reviews2000, Issue 1. [DOI: 10.1002/14651858.CD001299] ">Daya 2000</a>) for the use of GnRH agonists, it requires two to three weeks for desensitisation, with relatively high costs due to an increased requirement for gonadotrophin injections, and the need for hormonal and ultrasonographic measurements (<a href="./references#CD001750-bbs2-0150" title="OlivennesF , FanchinR , BouchardP , deZieglerD , TaiebJ , SelvaJ . The single or dual administration of the gonadotrophin‐releasing hormone antagonist cetrorelix in an in‐vitro fertilisation‐embryo transfer program. Fertility and Sterility1994;62(3):468‐76. ">Olivennes 1994</a>). </p> <p>A common complication associated with ovarian stimulation with exogenous gonadotrophins is ovarian hyperstimulation syndrome (OHSS) (<a href="./references#CD001750-bbs2-0145" title="MathurR , KailasamC , JenkinsJ . Review of the evidence base strategies to prevent ovarian hyperstimulation syndrome. Human Fertility2007;10:75‐85. ">Mathur 2007</a>). It usually occurs following a LH surge or after exposure to human chorionic gonadotrophin (hCG) (<a href="./references#CD001750-bbs2-0148" title="MozesM , BogokowskyH , AntebiE , LunenfeldB , RabauE , SerrDM , et al. Thromboembolic phenomena after ovarian stimulation with human gonadotrophins. Lancet1965;2:1213‐5. ">Mozes 1965</a>). Most cases of OHSS are mild with few or no clinical consequences. However, severe cases occur occasionally with serious morbidity and mortalities (<a href="./references#CD001750-bbs2-0128" title="DelvigneA , RozenbergS . Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Human Reproduction Update2002;8:559‐77. ">Delvigne 2002</a>). Gonadotrophin‐releasing hormone analogues (GnRH agonists and antagonists) stabilise the luteal phase thereby preventing premature LH surges and reducing the risk of OHSS. </p> </section> <section id="CD001750-sec-0025"> <h3 class="title" id="CD001750-sec-0025">Description of the intervention</h3> <p>In 1999, gonadotrophin‐releasing hormone antagonists (GnRH antagonist) were introduced to the market to prevent LH surge, and it was assumed that GnRH antagonists might be a more patient‐friendly protocol than the mid‐luteal GnRH agonist protocol. GnRH antagonists cause immediate, reversible and dose‐related inhibition of gonadotrophin release by competitive blockade of the GnRH receptors in the pituitary gland, and therefore treatment can be restricted to those days when a premature LH surge is likely to occur (<a href="./references#CD001750-bbs2-0129" title="DuijkersIJM , KlippingC , WillemsenWNP , KroneD , SchneiderE , NiebchG , et al. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin‐releasing hormone antagonist cetrorelix in healthy female volunteers. Human Reproduction1998;13(9):2392‐8. ">Duijkers 1998</a>; <a href="./references#CD001750-bbs2-0131" title="FelberbaumRE , ReissmannT , KuperW , BauerO , al HasaniS , DiedrichC , et al. Preserved pituitary response under ovarian stimulation with hMG and GnRH‐antagonists (cetrorelix) in women with tubal infertility. European Journal of Obstetrics, Gynecology, and Reproductive Biology1995;61(2):151‐5. ">Felberbaum 1995</a>; <a href="./references#CD001750-bbs2-0140" title="HuirneJA , HomburgR , LambalkCB . Are GnRH antagonists comparable to agonists for use in IVF?. Human Reproduction2007;11:2805‐13. ">Huirne 2007</a>). </p> <p>The first generation of GnRH antagonists were associated with allergic side‐effects due to an induced histamine release, which hampered the clinical development of these compounds. Third generation GnRH antagonists such as ganirelix (NV Organon, Oss, the Netherlands) and cetrorelix (ASTA‐Medica, Frankfurt am Main, Germany) have resolved these issues and are approved for clinical use (<a href="./references#CD001750-bbs2-0151" title="OlivennesF , AlvarezS , BouchardP , FanchinR , Salat‐BarouxJ , FrydmanR . The use of GnRH antagonist (cetrorelix) in a single dose protocol in IVF‐embryo transfer: a dose finding study of 3 versus 2mg. Human Reproduction (Oxford,England)1998;13(9):2411‐4. ">Olivennes 1998</a>). </p> <p>Two approaches have emerged in GnRH antagonist administration; the single‐dose protocol, in which one injection of GnRH antagonist (Cetrotide® 3 mg, Merck SeronoSA., Geneva, Switzerland ) is administered in the late phase of ovarian stimulation and the multiple‐dose regimen, in which 0.25 µg of cetrorelix or ganirelix is administered daily from stimulation day 6 onwards (fixed regimen). A flexible regimen based on the follicular size, has since been introduced to minimise the number and duration of GnRH antagonist injections (<a href="./references#CD001750-bbs2-0140" title="HuirneJA , HomburgR , LambalkCB . Are GnRH antagonists comparable to agonists for use in IVF?. Human Reproduction2007;11:2805‐13. ">Huirne 2007</a>). </p> <p>In a natural ovulatory cycle, ovulation, the release of the dominant follicle from the ovary, usually occurs about 36 hours after LH surge. In women undergoing controlled ovarian stimulation (COS) during assisted reproductive technology (ART), certain agents are usually administered to mimic the natural LH surge. Ultrasound scan and blood oestrogen levels are used to determine the day on which to administer the triggering agents. Ovulation triggering agents include hCG and GnRH agonist. These agents have different modes of action and their use might, therefore, differentially influence the effectiveness of GnRH antagonists. </p> </section> <section id="CD001750-sec-0026"> <h3 class="title" id="CD001750-sec-0026">How the intervention might work</h3> <p>Applying GnRH antagonists for pituitary desensitisation during COH is expected to result in a dramatic reduction in the duration of GnRH analogue treatment and to reduce the amount of gonadotrophin needed for stimulation as compared with the long agonist protocol. Other potential benefits include a lower risk of developing severe ovarian hyperstimulation syndrome (OHSS) and avoidance of oestrogen deprivation symptoms (for example hot flushes, sleep disturbances, headaches) frequently observed in the pre‐stimulation phase of a long agonist protocol. Whether the previously mentioned benefits justify a change in routine treatment from the standard long‐course GnRH agonist protocol to the GnRH antagonist regimen depends on whether the clinical outcomes using these protocols are similar. </p> </section> <section id="CD001750-sec-0027"> <h3 class="title" id="CD001750-sec-0027">Why it is important to do this review</h3> <p>The first Cochrane review on this topic was published in 2001 and was updated in 2006 and 2011. As further RCTs have been published, this is a further update of the evidence on the comparative effectiveness of GnRH antagonists versus GnRH agonists in women undergoing COH‐IVF or ICSI, with respect to reducing the risk of OHSS and cycle cancellation while maintaining the live birth rate. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001750-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001750-sec-0028"></div> <p>To evaluate the effectiveness and safety of gonadotrophin‐releasing hormone (GnRH) antagonists compared with the standard long protocol of GnRH agonists for controlled ovarian hyperstimulation in assisted conception cycles. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001750-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001750-sec-0029"></div> <section id="CD001750-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001750-sec-0031"> <h4 class="title">Types of studies</h4> <p>Only randomised controlled trials (RCTs) with a parallel design were eligible for inclusion. Quasi‐randomised trials were not included (e.g. studies with evidence of inadequate sequence generation such as alternate days, patient numbers) as they are associated with a high risk of bias. If cross‐over studies, with cross‐over occurring between cycles, were available, we would have included only the first cycle, before the cross‐over. </p> </section> <section id="CD001750-sec-0032"> <h4 class="title">Types of participants</h4> <p>Subfertile couples undergoing controlled ovarian hyperstimulation (COH) as part of an IVF or ICSI programme using GnRH antagonists or long‐course GnRH agonist protocols for the prevention of premature LH surges. </p> </section> <section id="CD001750-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Pituitary suppression with GnRH antagonists (for example cetrorelix, ganirelix) or long‐course GnRH agonists together with ovarian stimulation with recombinant or urinary human follicle stimulating hormone (hFSH) or human menopausal gonadotrophin (hMG), or both, or clomiphene citrate as part of an IVF or ICSI treatment cycles. Further, the use of oral contraceptive pill (OCP) pre‐treatment did not constitute an inclusion or exclusion criterion but rather was a variation in the protocols used. </p> </section> <section id="CD001750-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD001750-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD001750-list-0001"> <li> <p>Live birth rate (LBR) per woman randomised, defined as delivery of a live fetus after 20 completed weeks of gestation. </p> </li> <li> <p>Ovarian hyperstimulation syndrome (OHSS) rate per woman randomised, with grading as detected by clinical grading of OHSS, laboratory investigations (e.g. haematocrit, haemoglobin, renal function) or imaging techniques (ovarian and abdominal ultrasound, chest X‐ray), or both: all women, moderate or severe OHSS. </p> </li> </ul> </p> </section> <section id="CD001750-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD001750-list-0002"> <li> <p>Ongoing pregnancy rate (OPR) per woman randomised, defined as a pregnancy beyond 12 weeks' gestation. </p> </li> <li> <p>Clinical pregnancy rate (CPR) per woman randomised, defined as the presence of a gestational sac ± fetal heart beat at transvaginal ultrasound. </p> </li> <li> <p>Other adverse effects.</p> <ul id="CD001750-list-0003"> <li> <p>Miscarriage rate per woman randomised: miscarriage is defined as pregnancy loss before 20 weeks' gestation. Miscarriage rate per clinical pregnancy was analysed as a secondary analysis). </p> </li> <li> <p>Cycle cancellation rate per woman randomised. Two types of cycle cancellation were assessed in separate analyses: cycle cancellation due to high risk of OHSS and cycle cancellation due to poor ovarian response. </p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD001750-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all published and unpublished RCTs of GnRH antagonist versus the long‐course GnRH agonist protocol in women undergoing COH‐IVF or ICSI using the following search strategy, without language restriction and in consultation with the Gynaecology and Fertility Group (CGF) (formerly known as Menstrual Disorders and Subfertility Group (MDSG)) Information Specialist. We performed the most recent searches on 28 April 2015. </p> <section id="CD001750-sec-0038"> <h4 class="title">Electronic searches</h4> <p>The following electronic databases, trial registers and websites were searched (from their inception). </p> <p> <ul id="CD001750-list-0004"> <li> <p>Menstrual Disorders and Subfertility Group (MDSG) Specialised Register (updated search from 2010 to 28 April 2015) (<a href="./appendices#CD001750-sec-0104">Appendix 1</a>). </p> </li> <li> <p>Ovid Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library;</i> Issue 4 2015) (updated search from 2010 to 28 April 2015) (<a href="./appendices#CD001750-sec-0105">Appendix 2</a>). </p> </li> </ul> <ul id="CD001750-list-0005"> <li> <p>Ovid MEDLINE (updated search from 2010 to 28 April 2015) (<a href="./appendices#CD001750-sec-0106">Appendix 3</a>). The MEDLINE search was based on the Cochrane Highly Sensitive Search Strategy (HSSS) for identifying randomised trials in MEDLINE: sensitivity‐maximising version (<a href="./references#CD001750-bbs2-0144" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>). </p> </li> </ul> <ul id="CD001750-list-0006"> <li> <p>Ovid EMBASE (updated search 2010 up to 28 April 2015) (<a href="./appendices#CD001750-sec-0107">Appendix 4</a>). The EMBASE search was combined with the trial filter developed by the Scottish Intercollegiate Guidelines Network (SIGN) (<a href="http://sign.ac.uk/methodology/filters.html" target="_blank">http://sign.ac.uk/methodology/filters.html</a>). </p> </li> </ul> <ul id="CD001750-list-0007"> <li> <p>Ovid PsycINFO (updated search from 2010 to 28 April 2015) (<a href="./appendices#CD001750-sec-0108">Appendix 5</a>). The PsycINFO search was combined with the trial filter developed by the Scottish Intercollegiate Guidelines Network (SIGN) (<a href="http://sign.ac.uk/methodology/filters.html" target="_blank">http://sign.ac.uk/methodology/filters.html</a>). </p> </li> <li> <p>EBSCO CINAHL (Cumulative Index to Nursing and Allied Health Literature) (<a href="./appendices#CD001750-sec-0109">Appendix 6</a>). </p> </li> <li> <p>Trial registers for ongoing and registered trials: ISRCTN (<a href="http://www.isrctn.com/" target="_blank">http://www.isrctn.com/</a>), ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">https://clinicaltrials.gov/</a>), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal (<a href="http://www.who.int/trialsearch/Default.aspx" target="_blank">www.who.int/trialsearch/Default.aspx</a>). </p> </li> <li> <p>DARE (Database of abstracts of reviews of effectiveness) in <i>The Cochrane Library</i> at <a href="http://onlinelibrary.wiley.com/o/cochrane/cochrane_cldare_articles_fs.html" target="_blank">http://onlinelibrary.wiley.com/o/cochrane/cochrane_cldare_articles_fs.html</a> (for reference lists from relevant non‐Cochrane reviews </p> </li> <li> <p>LILACS database <a href="http://lilacs.bvsalud.org/en/" target="_blank">http://lilacs.bvsalud.org/en/</a> (for trials from the Portuguese and Spanish speaking world) </p> </li> <li> <p>Citation indexes on the ISI Web of Science (<a href="http://ipscience.thomsonreuters.com/product/web-of-science/" target="_blank">http://ipscience.thomsonreuters.com/product/web‐of‐science/</a>). </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Sciences) (<a href="http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis%26base=LILACS%E2%8C%A9=i%26form=F" target="_blank">http://bases.bireme.br/cgi‐bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&amp;base=LILACS&amp;lang=i&amp;form=F</a>). </p> </li> </ul> <ul id="CD001750-list-0008"> <li> <p>PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank">www.ncbi.nlm.nih.gov/pubmed/</a>). The PubMed search was combined with the random control filter for PubMed. </p> </li> <li> <p>OpenGrey ‐ <a href="http://www.opengrey.eu/" target="_blank">http://www.opengrey.eu/</a> for unpublished literature from Europe. </p> </li> </ul> </p> </section> <section id="CD001750-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We also searched the reference lists of all known primary studies, review articles, citation lists of relevant publications, abstracts of major scientific meetings (for example of the European Society of Human Reproduction and Embryology (ESHRE) and American Society for Reproductive Medicine (ASRM)). We contacted known experts and personal contacts regarding any unpublished materials. </p> <p>In addition, we handsearched appropriate journals. The list of journals is in the CGF Module, which can be found in <i>The Cochrane Library</i> under BROWSE ‐ 'By Review Group' ‐ 'Cochrane Gynaecology and Fertility Group' ‐ then 'about this group' at the top of this page. We liaised with the CGF Information Specialist to avoid duplication of handsearching. </p> </section> </section> <section id="CD001750-sec-0040"> <h3 class="title" id="CD001750-sec-0040">Data collection and analysis</h3> <section id="CD001750-sec-0041"> <h4 class="title">Selection of studies</h4> <p>After an initial screen of titles and abstracts retrieved by the search, we retrieved the full texts of all potentially eligible studies. Two review authors (RA and JB) independently examined these full‐text articles for compliance with the inclusion criteria and selected studies eligible for inclusion in the review. We contacted study investigators as required, to clarify study eligibility. We resolved disagreements as to study eligibility by discussion or by involving a third review author (MAY). We documented the selection process with a “PRISMA” flow chart (<a href="#CD001750-fig-0001">Figure 1</a>) (<a href="./references#CD001750-bbs2-0147" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA Statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097] ">Moher 2009</a>) </p> <div class="figure" id="CD001750-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001750-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD001750-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>We developed and piloted a standardised data extraction form for consistency and completeness. Three review authors (RA, JB or WSL) independently performed data extraction with discrepancies resolved by discussion. The data extraction forms included study demographics, patient characteristics and study risk of bias. We included this information in the review and presented it in the tables '<a href="./references#CD001750-sec-0119" title="">Characteristics of included studies</a>' and '<a href="./references#CD001750-sec-0120" title="">Characteristics of excluded studies</a>' according to the guidance given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001750-bbs2-0137" title="HigginsJPT , Deeks JJ(editors) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). Where studies had multiple publications the review authors collated multiple reports of the same study, so that each study rather than each report was the unit of interest in the review, and such studies would have a single study ID with multiple references. We contacted trial authors to request additional information or data. We also received a response from the sponsoring pharmaceutical companies. </p> </section> <section id="CD001750-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three authors (RA, JB and WSL) independently assessed the risk of bias of the included trials using The Cochrane 'Risk of bias' (RoB) tool (<a href="./references#CD001750-bbs2-0138" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). The domains assessed were: (1) sequence generation (for example; was the method used for allocation sequence adequately described?); (2) allocation concealment (for example, was allocation adequately concealed?); (3) blinding of participants, personnel and outcome assessors (for example; was knowledge of the allocated intervention adequately prevented during the study?); (4) incomplete outcome data (for example, were incomplete outcome data adequately addressed?); (5) selective outcome reporting (for example, were reports of the study free of suggestion of selective outcome reporting?); and (6) other sources of bias (for example, was the study apparently free of other problems that could put it at a high risk of bias?). Other potential sources of bias included baseline imbalances, source of funding, early stopping for benefit, and appropriateness of cross‐over design. We resolved disagreements by discussion or by consulting a fourth review author. We described all judgements fully and presented the conclusions in the 'Risk of bias' table (see the <a href="./references#CD001750-sec-0119" title="">Characteristics of included studies</a> table), which was incorporated into the interpretation of review findings by means of sensitivity analyses (see below). </p> <p>With respect to selective reporting, we sought published protocols and compared the outcomes between the protocol and the final published study, but the searches did not yield published protocols of any of the included studies. We took care to search for within‐trial selective reporting, such as non‐reporting of obvious outcomes, or reporting them in insufficient detail to allow for inclusion. Where identified studies failed to report the primary outcomes of live birth and OHSS but did report interim outcomes such as pregnancy, we undertook informal assessment as to whether the interim values (e.g. pregnancy rates) were similar to those reported in studies that also reported live birth. </p> </section> <section id="CD001750-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We only reported dichotomous data (e.g. live birth rates) in this review and we used the numbers of events in the control and intervention groups of each study to calculate Mantel‐Haenszel odds ratios (ORs). We reversed the direction of effect of individual studies, if required, to ensure consistency across trials. We presented 95% confidence intervals (CIs) for all outcomes. Where data to calculate ORs were not available, we utilised the most detailed numerical data available that facilitated similar analyses of included studies (e.g. test statistics, P values). We compared the magnitude and direction of effect reported by studies with how they were presented in the review, taking account of legitimate differences (<a href="./references#CD001750-bbs2-0127" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> <section id="CD001750-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>The primary analysis was per woman randomised. We also included per clinical pregnancy data for miscarriage. we contacted authors of studies that did not allow valid analysis of data (e.g. 'per cycle' data) and requested ‘per woman’ data. If no ‘per woman’ data was provided after contact, we did not include such studies in meta‐analyses. </p> </section> <section id="CD001750-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We analysed the data on an intention‐to‐treat basis as far as possible and made attempts to obtain missing data from the original trialists. Initially, we planned to undertake imputation of individual values for the primary outcomes if we were unable to obtain missing data from the original trialists but no data imputation was undertaken in the end and we analysed only the available data. </p> </section> <section id="CD001750-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity by the measure of the I<sup>2</sup> statistic (<a href="./references#CD001750-bbs2-0136" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). We took an I<sup>2</sup> statistic measurement greater than 50% to indicate substantial heterogeneity (<a href="./references#CD001750-bbs2-0127" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> <section id="CD001750-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, the review authors aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. We used a funnel plot to explore the possibility of small study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies) (<a href="./references#CD001750-bbs2-0130" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). </p> </section> <section id="CD001750-sec-0049"> <h4 class="title">Data synthesis</h4> <p>Where the studies were sufficiently similar, we combined the data using a fixed‐effect analysis (on the assumption that the underlying effect size was the same for all the trials in the analysis) comparing GnRH antagonist versus long course GnRH agonist. </p> <p>An increase in the odds of a particular outcome that were likely to be beneficial (e.g. live birth) or detrimental (e.g. adverse effects), were displayed graphically in the meta‐analyses to the right of the centre‐line and a decrease in the odds of an outcome to the left of the centre‐line. </p> <p>All analyses were performed using Review Manager software (RevMan) (<a href="./references#CD001750-bbs2-0152" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD001750-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where there were sufficient data we performed subgroup analyses for the following variables, for live birth and pregnancy outcomes. </p> <p> <ul id="CD001750-list-0009"> <li> <p>Triggering agent used for oocyte maturation (hCG, GnRH agonist, mixed (hCG/GnRH agonist) or unknown agent) </p> </li> <li> <p>Minimal or standard level of stimulation</p> </li> </ul> </p> <p>Where we detected substantial heterogeneity, we explored possible explanations in sensitivity analyses. We took any statistical heterogeneity into account when interpreting the results, especially where there was any variation in the direction of effect. </p> </section> <section id="CD001750-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses for LBR and OPR to determine whether the conclusions were robust to arbitrary decisions made regarding the eligibility and analysis (<a href="./references#CD001750-bbs2-0146" title="MoherD , JonesA , CookDJ , JadadAR , MoherM , TugwellP , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. The Lancet1999;352(9128):609‐18. ">Moher 1999</a>). These analyses included consideration of whether the review conclusions would have differed if: </p> <p> <ul id="CD001750-list-0010"> <li> <p>a random‐effects model had been adopted;</p> </li> <li> <p>the summary effect measure was risk ratio rather than odds ratio.</p> </li> </ul> </p> <section id="CD001750-sec-0052"> <h5 class="title">Overall quality of the body of evidence: 'Summary of findings' table</h5> <p>We prepared a 'Summary of findings' table using GRADEpro Guideline Development Tool (<a href="./references#CD001750-bbs2-0134" title="McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org. GRADEpro Guideline Develoopment Tool. McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org, 2015. ">GRADEpro GDT 2015</a>). This table evaluated the overall quality of the body of evidence for all review outcomes (live birth, OHSS, ongoing pregnancy, clinical pregnancy, miscarriage and cycle cancellation), using GRADE criteria (study limitations (i.e. risk of bias), consistency of effect, imprecision, indirectness and publication bias). Judgements about evidence quality (high, unclear (moderate) or low) were justified, documented, and incorporated into reporting of results for each outcome (<a href="./full#CD001750-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001750-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001750-sec-0053"></div> <section id="CD001750-sec-0054"> <h3 class="title">Description of studies</h3> <p>See the table '<a href="./references#CD001750-sec-0119" title="">Characteristics of included studies</a>'. </p> <section id="CD001750-sec-0055"> <h4 class="title">Results of the search</h4> <p>We retrieved 479 records after removal of duplicates, excluded 399 as ineligible, and assessed 80 full‐text articles. Of these, we excluded 51 and included 28 studies (29 reports). Seventy‐three randomised controlled studies (84 reports), involving 12,212 randomised women, met the inclusion criteria and were fully reviewed (<a href="./references#CD001750-sec-0119" title="">Characteristics of included studies</a>) (See <a href="#CD001750-fig-0001">Figure 1</a> for details of this process). </p> </section> <section id="CD001750-sec-0056"> <h4 class="title">Included studies</h4> <section id="CD001750-sec-0057"> <h5 class="title">Study characteristics</h5> <p> <ul id="CD001750-list-0011"> <li> <p>Twelve studies were multi‐centre (<a href="./references#CD001750-bbs2-0001" title="AlbanoC , FelberbaumR , SmitzJ , Riethmuller‐WinzenH , EngelJ , DiedrichK , et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone‐releasing hormone (LHRH)‐antagonist cetrorelix and the LHRH‐agonist buserlin. Human Reproduction2000;15(3):526‐31. LudwigM , FelberbaumRE , DevroeyP , AlbanoC , Riethmuller‐WinzenH , SchulerA , et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Archives of Gynecology and Obstetrics2000;264(1):29‐32. ">Albano 2000</a>; <a href="./references#CD001750-bbs2-0005" title="BaartEB , MartiniE , EijkemansMJ , VanOpstalD , BeckersNGM , VerhoeffA , et al. Milder ovarian stimulation for in‐vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Human Reproduction2007;22(4):980‐8. ">Baart 2007</a>; <a href="./references#CD001750-bbs2-0008" title="BarmatLI , ChantilisSJ , HurstBS , DickeyRP . A randomized prospective trial comparing gonadotropin‐releasing hormone (GnRH) antagonist/recombinant follicle‐stimulating hormone (r FSH) versus GnRH‐agonist/r FSH in women pretreated with oral contraceptives before in vitro fertilization. Fertility and Sterility2005;83(2):321‐30. [MEDLINE: 15705369] ">Barmat 2005</a>; <a href="./references#CD001750-bbs2-0018" title="European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction (Oxford, England)2001;16(4):644‐51. [MEDLINE: 11278211] SonntagB , KieselL , NieschlagE , BehreHM . Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing GnRH agonist versus antagonist protocols for ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics2004;21(7):249‐55. ">Euro Middle East 2001</a>; <a href="./references#CD001750-bbs2-0019" title="The European Orgalutran Study Group, BormG , MannaertsB . Treatment with the gonadotrophin‐releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction (Oxford, England) 15;7:1490‐8. ">Euro Orgalutran 2000</a>; <a href="./references#CD001750-bbs2-0023" title="FlukerM , GrifoJ , LeaderA , LevyM , MeldrumD , MuasherSJ , et al. for The North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility2001;75(1):38‐45. ">Fluker 2001</a>; <a href="./references#CD001750-bbs2-0028" title="HeijnenEM , EijkemansMJ , DeKlerkC , PolinderS , BeckersNG , KlinkertER , et al. A mild treatment strategy for in‐vitro fertilisation: a randomised non‐inferiority trial. The Lancet2007;369:743‐9. ">Heijnen 2007</a>; <a href="./references#CD001750-bbs2-0034" title="HuirneJA , VanLoenenAC , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. ">Huirne 2006</a>; <a href="./references#CD001750-bbs2-0055" title="OlivennesF , Belaisch‐Allart , EmperareJ , DechaudH , S Alvarez S , MoreauL . Prospective randomized, controlled study of in vitro fertilization‐embryo transfer with a single dose of a luteinizing hormone‐releasing hormone (LH‐RH) antagonist (cetrorelix) or a depot formula of an LH‐RH agonist (triptorelin). Fertility and Sterility2000;73(2):314‐20. ">Olivennes 2000</a>; <a href="./references#CD001750-bbs2-0058" title="QiaoJ , LuG , ZhangHW , ChenH , MaC , OlofssonJI , et al. A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates. Gynecological Endocrinology2012;28(10):800‐4. ">Qiao 2012</a>; <a href="./references#CD001750-bbs2-0062" title="RombautsL , HealyD , NormanRJ . A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction (Oxford, England)2006;21(1):95‐103. ">Rombauts 2006</a>; <a href="./references#CD001750-bbs2-0063" title="SauerMV , ThorntonMH , SchoolcraftW , FrishmanGN . Comparative efficacy and safety of cetrorelix with or without mid‐cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reproductive Biomedicine Online2004;9(5):487‐93. ">Sauer 2004</a>), 43 studies were single‐centre trials, while in the remaining studies it was unclear whether they were multi‐centre or single centre. </p> </li> <li> <p>We considered sample size calculations to be appropriate when the authors of the studies pre‐calculated the number needed in each arm prior to starting the trial. This helps to prevent the occurrence of type II errors. Fifteen studies reported that they had performed a priori sample size calculations (<a href="./references#CD001750-bbs2-0035" title="HwangJL , SeowK , LinY , HuangL , HsiehB , TsaiY , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. ">Hwang 2004</a>; <a href="./references#CD001750-bbs2-0005" title="BaartEB , MartiniE , EijkemansMJ , VanOpstalD , BeckersNGM , VerhoeffA , et al. Milder ovarian stimulation for in‐vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Human Reproduction2007;22(4):980‐8. ">Baart 2007</a>; <a href="./references#CD001750-bbs2-0014" title="CotaAM , OliveiraJB , PetersenCG , MauriAL , MassaroFC , SilvaLF , et al. GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology. Reproductive Biology and Endocrinology2012;10:33. LavoratoHL , OliveiraJB , PetersenCG , VagniniL , MauriAL , CavagnaM , et al. GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA fragmentation and apoptosis granulosa cells. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165:61‐5. ">Cota 2012</a>; <a href="./references#CD001750-bbs2-0017" title="EngmannL , DiLuigiA , SchmidtD , NulsenD , NulsenJ , BenadivaC . The use of gonadotropin‐releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high‐risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospsective randomised controlled study. Fertility and Sterility2008;89(1):84‐91. ">Engmann 2008a</a>; <a href="./references#CD001750-bbs2-0028" title="HeijnenEM , EijkemansMJ , DeKlerkC , PolinderS , BeckersNG , KlinkertER , et al. A mild treatment strategy for in‐vitro fertilisation: a randomised non‐inferiority trial. The Lancet2007;369:743‐9. ">Heijnen 2007</a>; <a href="./references#CD001750-bbs2-0034" title="HuirneJA , VanLoenenAC , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. ">Huirne 2006</a>; <a href="./references#CD001750-bbs2-0040" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐K , AhnJ‐W , JeonI , LeeJ‐W , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Abstracts of the 21st Annual Meeting of the ESHRE. Copenhagen, Denmark, 2005. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD001750-bbs2-0042" title="KurzawaR , CiepielaP , BaczkowskiT , SafranowK , BrelikP . Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non‐obese patients. A prospective randomized study. Journal for Assisted Reproduction and Genetics2008;25(8):365‐74. ">Kurzawa 2008</a>; <a href="./references#CD001750-bbs2-0045" title="BaslyM , AchourR , Ben JemaaS , ChnitirM , MessaoudiL , ChibaniM , et al. Flexible Gnrh antagonist protocol versus Gnrh agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Internet Journal of Gynecology &amp; Obstetrics2012;16(3):1. LainasTG , SfontourisIA , ZorzovilisIZ , PetsasGK , LainasGT , AlexopoulouE , et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Human Reproduction2010;25(3):683‐9. ">Lainas 2010</a>; <a href="./references#CD001750-bbs2-0064" title="SbraciaM , ColabianchiJ , GiallonardoA , GianniniP , PiscitelliC , MorgiaF , et al. Cetrorelix protocol versus gonadotropin‐releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40. Fertility and Sterility2009;91(5):1842‐7. ">Sbracia 2009</a>; <a href="./references#CD001750-bbs2-0067" title="SunkaraS , CoomarasamyA , FarisR , BraudeP , KhalafY . Effectiveness of the GnRH agonist long, GnRH agonist short and GnRH antagonist regimens in poor responders undergoing IVF treatment: a three arm randomised controlled trial. Human Reproduction. 2013; Vol. 28:i348. SunkaraSK , CoomarasamyA , FarisR , BraudeP , KhalafY . Long gonadotropin‐releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: A randomized controlled trial. Fertility and Sterility2014;101(1):147‐53. ">Sunkara 2014</a>; <a href="./references#CD001750-bbs2-0069" title="TehraninejadES , NasiriR , RashidiB , HaghollahiF , AtaieM . Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients. Archives of Gynecology and Obstetrics2010;282(3):319‐25. ">Tehraninejad 2010</a>; <a href="./references#CD001750-bbs2-0048" title="LinYH , HwangJL , SeowKM , HuangLW , HsiehBC , TzengCR . Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol ‐ a randomized study. Gynecological Endocrinology2006;22(6):297‐302. ">Lin 2006</a>; <a href="./references#CD001750-bbs2-0015" title="DepaloR , LorussoF , PalmisanoM , BassiE , TotaroI , VaccaM , et al. Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols for in vitro fertilisation and embryo transfer. Gynecological Endocrinology2009;25(5):328‐34. ">Depalo 2009</a>; <a href="./references#CD001750-bbs2-0068" title="TazegülA , GörkemliH , OzdemirS , AktanTM . Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial. Archives of Gynecology and Obstetrics2008;278(5):467‐72. ">Tazegul 2008</a>); 22 studies reported that they had not performed a sample size calculation; and it was not clear if sample size calculations had been performed in the remaining 36 studies. </p> </li> <li> <p>Twenty‐three studies said that they had performed intention‐to‐treat analysis (<a href="./references#CD001750-bbs2-0006" title="BadrawiA , Al‐InanyH , HusseinM , ZakiS , RamzyAM . Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis. Middle East Fertility Society Journal2005;10(1):49‐54. ">Badrawi 2005</a>; <a href="./references#CD001750-bbs2-0013" title="ChoiMH , KimHO , ChaSW , KoongMKK , KimJY , ParkCW . IVF comparison of ART outcomes in infertile PCOS women; in vitro maturation (IVM) vs. GnRH agonist vs. GnRH antagonist cycles. Clinical Experimental Reproductive MedicineDecember 2012;39(4):S210. ChoiMH , LeeSH , KimHO , ChaSH , KimJY , YangKM , et al. Comparison of assisted reproductive technology outcomes in infertile women with polycystic ovary syndrome: In vitro maturation, GnRH agonist, and GnRH antagonist cycles. Clinical &amp; Experimental Reproductive Medicine2012;39(4):166‐71. ">Choi 2012</a>; <a href="./references#CD001750-bbs2-0014" title="CotaAM , OliveiraJB , PetersenCG , MauriAL , MassaroFC , SilvaLF , et al. GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology. Reproductive Biology and Endocrinology2012;10:33. LavoratoHL , OliveiraJB , PetersenCG , VagniniL , MauriAL , CavagnaM , et al. GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA fragmentation and apoptosis granulosa cells. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165:61‐5. ">Cota 2012</a>; <a href="./references#CD001750-bbs2-0015" title="DepaloR , LorussoF , PalmisanoM , BassiE , TotaroI , VaccaM , et al. Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols for in vitro fertilisation and embryo transfer. Gynecological Endocrinology2009;25(5):328‐34. ">Depalo 2009</a>; <a href="./references#CD001750-bbs2-0017" title="EngmannL , DiLuigiA , SchmidtD , NulsenD , NulsenJ , BenadivaC . The use of gonadotropin‐releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high‐risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospsective randomised controlled study. Fertility and Sterility2008;89(1):84‐91. ">Engmann 2008a</a>; <a href="./references#CD001750-bbs2-0018" title="European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction (Oxford, England)2001;16(4):644‐51. [MEDLINE: 11278211] SonntagB , KieselL , NieschlagE , BehreHM . Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing GnRH agonist versus antagonist protocols for ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics2004;21(7):249‐55. ">Euro Middle East 2001</a>; <a href="./references#CD001750-bbs2-0019" title="The European Orgalutran Study Group, BormG , MannaertsB . Treatment with the gonadotrophin‐releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction (Oxford, England) 15;7:1490‐8. ">Euro Orgalutran 2000</a>; <a href="./references#CD001750-bbs2-0023" title="FlukerM , GrifoJ , LeaderA , LevyM , MeldrumD , MuasherSJ , et al. for The North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility2001;75(1):38‐45. ">Fluker 2001</a>; <a href="./references#CD001750-bbs2-0028" title="HeijnenEM , EijkemansMJ , DeKlerkC , PolinderS , BeckersNG , KlinkertER , et al. A mild treatment strategy for in‐vitro fertilisation: a randomised non‐inferiority trial. The Lancet2007;369:743‐9. ">Heijnen 2007</a>; <a href="./references#CD001750-bbs2-0032" title="HosseiniMA , AleyasinA , SaeediH , MahdaviA . Comparison of gonadotropin‐releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients. Journal of Obstetrics &amp; Gynaecology Research2010;36(3):605‐10. ">Hosseini 2010</a>; <a href="./references#CD001750-bbs2-0034" title="HuirneJA , VanLoenenAC , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. ">Huirne 2006</a>; <a href="./references#CD001750-bbs2-0035" title="HwangJL , SeowK , LinY , HuangL , HsiehB , TsaiY , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. ">Hwang 2004</a>; <a href="./references#CD001750-bbs2-0038" title="KhalafM , MittreH , LevalletJ , HanouxV , DenoualC , HerlicoviezM , et al. GnRH agonist and GnRH antagonist protocols in ovarian stimulation: differential regulation pathway of aromatase expression in human granulosa cells. Reproductive Biomedicine Online2010;21(1):56‐65. ">Khalaf 2010</a>; <a href="./references#CD001750-bbs2-0039" title="KimC‐H , LeeY‐J , HongS‐H , NahH‐Y , KimS‐H , ChaeH‐D , et al. Efficacy of a GnRH antagonist during early and late controlled ovarian hyperstimulation period in women with polycystic ovary syndrome undergoing IVF‐ET. Human Reproduction (Oxford, England)2004;19:i104‐5. ">Kim 2004</a>; <a href="./references#CD001750-bbs2-0040" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐K , AhnJ‐W , JeonI , LeeJ‐W , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Abstracts of the 21st Annual Meeting of the ESHRE. Copenhagen, Denmark, 2005. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD001750-bbs2-0048" title="LinYH , HwangJL , SeowKM , HuangLW , HsiehBC , TzengCR . Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol ‐ a randomized study. Gynecological Endocrinology2006;22(6):297‐302. ">Lin 2006</a>; <a href="./references#CD001750-bbs2-0049" title="LoutradisD , StefanidisK , DrakakisP , MilingosS , AntsaklisA , MichalasS . A modified gonadotropin‐releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol. Fertility and Sterility2004;82(5):1446‐8. [MEDLINE: 15533377] ">Loutradis 2004</a>; <a href="./references#CD001750-bbs2-0050" title="MarciR , CasertaD , DoloV , TatoneC , PavanA , MoscariniM . GnRH antagonist in IVF poor‐responder patients: results of a randomized trial. Reproductive Biomedicine Online2005;11(2):189‐93. MarciR , CasertaD , FarinaM , DessoleS , GermondM , TatoneC , et al. The use of GnRH antagonist in ovarian stimulation for IVF cycles can achieve good pregnancy rates in poor responder patients. Human Reproduction (Oxford, England)2002;17:115‐6. ">Marci 2005</a>; <a href="./references#CD001750-bbs2-0062" title="RombautsL , HealyD , NormanRJ . A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction (Oxford, England)2006;21(1):95‐103. ">Rombauts 2006</a>; <a href="./references#CD001750-bbs2-0063" title="SauerMV , ThorntonMH , SchoolcraftW , FrishmanGN . Comparative efficacy and safety of cetrorelix with or without mid‐cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reproductive Biomedicine Online2004;9(5):487‐93. ">Sauer 2004</a>; <a href="./references#CD001750-bbs2-0065" title="SerafiniP , YadidI , AlegrettiJ , PanzanM , CosloversuskyM , MottaE . A prospective, randomized trial of three ovulation induction protocols for IVF including a novel approach with low‐dose HCG and GnRH antagonist in the mid‐late follicular phase. Human Reproduction (Oxford, England)2003;18:1. SerafiniP , YadidI , MottaELA , AlegrettiJR , FioavantiJ , CoslovskyM . Ovarian stimulation with daily late follicular phase administration of low dose human chorionic gonadotropin for in vitro fertilization: a prospective randomized trial. Fertility and Sterility2006;86(4):830‐8. ">Serafini 2008</a>; <a href="./references#CD001750-bbs2-0067" title="SunkaraS , CoomarasamyA , FarisR , BraudeP , KhalafY . Effectiveness of the GnRH agonist long, GnRH agonist short and GnRH antagonist regimens in poor responders undergoing IVF treatment: a three arm randomised controlled trial. Human Reproduction. 2013; Vol. 28:i348. SunkaraSK , CoomarasamyA , FarisR , BraudeP , KhalafY . Long gonadotropin‐releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: A randomized controlled trial. Fertility and Sterility2014;101(1):147‐53. ">Sunkara 2014</a>; <a href="./references#CD001750-bbs2-0072" title="XavierP , GamboaC , CalejoL , SilvaJ , StevensonD , NunesA , et al. A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy. Eurpean Journal of Obstetrics, Gynecology, and Reproductive Biology2005;120(2):185‐9. [MEDLINE: 15925049] ">Xavier 2005</a>); 16 studies reported that the original analyses did not use the intention‐to‐treat principle (<a href="./references#CD001750-bbs2-0001" title="AlbanoC , FelberbaumR , SmitzJ , Riethmuller‐WinzenH , EngelJ , DiedrichK , et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone‐releasing hormone (LHRH)‐antagonist cetrorelix and the LHRH‐agonist buserlin. Human Reproduction2000;15(3):526‐31. LudwigM , FelberbaumRE , DevroeyP , AlbanoC , Riethmuller‐WinzenH , SchulerA , et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Archives of Gynecology and Obstetrics2000;264(1):29‐32. ">Albano 2000</a>; <a href="./references#CD001750-bbs2-0005" title="BaartEB , MartiniE , EijkemansMJ , VanOpstalD , BeckersNGM , VerhoeffA , et al. Milder ovarian stimulation for in‐vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Human Reproduction2007;22(4):980‐8. ">Baart 2007</a>; <a href="./references#CD001750-bbs2-0007" title="BahceciM , UlugU , Ben‐ShlomoI , ErdenHF , AkmanMA . Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. Journal of Reproductive Medicine2005;50(2):84‐90. [MEDLINE: 15755044] ">Bahceci 2005</a>; <a href="./references#CD001750-bbs2-0012" title="CheungLP , LamPM , LokIH , ChiuTT , YeungSY , TjerCC , et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Human Reproduction (Oxford, England)2005;20(3):616‐21. [MEDLINE: 15608037] ">Cheung 2005</a>; <a href="./references#CD001750-bbs2-0016" title="ElSahwiS . GnRH agonists versus GnRH antagonists in controlled ovarian stimulation in ICSI trials. Book of Abstracts, 8th International Symposium on GnRH Analogues in Cancer and Human Reproduction. Salzburg, Austria. 2005:A65. ">El Sahwi 2005</a>; <a href="./references#CD001750-bbs2-0022" title="FirouzabadiRD , AhmadiS , OskouianH , DavarR . Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART. Archives of Gynecology and Obstetrics2010;281(1):81‐5. [PUBMED: PMID: 19357861 ] ">Firouzabadi 2010</a>; <a href="./references#CD001750-bbs2-0030" title="HohmannFP , MacklonNS , FauserBC . A randomized comparison of two ovarian stimulation protocols with gonadotropin‐releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle‐stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. The Journal of Clinical Endocrinology and Metabolism2003;88(1):166‐73. ">Hohmann 2003</a>; <a href="./references#CD001750-bbs2-0036" title="InzaR , VanThilloG , LombardiE , BisioliC , DiradourianM , KennyA . Reproductive performance in second IVF cycles treated with the use of either GnRH antagonists (‐antag) vs GnRH agonists (‐ag) after failure with long protocols with GnRH agonists: a prospective randomized trial. Fertility and Sterility2004;82 Suppl:233‐4. ">Inza 2004</a>; <a href="./references#CD001750-bbs2-0042" title="KurzawaR , CiepielaP , BaczkowskiT , SafranowK , BrelikP . Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non‐obese patients. A prospective randomized study. Journal for Assisted Reproduction and Genetics2008;25(8):365‐74. ">Kurzawa 2008</a>; <a href="./references#CD001750-bbs2-0043" title="KyonoK , FuchinoueK , NakajoY , YagiA , SasakiK . A prospective randomized study of three ovulation induction protocols for IVF: GnRH agonist versus antagonist with and without low dose hCG. Fertility and Sterility2004;82 Suppl:31. KyonoK , NakajoY , SasakiS , KumagaiS , SuzukiS . A prospective randomized study of three different controlled ovarian hyperstimulation (COH) protocols. Fertility and Sterility2005;84 Suppl 1:299. ">Kyono 2005</a>; <a href="./references#CD001750-bbs2-0047" title="LeeTH , WuMH , ChenHF , ChenMJ , HoHN , YangYS . Ovarian response and follicular development for single‐dose and multiple‐dose protocols for gonadotropin‐releasing hormone antagonist administration. Fertility and Sterility2005;83(6):1700‐7. ">Lee 2005</a>; <a href="./references#CD001750-bbs2-0055" title="OlivennesF , Belaisch‐Allart , EmperareJ , DechaudH , S Alvarez S , MoreauL . Prospective randomized, controlled study of in vitro fertilization‐embryo transfer with a single dose of a luteinizing hormone‐releasing hormone (LH‐RH) antagonist (cetrorelix) or a depot formula of an LH‐RH agonist (triptorelin). Fertility and Sterility2000;73(2):314‐20. ">Olivennes 2000</a>; <a href="./references#CD001750-bbs2-0064" title="SbraciaM , ColabianchiJ , GiallonardoA , GianniniP , PiscitelliC , MorgiaF , et al. Cetrorelix protocol versus gonadotropin‐releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40. Fertility and Sterility2009;91(5):1842‐7. ">Sbracia 2009</a>; <a href="./references#CD001750-bbs2-0068" title="TazegülA , GörkemliH , OzdemirS , AktanTM . Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial. Archives of Gynecology and Obstetrics2008;278(5):467‐72. ">Tazegul 2008</a>; <a href="./references#CD001750-bbs2-0069" title="TehraninejadES , NasiriR , RashidiB , HaghollahiF , AtaieM . Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients. Archives of Gynecology and Obstetrics2010;282(3):319‐25. ">Tehraninejad 2010</a>; <a href="./references#CD001750-bbs2-0073" title="YeH , HuangG , ZengP , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;2(3):105‐11. ">Ye 2009</a>); it was not reported clearly in the rest of the studies. </p> </li> </ul> </p> </section> <section id="CD001750-sec-0058"> <h5 class="title">Participants</h5> <p> <ul id="CD001750-list-0012"> <li> <p>Seventy out of 73 studies reported that baseline characteristics were comparable between groups (<a href="./references#CD001750-sec-0119" title="">Characteristics of included studies</a> table) and three did not report information on this. In eighteen of the studies, age was the only reported characteristic compared. </p> </li> <li> <p>Of the 73 included studies, 49 trials involved an unspecified population of infertile couples, while the remaining trials were performed in specific infertile populations. These populations were or included 'poor responders' (<a href="./references#CD001750-bbs2-0002" title="Al‐KarakiR , IrzouqiR , KhalifaF , TaherM , SarrafM . Effectiveness of flexible GnRH antagonist protocol versus minidose long GnRH agonist protocol in poor‐responder patients undergoing IVF. Human Reproduction2011;26(1):i47. ">Al‐Karaki 2011</a>; <a href="./references#CD001750-bbs2-0012" title="CheungLP , LamPM , LokIH , ChiuTT , YeungSY , TjerCC , et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Human Reproduction (Oxford, England)2005;20(3):616‐21. [MEDLINE: 15608037] ">Cheung 2005</a>; <a href="./references#CD001750-bbs2-0036" title="InzaR , VanThilloG , LombardiE , BisioliC , DiradourianM , KennyA . Reproductive performance in second IVF cycles treated with the use of either GnRH antagonists (‐antag) vs GnRH agonists (‐ag) after failure with long protocols with GnRH agonists: a prospective randomized trial. Fertility and Sterility2004;82 Suppl:233‐4. ">Inza 2004</a>; <a href="./references#CD001750-bbs2-0040" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐K , AhnJ‐W , JeonI , LeeJ‐W , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Abstracts of the 21st Annual Meeting of the ESHRE. Copenhagen, Denmark, 2005. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD001750-bbs2-0041" title="KimC‐H , MoonJ‐W , KangH‐J , AhnJ‐W , KimS‐H , ChaeH‐D , et al. Effectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase compared with GnRH agonist long protocol in non‐obese and obese patients with polycystic ovary syndrome undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2012;39(1):22‐7. ">Kim 2012</a>; <a href="./references#CD001750-bbs2-0050" title="MarciR , CasertaD , DoloV , TatoneC , PavanA , MoscariniM . GnRH antagonist in IVF poor‐responder patients: results of a randomized trial. Reproductive Biomedicine Online2005;11(2):189‐93. MarciR , CasertaD , FarinaM , DessoleS , GermondM , TatoneC , et al. The use of GnRH antagonist in ovarian stimulation for IVF cycles can achieve good pregnancy rates in poor responder patients. Human Reproduction (Oxford, England)2002;17:115‐6. ">Marci 2005</a>; <a href="./references#CD001750-bbs2-0052" title="MohamedKA , DaviesWAR , LashenH . Effect of gonadotropin‐releasing hormone agonist and antagonist on steroidogenesis of low responders undergoing in vitro fertilization. Gynecological Endocrinology2006;22(2):57‐62. ">Mohamed 2006</a>; <a href="./references#CD001750-bbs2-0057" title="PrapasY , PetousisS , DagklisT , PanagiotidisY , PapatheodorouA , AssuntaI , et al. GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2013;166(1):43‐6. ">Prapas 2013</a>; <a href="./references#CD001750-bbs2-0060" title="RevelliA , ChiadòA , DalmassoP , StabileV , EvangelistaF , BassoG , et al. “Mild” vs. “long” protocol for controlled ovarian hyperstimulation in patients with expected poor ovarian responsiveness undergoing in vitro fertilization (IVF): a large prospective randomized trial. Journal of Assisted Reproduction and GeneticsJuly 2014;31(7):809‐15. [DOI: 10.1007/s10815‐014‐0227‐y] ">Revelli 2014</a>; <a href="./references#CD001750-bbs2-0064" title="SbraciaM , ColabianchiJ , GiallonardoA , GianniniP , PiscitelliC , MorgiaF , et al. Cetrorelix protocol versus gonadotropin‐releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40. Fertility and Sterility2009;91(5):1842‐7. ">Sbracia 2009</a>; <a href="./references#CD001750-bbs2-0067" title="SunkaraS , CoomarasamyA , FarisR , BraudeP , KhalafY . Effectiveness of the GnRH agonist long, GnRH agonist short and GnRH antagonist regimens in poor responders undergoing IVF treatment: a three arm randomised controlled trial. Human Reproduction. 2013; Vol. 28:i348. SunkaraSK , CoomarasamyA , FarisR , BraudeP , KhalafY . Long gonadotropin‐releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: A randomized controlled trial. Fertility and Sterility2014;101(1):147‐53. ">Sunkara 2014</a>; <a href="./references#CD001750-bbs2-0068" title="TazegülA , GörkemliH , OzdemirS , AktanTM . Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial. Archives of Gynecology and Obstetrics2008;278(5):467‐72. ">Tazegul 2008</a>; <a href="./references#CD001750-bbs2-0071" title="ToltagerM , BogstadJ , Lossl , K , et al. Pregnancy rates and risk of ovarian hyperstimulation syndrome (OHSS) in a fixed GnRH‐antagonist versus GnRH‐agonist protocol: randomised controlled trial including 1099 first IVF/ICSI CYCLES. Abstract of the 31st annual meeting of ESHRE I Lisbon, Portigal. 2015:i94. ">Toltager 2015</a>) or had polycystic ovary syndrome (<a href="./references#CD001750-bbs2-0007" title="BahceciM , UlugU , Ben‐ShlomoI , ErdenHF , AkmanMA . Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. Journal of Reproductive Medicine2005;50(2):84‐90. [MEDLINE: 15755044] ">Bahceci 2005</a>; <a href="./references#CD001750-bbs2-0013" title="ChoiMH , KimHO , ChaSW , KoongMKK , KimJY , ParkCW . IVF comparison of ART outcomes in infertile PCOS women; in vitro maturation (IVM) vs. GnRH agonist vs. GnRH antagonist cycles. Clinical Experimental Reproductive MedicineDecember 2012;39(4):S210. ChoiMH , LeeSH , KimHO , ChaSH , KimJY , YangKM , et al. Comparison of assisted reproductive technology outcomes in infertile women with polycystic ovary syndrome: In vitro maturation, GnRH agonist, and GnRH antagonist cycles. Clinical &amp; Experimental Reproductive Medicine2012;39(4):166‐71. ">Choi 2012</a>; <a href="./references#CD001750-bbs2-0017" title="EngmannL , DiLuigiA , SchmidtD , NulsenD , NulsenJ , BenadivaC . The use of gonadotropin‐releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high‐risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospsective randomised controlled study. Fertility and Sterility2008;89(1):84‐91. ">Engmann 2008a</a>; <a href="./references#CD001750-bbs2-0027" title="HaydardedeogluB , KilicdagEB , ParlakgumusAH , ZeynelogluHB . IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial. Archives of Gynecology and ObstetricsSeptember 2012;286(3):763‐769. ">Haydardedeoglu 2012</a>; <a href="./references#CD001750-bbs2-0032" title="HosseiniMA , AleyasinA , SaeediH , MahdaviA . Comparison of gonadotropin‐releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients. Journal of Obstetrics &amp; Gynaecology Research2010;36(3):605‐10. ">Hosseini 2010</a>; <a href="./references#CD001750-bbs2-0035" title="HwangJL , SeowK , LinY , HuangL , HsiehB , TsaiY , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. ">Hwang 2004</a>; <a href="./references#CD001750-bbs2-0039" title="KimC‐H , LeeY‐J , HongS‐H , NahH‐Y , KimS‐H , ChaeH‐D , et al. Efficacy of a GnRH antagonist during early and late controlled ovarian hyperstimulation period in women with polycystic ovary syndrome undergoing IVF‐ET. Human Reproduction (Oxford, England)2004;19:i104‐5. ">Kim 2004</a>; <a href="./references#CD001750-bbs2-0042" title="KurzawaR , CiepielaP , BaczkowskiT , SafranowK , BrelikP . Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non‐obese patients. A prospective randomized study. Journal for Assisted Reproduction and Genetics2008;25(8):365‐74. ">Kurzawa 2008</a>; <a href="./references#CD001750-bbs2-0044" title="LainasTG , PetsasGK , ZorovilisIZ , LliadisGS , LainasGT , GazlarisHE , et al. Initiation of GnRH antagonist on day 1 of stimulation as compared to the long agonist protocol in PCOS patients: a randomised controlled trial: effect on hormonal levels and follicular development. Human Reproduction2007;22(6):1540‐6. ">Lainas 2007</a>; <a href="./references#CD001750-bbs2-0045" title="BaslyM , AchourR , Ben JemaaS , ChnitirM , MessaoudiL , ChibaniM , et al. Flexible Gnrh antagonist protocol versus Gnrh agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Internet Journal of Gynecology &amp; Obstetrics2012;16(3):1. LainasTG , SfontourisIA , ZorzovilisIZ , PetsasGK , LainasGT , AlexopoulouE , et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Human Reproduction2010;25(3):683‐9. ">Lainas 2010</a>; <a href="./references#CD001750-bbs2-0054" title="MoshinV , CroitorM , HotineanuA . GnRH antagonist versus long GnRH agonists protocol in PCOS patients undergoing IVF treatment. Abstracts of the 23rd Annual Meeting of the ESHRE, Lyon, France2007;22 Suppl 1:i121. ">Moshin 2007</a>; <a href="./references#CD001750-bbs2-0069" title="TehraninejadES , NasiriR , RashidiB , HaghollahiF , AtaieM . Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients. Archives of Gynecology and Obstetrics2010;282(3):319‐25. ">Tehraninejad 2010</a>). </p> </li> <li> <p>The number of randomised women ranged from 20 (<a href="./references#CD001750-bbs2-0024" title="Franco JrJG , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH After 2nd phase protocols with GnRH Analogs (I‐estradiol + ganirelix versus II‐nafarelin) [Comparacao da estimulacao ovariana com FSH recombinante apos protocolo de 2A fase com analogos do GNRH (I ‐estradiol + ganirelix versus II‐nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco 2003</a>) to 1099 (<a href="./references#CD001750-bbs2-0071" title="ToltagerM , BogstadJ , Lossl , K , et al. Pregnancy rates and risk of ovarian hyperstimulation syndrome (OHSS) in a fixed GnRH‐antagonist versus GnRH‐agonist protocol: randomised controlled trial including 1099 first IVF/ICSI CYCLES. Abstract of the 31st annual meeting of ESHRE I Lisbon, Portigal. 2015:i94. ">Toltager 2015</a>), including both the GnRH agonist and antagonist groups. </p> </li> <li> <p>Fifteen studies included 300 or more participants (<a href="./references#CD001750-bbs2-0004" title="AwataS , TanakaA , NagayoshiM . Selection of an optimal controlled ovarian hyperstimulation method in relation to the number of antral follicles in patients less than 40 years old. Fertility and Sterility2010;94 suppl 1(4):S164 Abstract no. P‐244. ">Awata 2010</a>; <a href="./references#CD001750-bbs2-0018" title="European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction (Oxford, England)2001;16(4):644‐51. [MEDLINE: 11278211] SonntagB , KieselL , NieschlagE , BehreHM . Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing GnRH agonist versus antagonist protocols for ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics2004;21(7):249‐55. ">Euro Middle East 2001</a>; <a href="./references#CD001750-bbs2-0019" title="The European Orgalutran Study Group, BormG , MannaertsB . Treatment with the gonadotrophin‐releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction (Oxford, England) 15;7:1490‐8. ">Euro Orgalutran 2000</a>; <a href="./references#CD001750-bbs2-0070" title="NezamabadiAG , TehraninejadES , RashidiB . GnRH Antagonist versus Agonist in Normoresponders Undergoing ICSI: A Randomized Clinical Trial in Iran. International Journal of Fertility and Sterility2013;7(1):106. TehraninejadE , NezamabadiAG , RashidiB , SohrabiM , BagheriM , HaghollahiF , et al. GnRH antagonist versus agonist in normoresponders undergoing ICSI: a randomized clinical trial in Iran. Iranian Journal of Reproductive Medicine2011;9(3):171‐6. [IRCT138902283950N1]] ">Tehraninejad 2011</a>; <a href="./references#CD001750-bbs2-0026" title="GizzoS , AndrisaniA , EspositoF , NoventaM , DiGangiS , AngioniS , et al. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial. Gynecological Endocrinology2014;30(12):902‐8. [DOI: 10.3109/09513590.2014.964638] ">Gizzo 2014</a>; <a href="./references#CD001750-bbs2-0027" title="HaydardedeogluB , KilicdagEB , ParlakgumusAH , ZeynelogluHB . IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial. Archives of Gynecology and ObstetricsSeptember 2012;286(3):763‐769. ">Haydardedeoglu 2012</a>; <a href="./references#CD001750-bbs2-0028" title="HeijnenEM , EijkemansMJ , DeKlerkC , PolinderS , BeckersNG , KlinkertER , et al. A mild treatment strategy for in‐vitro fertilisation: a randomised non‐inferiority trial. The Lancet2007;369:743‐9. ">Heijnen 2007</a>; <a href="./references#CD001750-bbs2-0051" title="MartínezF , CluaE , PareraN , RodríguezI , BoadaM , CoroleuB . Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle‐stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients. Gynecological Endocrinology2008;24(4):188‐93. ">Martinez 2008</a>; <a href="./references#CD001750-bbs2-0057" title="PrapasY , PetousisS , DagklisT , PanagiotidisY , PapatheodorouA , AssuntaI , et al. GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2013;166(1):43‐6. ">Prapas 2013</a>; <a href="./references#CD001750-bbs2-0060" title="RevelliA , ChiadòA , DalmassoP , StabileV , EvangelistaF , BassoG , et al. “Mild” vs. “long” protocol for controlled ovarian hyperstimulation in patients with expected poor ovarian responsiveness undergoing in vitro fertilization (IVF): a large prospective randomized trial. Journal of Assisted Reproduction and GeneticsJuly 2014;31(7):809‐15. [DOI: 10.1007/s10815‐014‐0227‐y] ">Revelli 2014</a>; <a href="./references#CD001750-bbs2-0061" title="RinaldiL , LisiF , SelmanH . Mild/minimal stimulation protocol for ovarian stimulation of patients at high risk of developing ovarian hyperstimulation syndrome. Journal of Endocrinological Investigation2014;37:65‐70. ">Rinaldi 2014</a>; <a href="./references#CD001750-bbs2-0062" title="RombautsL , HealyD , NormanRJ . A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction (Oxford, England)2006;21(1):95‐103. ">Rombauts 2006</a>; <a href="./references#CD001750-bbs2-0064" title="SbraciaM , ColabianchiJ , GiallonardoA , GianniniP , PiscitelliC , MorgiaF , et al. Cetrorelix protocol versus gonadotropin‐releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40. Fertility and Sterility2009;91(5):1842‐7. ">Sbracia 2009</a>; <a href="./references#CD001750-bbs2-0071" title="ToltagerM , BogstadJ , Lossl , K , et al. Pregnancy rates and risk of ovarian hyperstimulation syndrome (OHSS) in a fixed GnRH‐antagonist versus GnRH‐agonist protocol: randomised controlled trial including 1099 first IVF/ICSI CYCLES. Abstract of the 31st annual meeting of ESHRE I Lisbon, Portigal. 2015:i94. ">Toltager 2015</a>). There were 30 studies with fewer than 100 participants (<a href="./references#CD001750-bbs2-0003" title="AndersonS , PereiraNE , BrasileDR , OrrisJJ , DaviesEB , GlassnerMJ . Comparison of antagonist to agonist in controlled ovarian stimulation (COS) cycles using human‐derived gonadotropin on in vitro fertilization (IVF) outcomes. A prospective randomized controlled study. Fertility and sterility. 2014; Vol. 102 (3; Suppl 1):e224. ">Anderson 2014</a>; <a href="./references#CD001750-bbs2-0008" title="BarmatLI , ChantilisSJ , HurstBS , DickeyRP . A randomized prospective trial comparing gonadotropin‐releasing hormone (GnRH) antagonist/recombinant follicle‐stimulating hormone (r FSH) versus GnRH‐agonist/r FSH in women pretreated with oral contraceptives before in vitro fertilization. Fertility and Sterility2005;83(2):321‐30. [MEDLINE: 15705369] ">Barmat 2005</a>; <a href="./references#CD001750-bbs2-0010" title="CelikN , CelikO , AktanE , OzerolE , CelikE , BozkurtK , et al. Plasma urocortin levels in women undergoing long agonist and antagonist protocols for IVF. Human Reproduction2011;26(1):i203. ">Celik 2011</a>; <a href="./references#CD001750-bbs2-0011" title="CheckML , CheckJH , ChoelJK , DaviesE , KieferD . Effect of antagonists vs agonists on in vitro fertilization outcome. Clinical and Experimental Obstetrics &amp; Gynecology2004;31(4):257‐9. [MEDLINE: 15672958] ">Check 2004</a>; <a href="./references#CD001750-bbs2-0012" title="CheungLP , LamPM , LokIH , ChiuTT , YeungSY , TjerCC , et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Human Reproduction (Oxford, England)2005;20(3):616‐21. [MEDLINE: 15608037] ">Cheung 2005</a>; <a href="./references#CD001750-bbs2-0013" title="ChoiMH , KimHO , ChaSW , KoongMKK , KimJY , ParkCW . IVF comparison of ART outcomes in infertile PCOS women; in vitro maturation (IVM) vs. GnRH agonist vs. GnRH antagonist cycles. Clinical Experimental Reproductive MedicineDecember 2012;39(4):S210. ChoiMH , LeeSH , KimHO , ChaSH , KimJY , YangKM , et al. Comparison of assisted reproductive technology outcomes in infertile women with polycystic ovary syndrome: In vitro maturation, GnRH agonist, and GnRH antagonist cycles. Clinical &amp; Experimental Reproductive Medicine2012;39(4):166‐71. ">Choi 2012</a>; <a href="./references#CD001750-bbs2-0014" title="CotaAM , OliveiraJB , PetersenCG , MauriAL , MassaroFC , SilvaLF , et al. GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology. Reproductive Biology and Endocrinology2012;10:33. LavoratoHL , OliveiraJB , PetersenCG , VagniniL , MauriAL , CavagnaM , et al. GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA fragmentation and apoptosis granulosa cells. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165:61‐5. ">Cota 2012</a>; <a href="./references#CD001750-bbs2-0017" title="EngmannL , DiLuigiA , SchmidtD , NulsenD , NulsenJ , BenadivaC . The use of gonadotropin‐releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high‐risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospsective randomised controlled study. Fertility and Sterility2008;89(1):84‐91. ">Engmann 2008a</a>; <a href="./references#CD001750-bbs2-0020" title="FerrariB , PezzutoA , BarusiL , CoppolaF . Follicular fluid vascular endothelial growth factor concentrations are increased during GnRH antagonist/FSH ovarian stimulation cycles. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;124(1):70‐6. FerrariB , PezzutoA , BarusiL , CoppolaF . Gonadotrophin‐releasing hormone antagonists increase follicular fluid insulin‐like growth factor‐I and vascular endothelial growth factor during ovarian stimulation cycles. Gynecological EndocrinologyJune 2006;22(6):289‐96. [DOI: 10.1080/09513590600777602] ">Ferrari 2006</a>; <a href="./references#CD001750-bbs2-0024" title="Franco JrJG , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH After 2nd phase protocols with GnRH Analogs (I‐estradiol + ganirelix versus II‐nafarelin) [Comparacao da estimulacao ovariana com FSH recombinante apos protocolo de 2A fase com analogos do GNRH (I ‐estradiol + ganirelix versus II‐nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco 2003</a>; <a href="./references#CD001750-bbs2-0025" title="FriedlerS , GilboaS , SchachterM , RazielR , StrassburgerD , KastersteinE , et al. Luteal phase characteristics following GnRH antagonist or agonist treatment: a randomized comparative study. Human Reproduction (Oxford, England)2003;18 Suppl 1:26. ">Friedler 2003</a>; <a href="./references#CD001750-bbs2-0029" title="Hershko KlementA , BerkovitzA , WiserA , GonenO , AmichayK , CohenI , et al. GnRH‐antagonist programming versus GnRH agonist protocol: a randomized trial. European Journal of Obstetrics Gynecology and Reproductive Biology2015;185:170‐3. Hershko KlementA , BerkovitzA , WiserA , GonenO , AmichayK , ShulmanA . Follicular estrogen for GnRH‐antagonist protocol programming: a prospective randomized clinical trial. Fertility and Sterility. 2013; Vol. 1:S523. ">Hershko Klement 2015</a>; <a href="./references#CD001750-bbs2-0031" title="HoseiniFS , MugahiSM , Akbari‐AsbaghF , Eftekhari‐YazdiP , AflatoonianB , Aghaee‐BakhtiariSH , et al. A randomized controlled trial of gonadotropin‐releasing hormone antagonist in Iranian infertile couples: oocyte gene expression. Journal of Pharmaceutical Sciences2014;22:67. ">Hoseini 2014</a>; <a href="./references#CD001750-bbs2-0035" title="HwangJL , SeowK , LinY , HuangL , HsiehB , TsaiY , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. ">Hwang 2004</a>; <a href="./references#CD001750-bbs2-0036" title="InzaR , VanThilloG , LombardiE , BisioliC , DiradourianM , KennyA . Reproductive performance in second IVF cycles treated with the use of either GnRH antagonists (‐antag) vs GnRH agonists (‐ag) after failure with long protocols with GnRH agonists: a prospective randomized trial. Fertility and Sterility2004;82 Suppl:233‐4. ">Inza 2004</a>; <a href="./references#CD001750-bbs2-0038" title="KhalafM , MittreH , LevalletJ , HanouxV , DenoualC , HerlicoviezM , et al. GnRH agonist and GnRH antagonist protocols in ovarian stimulation: differential regulation pathway of aromatase expression in human granulosa cells. Reproductive Biomedicine Online2010;21(1):56‐65. ">Khalaf 2010</a>; <a href="./references#CD001750-bbs2-0039" title="KimC‐H , LeeY‐J , HongS‐H , NahH‐Y , KimS‐H , ChaeH‐D , et al. Efficacy of a GnRH antagonist during early and late controlled ovarian hyperstimulation period in women with polycystic ovary syndrome undergoing IVF‐ET. Human Reproduction (Oxford, England)2004;19:i104‐5. ">Kim 2004</a>; <a href="./references#CD001750-bbs2-0042" title="KurzawaR , CiepielaP , BaczkowskiT , SafranowK , BrelikP . Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non‐obese patients. A prospective randomized study. Journal for Assisted Reproduction and Genetics2008;25(8):365‐74. ">Kurzawa 2008</a>; <a href="./references#CD001750-bbs2-0044" title="LainasTG , PetsasGK , ZorovilisIZ , LliadisGS , LainasGT , GazlarisHE , et al. Initiation of GnRH antagonist on day 1 of stimulation as compared to the long agonist protocol in PCOS patients: a randomised controlled trial: effect on hormonal levels and follicular development. Human Reproduction2007;22(6):1540‐6. ">Lainas 2007</a>; <a href="./references#CD001750-bbs2-0046" title="LavoratoHL , OliveiraJB , PetersenCG , VagniniL , MaurAL , CavagnaM , et al. GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA fragmentation and apoptosis in granulosa cells. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(1):61‐5. ">Lavorato 2012</a>; <a href="./references#CD001750-bbs2-0047" title="LeeTH , WuMH , ChenHF , ChenMJ , HoHN , YangYS . Ovarian response and follicular development for single‐dose and multiple‐dose protocols for gonadotropin‐releasing hormone antagonist administration. Fertility and Sterility2005;83(6):1700‐7. ">Lee 2005</a>; <a href="./references#CD001750-bbs2-0050" title="MarciR , CasertaD , DoloV , TatoneC , PavanA , MoscariniM . GnRH antagonist in IVF poor‐responder patients: results of a randomized trial. Reproductive Biomedicine Online2005;11(2):189‐93. MarciR , CasertaD , FarinaM , DessoleS , GermondM , TatoneC , et al. The use of GnRH antagonist in ovarian stimulation for IVF cycles can achieve good pregnancy rates in poor responder patients. Human Reproduction (Oxford, England)2002;17:115‐6. ">Marci 2005</a>; <a href="./references#CD001750-bbs2-0052" title="MohamedKA , DaviesWAR , LashenH . Effect of gonadotropin‐releasing hormone agonist and antagonist on steroidogenesis of low responders undergoing in vitro fertilization. Gynecological Endocrinology2006;22(2):57‐62. ">Mohamed 2006</a>; <a href="./references#CD001750-bbs2-0053" title="MoralogluO , KilicS , KarayalçinR , YukselB , TasdemirN , UgurM . Comparison of GnRH agonists and antagonists in normo‐responder IVF/ICSI in Turkish female patients. Advances in Therapy2008;25(3):266‐73. ">Moraloglu 2008</a>; <a href="./references#CD001750-bbs2-0054" title="MoshinV , CroitorM , HotineanuA . GnRH antagonist versus long GnRH agonists protocol in PCOS patients undergoing IVF treatment. Abstracts of the 23rd Annual Meeting of the ESHRE, Lyon, France2007;22 Suppl 1:i121. ">Moshin 2007</a>; <a href="./references#CD001750-bbs2-0063" title="SauerMV , ThorntonMH , SchoolcraftW , FrishmanGN . Comparative efficacy and safety of cetrorelix with or without mid‐cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reproductive Biomedicine Online2004;9(5):487‐93. ">Sauer 2004</a>; <a href="./references#CD001750-bbs2-0065" title="SerafiniP , YadidI , AlegrettiJ , PanzanM , CosloversuskyM , MottaE . A prospective, randomized trial of three ovulation induction protocols for IVF including a novel approach with low‐dose HCG and GnRH antagonist in the mid‐late follicular phase. Human Reproduction (Oxford, England)2003;18:1. SerafiniP , YadidI , MottaELA , AlegrettiJR , FioavantiJ , CoslovskyM . Ovarian stimulation with daily late follicular phase administration of low dose human chorionic gonadotropin for in vitro fertilization: a prospective randomized trial. Fertility and Sterility2006;86(4):830‐8. ">Serafini 2008</a>; <a href="./references#CD001750-bbs2-0066" title="StenbaekDS , ToftagerM , HjordtLV , JensenPS , HolstKK , BryndorfT , et al. Mental distress and personality in women undergoing GnRH agonist versus GnRH antagonist protocols for assisted reproductive technology. Human Reproduction2015;30(1):103‐10. ">Stenbaek 2015</a><a href="./references#CD001750-bbs2-0068" title="TazegülA , GörkemliH , OzdemirS , AktanTM . Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial. Archives of Gynecology and Obstetrics2008;278(5):467‐72. ">Tazegul 2008</a>; <a href="./references#CD001750-bbs2-0069" title="TehraninejadES , NasiriR , RashidiB , HaghollahiF , AtaieM . Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients. Archives of Gynecology and Obstetrics2010;282(3):319‐25. ">Tehraninejad 2010</a>). </p> </li> <li> <p>Five studies were published before 2002. There were 28 studies published between 2002 and 2006, 18 studies published between 2007 and 2010 and 23 studies between 2011 and 2015 </p> </li> </ul> </p> </section> <section id="CD001750-sec-0059"> <h5 class="title">Intervention</h5> <p> <ul id="CD001750-list-0013"> <li> <p>All included studies compared GnRH antagonist with long‐course GnRH agonist protocols in women undergoing IVF or ICSI cycles. </p> </li> <li> <p>We identified three types of antagonist protocols: (1) single, long‐acting administration (<a href="./references#CD001750-bbs2-0033" title="HsiehYY , ChangCC , TsaiHD . Comparisons of different dosages of gonadotropin‐releasing hormone (GnRH) antagonist, short‐acting form and single, half‐dose, long‐acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. Taiwan Journal of Obstetrics and Gynecology2008;47:66‐74. ">Hsieh 2008</a>; <a href="./references#CD001750-bbs2-0047" title="LeeTH , WuMH , ChenHF , ChenMJ , HoHN , YangYS . Ovarian response and follicular development for single‐dose and multiple‐dose protocols for gonadotropin‐releasing hormone antagonist administration. Fertility and Sterility2005;83(6):1700‐7. ">Lee 2005</a>; <a href="./references#CD001750-bbs2-0054" title="MoshinV , CroitorM , HotineanuA . GnRH antagonist versus long GnRH agonists protocol in PCOS patients undergoing IVF treatment. Abstracts of the 23rd Annual Meeting of the ESHRE, Lyon, France2007;22 Suppl 1:i121. ">Moshin 2007</a>; <a href="./references#CD001750-bbs2-0055" title="OlivennesF , Belaisch‐Allart , EmperareJ , DechaudH , S Alvarez S , MoreauL . Prospective randomized, controlled study of in vitro fertilization‐embryo transfer with a single dose of a luteinizing hormone‐releasing hormone (LH‐RH) antagonist (cetrorelix) or a depot formula of an LH‐RH agonist (triptorelin). Fertility and Sterility2000;73(2):314‐20. ">Olivennes 2000</a>); (2) fixed, daily administration (<a href="./references#CD001750-bbs2-0001" title="AlbanoC , FelberbaumR , SmitzJ , Riethmuller‐WinzenH , EngelJ , DiedrichK , et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone‐releasing hormone (LHRH)‐antagonist cetrorelix and the LHRH‐agonist buserlin. Human Reproduction2000;15(3):526‐31. LudwigM , FelberbaumRE , DevroeyP , AlbanoC , Riethmuller‐WinzenH , SchulerA , et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Archives of Gynecology and Obstetrics2000;264(1):29‐32. ">Albano 2000</a>; <a href="./references#CD001750-bbs2-0012" title="CheungLP , LamPM , LokIH , ChiuTT , YeungSY , TjerCC , et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Human Reproduction (Oxford, England)2005;20(3):616‐21. [MEDLINE: 15608037] ">Cheung 2005</a>; <a href="./references#CD001750-bbs2-0018" title="European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction (Oxford, England)2001;16(4):644‐51. [MEDLINE: 11278211] SonntagB , KieselL , NieschlagE , BehreHM . Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing GnRH agonist versus antagonist protocols for ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics2004;21(7):249‐55. ">Euro Middle East 2001</a>; <a href="./references#CD001750-bbs2-0019" title="The European Orgalutran Study Group, BormG , MannaertsB . Treatment with the gonadotrophin‐releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction (Oxford, England) 15;7:1490‐8. ">Euro Orgalutran 2000</a>; <a href="./references#CD001750-bbs2-0022" title="FirouzabadiRD , AhmadiS , OskouianH , DavarR . Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART. Archives of Gynecology and Obstetrics2010;281(1):81‐5. [PUBMED: PMID: 19357861 ] ">Firouzabadi 2010</a>; <a href="./references#CD001750-bbs2-0023" title="FlukerM , GrifoJ , LeaderA , LevyM , MeldrumD , MuasherSJ , et al. for The North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility2001;75(1):38‐45. ">Fluker 2001</a>; <a href="./references#CD001750-bbs2-0027" title="HaydardedeogluB , KilicdagEB , ParlakgumusAH , ZeynelogluHB . IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial. Archives of Gynecology and ObstetricsSeptember 2012;286(3):763‐769. ">Haydardedeoglu 2012</a>; <a href="./references#CD001750-bbs2-0031" title="HoseiniFS , MugahiSM , Akbari‐AsbaghF , Eftekhari‐YazdiP , AflatoonianB , Aghaee‐BakhtiariSH , et al. A randomized controlled trial of gonadotropin‐releasing hormone antagonist in Iranian infertile couples: oocyte gene expression. Journal of Pharmaceutical Sciences2014;22:67. ">Hoseini 2014</a>; <a href="./references#CD001750-bbs2-0033" title="HsiehYY , ChangCC , TsaiHD . Comparisons of different dosages of gonadotropin‐releasing hormone (GnRH) antagonist, short‐acting form and single, half‐dose, long‐acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. Taiwan Journal of Obstetrics and Gynecology2008;47:66‐74. ">Hsieh 2008</a>; <a href="./references#CD001750-bbs2-0034" title="HuirneJA , VanLoenenAC , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. ">Huirne 2006</a>; <a href="./references#CD001750-bbs2-0035" title="HwangJL , SeowK , LinY , HuangL , HsiehB , TsaiY , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. ">Hwang 2004</a>; <a href="./references#CD001750-bbs2-0051" title="MartínezF , CluaE , PareraN , RodríguezI , BoadaM , CoroleuB . Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle‐stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients. Gynecological Endocrinology2008;24(4):188‐93. ">Martinez 2008</a>; <a href="./references#CD001750-bbs2-0054" title="MoshinV , CroitorM , HotineanuA . GnRH antagonist versus long GnRH agonists protocol in PCOS patients undergoing IVF treatment. Abstracts of the 23rd Annual Meeting of the ESHRE, Lyon, France2007;22 Suppl 1:i121. ">Moshin 2007</a>; <a href="./references#CD001750-bbs2-0063" title="SauerMV , ThorntonMH , SchoolcraftW , FrishmanGN . Comparative efficacy and safety of cetrorelix with or without mid‐cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reproductive Biomedicine Online2004;9(5):487‐93. ">Sauer 2004</a>); and (3) flexible daily administration (<a href="./references#CD001750-bbs2-0005" title="BaartEB , MartiniE , EijkemansMJ , VanOpstalD , BeckersNGM , VerhoeffA , et al. Milder ovarian stimulation for in‐vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Human Reproduction2007;22(4):980‐8. ">Baart 2007</a>; <a href="./references#CD001750-bbs2-0006" title="BadrawiA , Al‐InanyH , HusseinM , ZakiS , RamzyAM . Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis. Middle East Fertility Society Journal2005;10(1):49‐54. ">Badrawi 2005</a>; <a href="./references#CD001750-bbs2-0007" title="BahceciM , UlugU , Ben‐ShlomoI , ErdenHF , AkmanMA . Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. Journal of Reproductive Medicine2005;50(2):84‐90. [MEDLINE: 15755044] ">Bahceci 2005</a>; <a href="./references#CD001750-bbs2-0008" title="BarmatLI , ChantilisSJ , HurstBS , DickeyRP . A randomized prospective trial comparing gonadotropin‐releasing hormone (GnRH) antagonist/recombinant follicle‐stimulating hormone (r FSH) versus GnRH‐agonist/r FSH in women pretreated with oral contraceptives before in vitro fertilization. Fertility and Sterility2005;83(2):321‐30. [MEDLINE: 15705369] ">Barmat 2005</a>; <a href="./references#CD001750-bbs2-0009" title="BrelikP , KurzawaR , BaczkowskiT , SienkiewiczR , GlabowskiW . Assessment of the predictive value of LH levels in IVF cycles stimulated with GnRH antagonists and agonists. Human Reproduction2004;19:i62. ">Brelik 2004</a>; <a href="./references#CD001750-bbs2-0011" title="CheckML , CheckJH , ChoelJK , DaviesE , KieferD . Effect of antagonists vs agonists on in vitro fertilization outcome. Clinical and Experimental Obstetrics &amp; Gynecology2004;31(4):257‐9. [MEDLINE: 15672958] ">Check 2004</a>; <a href="./references#CD001750-bbs2-0013" title="ChoiMH , KimHO , ChaSW , KoongMKK , KimJY , ParkCW . IVF comparison of ART outcomes in infertile PCOS women; in vitro maturation (IVM) vs. GnRH agonist vs. GnRH antagonist cycles. Clinical Experimental Reproductive MedicineDecember 2012;39(4):S210. ChoiMH , LeeSH , KimHO , ChaSH , KimJY , YangKM , et al. Comparison of assisted reproductive technology outcomes in infertile women with polycystic ovary syndrome: In vitro maturation, GnRH agonist, and GnRH antagonist cycles. Clinical &amp; Experimental Reproductive Medicine2012;39(4):166‐71. ">Choi 2012</a>; <a href="./references#CD001750-bbs2-0015" title="DepaloR , LorussoF , PalmisanoM , BassiE , TotaroI , VaccaM , et al. Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols for in vitro fertilisation and embryo transfer. Gynecological Endocrinology2009;25(5):328‐34. ">Depalo 2009</a>; <a href="./references#CD001750-bbs2-0016" title="ElSahwiS . GnRH agonists versus GnRH antagonists in controlled ovarian stimulation in ICSI trials. Book of Abstracts, 8th International Symposium on GnRH Analogues in Cancer and Human Reproduction. Salzburg, Austria. 2005:A65. ">El Sahwi 2005</a>; <a href="./references#CD001750-bbs2-0017" title="EngmannL , DiLuigiA , SchmidtD , NulsenD , NulsenJ , BenadivaC . The use of gonadotropin‐releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high‐risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospsective randomised controlled study. Fertility and Sterility2008;89(1):84‐91. ">Engmann 2008a</a>; <a href="./references#CD001750-bbs2-0024" title="Franco JrJG , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH After 2nd phase protocols with GnRH Analogs (I‐estradiol + ganirelix versus II‐nafarelin) [Comparacao da estimulacao ovariana com FSH recombinante apos protocolo de 2A fase com analogos do GNRH (I ‐estradiol + ganirelix versus II‐nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco 2003</a>; <a href="./references#CD001750-bbs2-0029" title="Hershko KlementA , BerkovitzA , WiserA , GonenO , AmichayK , CohenI , et al. GnRH‐antagonist programming versus GnRH agonist protocol: a randomized trial. European Journal of Obstetrics Gynecology and Reproductive Biology2015;185:170‐3. Hershko KlementA , BerkovitzA , WiserA , GonenO , AmichayK , ShulmanA . Follicular estrogen for GnRH‐antagonist protocol programming: a prospective randomized clinical trial. Fertility and Sterility. 2013; Vol. 1:S523. ">Hershko Klement 2015</a>; <a href="./references#CD001750-bbs2-0030" title="HohmannFP , MacklonNS , FauserBC . A randomized comparison of two ovarian stimulation protocols with gonadotropin‐releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle‐stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. The Journal of Clinical Endocrinology and Metabolism2003;88(1):166‐73. ">Hohmann 2003</a>; <a href="./references#CD001750-bbs2-0037" title="KarimzadehMA , AhmadiS , OskouianH , RahmaniE . Comparison of mild stimulation and conventional stimulation in ART outcome. Archives of Gynecology and Obstetrics2010;281(4):741‐6. ">Karimzadeh 2010</a>; <a href="./references#CD001750-bbs2-0039" title="KimC‐H , LeeY‐J , HongS‐H , NahH‐Y , KimS‐H , ChaeH‐D , et al. Efficacy of a GnRH antagonist during early and late controlled ovarian hyperstimulation period in women with polycystic ovary syndrome undergoing IVF‐ET. Human Reproduction (Oxford, England)2004;19:i104‐5. ">Kim 2004</a>; <a href="./references#CD001750-bbs2-0040" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐K , AhnJ‐W , JeonI , LeeJ‐W , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Abstracts of the 21st Annual Meeting of the ESHRE. Copenhagen, Denmark, 2005. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD001750-bbs2-0042" title="KurzawaR , CiepielaP , BaczkowskiT , SafranowK , BrelikP . Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non‐obese patients. A prospective randomized study. Journal for Assisted Reproduction and Genetics2008;25(8):365‐74. ">Kurzawa 2008</a>; <a href="./references#CD001750-bbs2-0044" title="LainasTG , PetsasGK , ZorovilisIZ , LliadisGS , LainasGT , GazlarisHE , et al. Initiation of GnRH antagonist on day 1 of stimulation as compared to the long agonist protocol in PCOS patients: a randomised controlled trial: effect on hormonal levels and follicular development. Human Reproduction2007;22(6):1540‐6. ">Lainas 2007</a>; <a href="./references#CD001750-bbs2-0045" title="BaslyM , AchourR , Ben JemaaS , ChnitirM , MessaoudiL , ChibaniM , et al. Flexible Gnrh antagonist protocol versus Gnrh agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Internet Journal of Gynecology &amp; Obstetrics2012;16(3):1. LainasTG , SfontourisIA , ZorzovilisIZ , PetsasGK , LainasGT , AlexopoulouE , et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Human Reproduction2010;25(3):683‐9. ">Lainas 2010</a>; <a href="./references#CD001750-bbs2-0047" title="LeeTH , WuMH , ChenHF , ChenMJ , HoHN , YangYS . Ovarian response and follicular development for single‐dose and multiple‐dose protocols for gonadotropin‐releasing hormone antagonist administration. Fertility and Sterility2005;83(6):1700‐7. ">Lee 2005</a>; <a href="./references#CD001750-bbs2-0048" title="LinYH , HwangJL , SeowKM , HuangLW , HsiehBC , TzengCR . Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol ‐ a randomized study. Gynecological Endocrinology2006;22(6):297‐302. ">Lin 2006</a>; <a href="./references#CD001750-bbs2-0049" title="LoutradisD , StefanidisK , DrakakisP , MilingosS , AntsaklisA , MichalasS . A modified gonadotropin‐releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol. Fertility and Sterility2004;82(5):1446‐8. [MEDLINE: 15533377] ">Loutradis 2004</a>; <a href="./references#CD001750-bbs2-0050" title="MarciR , CasertaD , DoloV , TatoneC , PavanA , MoscariniM . GnRH antagonist in IVF poor‐responder patients: results of a randomized trial. Reproductive Biomedicine Online2005;11(2):189‐93. MarciR , CasertaD , FarinaM , DessoleS , GermondM , TatoneC , et al. The use of GnRH antagonist in ovarian stimulation for IVF cycles can achieve good pregnancy rates in poor responder patients. Human Reproduction (Oxford, England)2002;17:115‐6. ">Marci 2005</a>; <a href="./references#CD001750-bbs2-0053" title="MoralogluO , KilicS , KarayalçinR , YukselB , TasdemirN , UgurM . Comparison of GnRH agonists and antagonists in normo‐responder IVF/ICSI in Turkish female patients. Advances in Therapy2008;25(3):266‐73. ">Moraloglu 2008</a>; <a href="./references#CD001750-bbs2-0062" title="RombautsL , HealyD , NormanRJ . A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction (Oxford, England)2006;21(1):95‐103. ">Rombauts 2006</a>; <a href="./references#CD001750-bbs2-0064" title="SbraciaM , ColabianchiJ , GiallonardoA , GianniniP , PiscitelliC , MorgiaF , et al. Cetrorelix protocol versus gonadotropin‐releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40. Fertility and Sterility2009;91(5):1842‐7. ">Sbracia 2009</a>; <a href="./references#CD001750-bbs2-0065" title="SerafiniP , YadidI , AlegrettiJ , PanzanM , CosloversuskyM , MottaE . A prospective, randomized trial of three ovulation induction protocols for IVF including a novel approach with low‐dose HCG and GnRH antagonist in the mid‐late follicular phase. Human Reproduction (Oxford, England)2003;18:1. SerafiniP , YadidI , MottaELA , AlegrettiJR , FioavantiJ , CoslovskyM . Ovarian stimulation with daily late follicular phase administration of low dose human chorionic gonadotropin for in vitro fertilization: a prospective randomized trial. Fertility and Sterility2006;86(4):830‐8. ">Serafini 2008</a>; <a href="./references#CD001750-bbs2-0068" title="TazegülA , GörkemliH , OzdemirS , AktanTM . Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial. Archives of Gynecology and Obstetrics2008;278(5):467‐72. ">Tazegul 2008</a>; <a href="./references#CD001750-bbs2-0069" title="TehraninejadES , NasiriR , RashidiB , HaghollahiF , AtaieM . Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients. Archives of Gynecology and Obstetrics2010;282(3):319‐25. ">Tehraninejad 2010</a>; <a href="./references#CD001750-bbs2-0072" title="XavierP , GamboaC , CalejoL , SilvaJ , StevensonD , NunesA , et al. A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy. Eurpean Journal of Obstetrics, Gynecology, and Reproductive Biology2005;120(2):185‐9. [MEDLINE: 15925049] ">Xavier 2005</a>; <a href="./references#CD001750-bbs2-0073" title="YeH , HuangG , ZengP , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;2(3):105‐11. ">Ye 2009</a>). In the fixed daily protocol, in most of the studies, GnRH antagonist was begun on day six of FSH treatment regardless of follicle size. In the flexible daily protocol, GnRH antagonist was administered according to the lead follicle size and not the cycle date, nor the day of FSH administration. In 25 of the included studies, the type of antagonist protocol used was not reported. </p> </li> <li> <p>In 44 included trials, the antagonist cetrorelix was administered (<a href="./references#CD001750-bbs2-0001" title="AlbanoC , FelberbaumR , SmitzJ , Riethmuller‐WinzenH , EngelJ , DiedrichK , et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone‐releasing hormone (LHRH)‐antagonist cetrorelix and the LHRH‐agonist buserlin. Human Reproduction2000;15(3):526‐31. LudwigM , FelberbaumRE , DevroeyP , AlbanoC , Riethmuller‐WinzenH , SchulerA , et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Archives of Gynecology and Obstetrics2000;264(1):29‐32. ">Albano 2000</a>; <a href="./references#CD001750-bbs2-0002" title="Al‐KarakiR , IrzouqiR , KhalifaF , TaherM , SarrafM . Effectiveness of flexible GnRH antagonist protocol versus minidose long GnRH agonist protocol in poor‐responder patients undergoing IVF. Human Reproduction2011;26(1):i47. ">Al‐Karaki 2011</a>; <a href="./references#CD001750-bbs2-0007" title="BahceciM , UlugU , Ben‐ShlomoI , ErdenHF , AkmanMA . Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. Journal of Reproductive Medicine2005;50(2):84‐90. [MEDLINE: 15755044] ">Bahceci 2005</a>; <a href="./references#CD001750-bbs2-0009" title="BrelikP , KurzawaR , BaczkowskiT , SienkiewiczR , GlabowskiW . Assessment of the predictive value of LH levels in IVF cycles stimulated with GnRH antagonists and agonists. Human Reproduction2004;19:i62. ">Brelik 2004</a>; <a href="./references#CD001750-bbs2-0012" title="CheungLP , LamPM , LokIH , ChiuTT , YeungSY , TjerCC , et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Human Reproduction (Oxford, England)2005;20(3):616‐21. [MEDLINE: 15608037] ">Cheung 2005</a>; <a href="./references#CD001750-bbs2-0014" title="CotaAM , OliveiraJB , PetersenCG , MauriAL , MassaroFC , SilvaLF , et al. GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology. Reproductive Biology and Endocrinology2012;10:33. LavoratoHL , OliveiraJB , PetersenCG , VagniniL , MauriAL , CavagnaM , et al. GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA fragmentation and apoptosis granulosa cells. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165:61‐5. ">Cota 2012</a>; <a href="./references#CD001750-bbs2-0015" title="DepaloR , LorussoF , PalmisanoM , BassiE , TotaroI , VaccaM , et al. Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols for in vitro fertilisation and embryo transfer. Gynecological Endocrinology2009;25(5):328‐34. ">Depalo 2009</a>; <a href="./references#CD001750-bbs2-0016" title="ElSahwiS . GnRH agonists versus GnRH antagonists in controlled ovarian stimulation in ICSI trials. Book of Abstracts, 8th International Symposium on GnRH Analogues in Cancer and Human Reproduction. Salzburg, Austria. 2005:A65. ">El Sahwi 2005</a>; <a href="./references#CD001750-bbs2-0020" title="FerrariB , PezzutoA , BarusiL , CoppolaF . Follicular fluid vascular endothelial growth factor concentrations are increased during GnRH antagonist/FSH ovarian stimulation cycles. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;124(1):70‐6. FerrariB , PezzutoA , BarusiL , CoppolaF . Gonadotrophin‐releasing hormone antagonists increase follicular fluid insulin‐like growth factor‐I and vascular endothelial growth factor during ovarian stimulation cycles. Gynecological EndocrinologyJune 2006;22(6):289‐96. [DOI: 10.1080/09513590600777602] ">Ferrari 2006</a>; <a href="./references#CD001750-bbs2-0021" title="FerreroS , AbbamonteL H , PrivameraMR , LeviS , VenturiniPL , AnseriniP . Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients at high risk of ovarian hyperstimulation syndrome: A prospective randomized controlled trial. Fertility and Sterility2010;94 suppl 1(4):S28 Abstract no. O‐92. ">Ferrero 2010</a>; <a href="./references#CD001750-bbs2-0029" title="Hershko KlementA , BerkovitzA , WiserA , GonenO , AmichayK , CohenI , et al. GnRH‐antagonist programming versus GnRH agonist protocol: a randomized trial. European Journal of Obstetrics Gynecology and Reproductive Biology2015;185:170‐3. Hershko KlementA , BerkovitzA , WiserA , GonenO , AmichayK , ShulmanA . Follicular estrogen for GnRH‐antagonist protocol programming: a prospective randomized clinical trial. Fertility and Sterility. 2013; Vol. 1:S523. ">Hershko Klement 2015</a>; <a href="./references#CD001750-bbs2-0030" title="HohmannFP , MacklonNS , FauserBC . A randomized comparison of two ovarian stimulation protocols with gonadotropin‐releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle‐stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. The Journal of Clinical Endocrinology and Metabolism2003;88(1):166‐73. ">Hohmann 2003</a>; <a href="./references#CD001750-bbs2-0031" title="HoseiniFS , MugahiSM , Akbari‐AsbaghF , Eftekhari‐YazdiP , AflatoonianB , Aghaee‐BakhtiariSH , et al. A randomized controlled trial of gonadotropin‐releasing hormone antagonist in Iranian infertile couples: oocyte gene expression. Journal of Pharmaceutical Sciences2014;22:67. ">Hoseini 2014</a>; <a href="./references#CD001750-bbs2-0032" title="HosseiniMA , AleyasinA , SaeediH , MahdaviA . Comparison of gonadotropin‐releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients. Journal of Obstetrics &amp; Gynaecology Research2010;36(3):605‐10. ">Hosseini 2010</a>; <a href="./references#CD001750-bbs2-0033" title="HsiehYY , ChangCC , TsaiHD . Comparisons of different dosages of gonadotropin‐releasing hormone (GnRH) antagonist, short‐acting form and single, half‐dose, long‐acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. Taiwan Journal of Obstetrics and Gynecology2008;47:66‐74. ">Hsieh 2008</a>; <a href="./references#CD001750-bbs2-0034" title="HuirneJA , VanLoenenAC , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. ">Huirne 2006</a>; <a href="./references#CD001750-bbs2-0035" title="HwangJL , SeowK , LinY , HuangL , HsiehB , TsaiY , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. ">Hwang 2004</a>; <a href="./references#CD001750-bbs2-0038" title="KhalafM , MittreH , LevalletJ , HanouxV , DenoualC , HerlicoviezM , et al. GnRH agonist and GnRH antagonist protocols in ovarian stimulation: differential regulation pathway of aromatase expression in human granulosa cells. Reproductive Biomedicine Online2010;21(1):56‐65. ">Khalaf 2010</a>; <a href="./references#CD001750-bbs2-0039" title="KimC‐H , LeeY‐J , HongS‐H , NahH‐Y , KimS‐H , ChaeH‐D , et al. Efficacy of a GnRH antagonist during early and late controlled ovarian hyperstimulation period in women with polycystic ovary syndrome undergoing IVF‐ET. Human Reproduction (Oxford, England)2004;19:i104‐5. ">Kim 2004</a>; <a href="./references#CD001750-bbs2-0040" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐K , AhnJ‐W , JeonI , LeeJ‐W , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Abstracts of the 21st Annual Meeting of the ESHRE. Copenhagen, Denmark, 2005. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD001750-bbs2-0041" title="KimC‐H , MoonJ‐W , KangH‐J , AhnJ‐W , KimS‐H , ChaeH‐D , et al. Effectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase compared with GnRH agonist long protocol in non‐obese and obese patients with polycystic ovary syndrome undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2012;39(1):22‐7. ">Kim 2012</a>; <a href="./references#CD001750-bbs2-0042" title="KurzawaR , CiepielaP , BaczkowskiT , SafranowK , BrelikP . Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non‐obese patients. A prospective randomized study. Journal for Assisted Reproduction and Genetics2008;25(8):365‐74. ">Kurzawa 2008</a>; <a href="./references#CD001750-bbs2-0043" title="KyonoK , FuchinoueK , NakajoY , YagiA , SasakiK . A prospective randomized study of three ovulation induction protocols for IVF: GnRH agonist versus antagonist with and without low dose hCG. Fertility and Sterility2004;82 Suppl:31. KyonoK , NakajoY , SasakiS , KumagaiS , SuzukiS . A prospective randomized study of three different controlled ovarian hyperstimulation (COH) protocols. Fertility and Sterility2005;84 Suppl 1:299. ">Kyono 2005</a>; <a href="./references#CD001750-bbs2-0045" title="BaslyM , AchourR , Ben JemaaS , ChnitirM , MessaoudiL , ChibaniM , et al. Flexible Gnrh antagonist protocol versus Gnrh agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Internet Journal of Gynecology &amp; Obstetrics2012;16(3):1. LainasTG , SfontourisIA , ZorzovilisIZ , PetsasGK , LainasGT , AlexopoulouE , et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Human Reproduction2010;25(3):683‐9. ">Lainas 2010</a>; <a href="./references#CD001750-bbs2-0046" title="LavoratoHL , OliveiraJB , PetersenCG , VagniniL , MaurAL , CavagnaM , et al. GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA fragmentation and apoptosis in granulosa cells. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(1):61‐5. ">Lavorato 2012</a>; <a href="./references#CD001750-bbs2-0047" title="LeeTH , WuMH , ChenHF , ChenMJ , HoHN , YangYS . Ovarian response and follicular development for single‐dose and multiple‐dose protocols for gonadotropin‐releasing hormone antagonist administration. Fertility and Sterility2005;83(6):1700‐7. ">Lee 2005</a>; <a href="./references#CD001750-bbs2-0048" title="LinYH , HwangJL , SeowKM , HuangLW , HsiehBC , TzengCR . Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol ‐ a randomized study. Gynecological Endocrinology2006;22(6):297‐302. ">Lin 2006</a>; <a href="./references#CD001750-bbs2-0049" title="LoutradisD , StefanidisK , DrakakisP , MilingosS , AntsaklisA , MichalasS . A modified gonadotropin‐releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol. Fertility and Sterility2004;82(5):1446‐8. [MEDLINE: 15533377] ">Loutradis 2004</a>; <a href="./references#CD001750-bbs2-0050" title="MarciR , CasertaD , DoloV , TatoneC , PavanA , MoscariniM . GnRH antagonist in IVF poor‐responder patients: results of a randomized trial. Reproductive Biomedicine Online2005;11(2):189‐93. MarciR , CasertaD , FarinaM , DessoleS , GermondM , TatoneC , et al. The use of GnRH antagonist in ovarian stimulation for IVF cycles can achieve good pregnancy rates in poor responder patients. Human Reproduction (Oxford, England)2002;17:115‐6. ">Marci 2005</a>; <a href="./references#CD001750-bbs2-0052" title="MohamedKA , DaviesWAR , LashenH . Effect of gonadotropin‐releasing hormone agonist and antagonist on steroidogenesis of low responders undergoing in vitro fertilization. Gynecological Endocrinology2006;22(2):57‐62. ">Mohamed 2006</a>; <a href="./references#CD001750-bbs2-0053" title="MoralogluO , KilicS , KarayalçinR , YukselB , TasdemirN , UgurM . Comparison of GnRH agonists and antagonists in normo‐responder IVF/ICSI in Turkish female patients. Advances in Therapy2008;25(3):266‐73. ">Moraloglu 2008</a>; <a href="./references#CD001750-bbs2-0054" title="MoshinV , CroitorM , HotineanuA . GnRH antagonist versus long GnRH agonists protocol in PCOS patients undergoing IVF treatment. Abstracts of the 23rd Annual Meeting of the ESHRE, Lyon, France2007;22 Suppl 1:i121. ">Moshin 2007</a>; <a href="./references#CD001750-bbs2-0055" title="OlivennesF , Belaisch‐Allart , EmperareJ , DechaudH , S Alvarez S , MoreauL . Prospective randomized, controlled study of in vitro fertilization‐embryo transfer with a single dose of a luteinizing hormone‐releasing hormone (LH‐RH) antagonist (cetrorelix) or a depot formula of an LH‐RH agonist (triptorelin). Fertility and Sterility2000;73(2):314‐20. ">Olivennes 2000</a>; <a href="./references#CD001750-bbs2-0059" title="RabatiBK , ZeidiSN . Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin‐releasing hormone protocol. Journal of Research in Medical Sciences2012;17(11):1063‐6. ">Rabati 2012</a>; <a href="./references#CD001750-bbs2-0060" title="RevelliA , ChiadòA , DalmassoP , StabileV , EvangelistaF , BassoG , et al. “Mild” vs. “long” protocol for controlled ovarian hyperstimulation in patients with expected poor ovarian responsiveness undergoing in vitro fertilization (IVF): a large prospective randomized trial. Journal of Assisted Reproduction and GeneticsJuly 2014;31(7):809‐15. [DOI: 10.1007/s10815‐014‐0227‐y] ">Revelli 2014</a>; <a href="./references#CD001750-bbs2-0061" title="RinaldiL , LisiF , SelmanH . Mild/minimal stimulation protocol for ovarian stimulation of patients at high risk of developing ovarian hyperstimulation syndrome. Journal of Endocrinological Investigation2014;37:65‐70. ">Rinaldi 2014</a>; <a href="./references#CD001750-bbs2-0063" title="SauerMV , ThorntonMH , SchoolcraftW , FrishmanGN . Comparative efficacy and safety of cetrorelix with or without mid‐cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reproductive Biomedicine Online2004;9(5):487‐93. ">Sauer 2004</a>; <a href="./references#CD001750-bbs2-0064" title="SbraciaM , ColabianchiJ , GiallonardoA , GianniniP , PiscitelliC , MorgiaF , et al. Cetrorelix protocol versus gonadotropin‐releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40. Fertility and Sterility2009;91(5):1842‐7. ">Sbracia 2009</a>; <a href="./references#CD001750-bbs2-0065" title="SerafiniP , YadidI , AlegrettiJ , PanzanM , CosloversuskyM , MottaE . A prospective, randomized trial of three ovulation induction protocols for IVF including a novel approach with low‐dose HCG and GnRH antagonist in the mid‐late follicular phase. Human Reproduction (Oxford, England)2003;18:1. SerafiniP , YadidI , MottaELA , AlegrettiJR , FioavantiJ , CoslovskyM . Ovarian stimulation with daily late follicular phase administration of low dose human chorionic gonadotropin for in vitro fertilization: a prospective randomized trial. Fertility and Sterility2006;86(4):830‐8. ">Serafini 2008</a>; <a href="./references#CD001750-bbs2-0067" title="SunkaraS , CoomarasamyA , FarisR , BraudeP , KhalafY . Effectiveness of the GnRH agonist long, GnRH agonist short and GnRH antagonist regimens in poor responders undergoing IVF treatment: a three arm randomised controlled trial. Human Reproduction. 2013; Vol. 28:i348. SunkaraSK , CoomarasamyA , FarisR , BraudeP , KhalafY . Long gonadotropin‐releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: A randomized controlled trial. Fertility and Sterility2014;101(1):147‐53. ">Sunkara 2014</a>; <a href="./references#CD001750-bbs2-0069" title="TehraninejadES , NasiriR , RashidiB , HaghollahiF , AtaieM . Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients. Archives of Gynecology and Obstetrics2010;282(3):319‐25. ">Tehraninejad 2010</a>; <a href="./references#CD001750-bbs2-0070" title="NezamabadiAG , TehraninejadES , RashidiB . GnRH Antagonist versus Agonist in Normoresponders Undergoing ICSI: A Randomized Clinical Trial in Iran. International Journal of Fertility and Sterility2013;7(1):106. TehraninejadE , NezamabadiAG , RashidiB , SohrabiM , BagheriM , HaghollahiF , et al. GnRH antagonist versus agonist in normoresponders undergoing ICSI: a randomized clinical trial in Iran. Iranian Journal of Reproductive Medicine2011;9(3):171‐6. [IRCT138902283950N1]] ">Tehraninejad 2011</a>; <a href="./references#CD001750-bbs2-0072" title="XavierP , GamboaC , CalejoL , SilvaJ , StevensonD , NunesA , et al. A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy. Eurpean Journal of Obstetrics, Gynecology, and Reproductive Biology2005;120(2):185‐9. [MEDLINE: 15925049] ">Xavier 2005</a>; <a href="./references#CD001750-bbs2-0073" title="YeH , HuangG , ZengP , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;2(3):105‐11. ">Ye 2009</a>). In 19 trials, the antagonist ganirelix was administered (<a href="./references#CD001750-bbs2-0005" title="BaartEB , MartiniE , EijkemansMJ , VanOpstalD , BeckersNGM , VerhoeffA , et al. Milder ovarian stimulation for in‐vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Human Reproduction2007;22(4):980‐8. ">Baart 2007</a>; <a href="./references#CD001750-bbs2-0006" title="BadrawiA , Al‐InanyH , HusseinM , ZakiS , RamzyAM . Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis. Middle East Fertility Society Journal2005;10(1):49‐54. ">Badrawi 2005</a>; <a href="./references#CD001750-bbs2-0008" title="BarmatLI , ChantilisSJ , HurstBS , DickeyRP . A randomized prospective trial comparing gonadotropin‐releasing hormone (GnRH) antagonist/recombinant follicle‐stimulating hormone (r FSH) versus GnRH‐agonist/r FSH in women pretreated with oral contraceptives before in vitro fertilization. Fertility and Sterility2005;83(2):321‐30. [MEDLINE: 15705369] ">Barmat 2005</a>; <a href="./references#CD001750-bbs2-0011" title="CheckML , CheckJH , ChoelJK , DaviesE , KieferD . Effect of antagonists vs agonists on in vitro fertilization outcome. Clinical and Experimental Obstetrics &amp; Gynecology2004;31(4):257‐9. [MEDLINE: 15672958] ">Check 2004</a>; <a href="./references#CD001750-bbs2-0017" title="EngmannL , DiLuigiA , SchmidtD , NulsenD , NulsenJ , BenadivaC . The use of gonadotropin‐releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high‐risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospsective randomised controlled study. Fertility and Sterility2008;89(1):84‐91. ">Engmann 2008a</a>; <a href="./references#CD001750-bbs2-0018" title="European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction (Oxford, England)2001;16(4):644‐51. [MEDLINE: 11278211] SonntagB , KieselL , NieschlagE , BehreHM . Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing GnRH agonist versus antagonist protocols for ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics2004;21(7):249‐55. ">Euro Middle East 2001</a>; <a href="./references#CD001750-bbs2-0019" title="The European Orgalutran Study Group, BormG , MannaertsB . Treatment with the gonadotrophin‐releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction (Oxford, England) 15;7:1490‐8. ">Euro Orgalutran 2000</a>; <a href="./references#CD001750-bbs2-0022" title="FirouzabadiRD , AhmadiS , OskouianH , DavarR . Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART. Archives of Gynecology and Obstetrics2010;281(1):81‐5. [PUBMED: PMID: 19357861 ] ">Firouzabadi 2010</a>; <a href="./references#CD001750-bbs2-0023" title="FlukerM , GrifoJ , LeaderA , LevyM , MeldrumD , MuasherSJ , et al. for The North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility2001;75(1):38‐45. ">Fluker 2001</a>; <a href="./references#CD001750-bbs2-0024" title="Franco JrJG , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH After 2nd phase protocols with GnRH Analogs (I‐estradiol + ganirelix versus II‐nafarelin) [Comparacao da estimulacao ovariana com FSH recombinante apos protocolo de 2A fase com analogos do GNRH (I ‐estradiol + ganirelix versus II‐nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco 2003</a>; <a href="./references#CD001750-bbs2-0026" title="GizzoS , AndrisaniA , EspositoF , NoventaM , DiGangiS , AngioniS , et al. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial. Gynecological Endocrinology2014;30(12):902‐8. [DOI: 10.3109/09513590.2014.964638] ">Gizzo 2014</a>; <a href="./references#CD001750-bbs2-0027" title="HaydardedeogluB , KilicdagEB , ParlakgumusAH , ZeynelogluHB . IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial. Archives of Gynecology and ObstetricsSeptember 2012;286(3):763‐769. ">Haydardedeoglu 2012</a>; <a href="./references#CD001750-bbs2-0037" title="KarimzadehMA , AhmadiS , OskouianH , RahmaniE . Comparison of mild stimulation and conventional stimulation in ART outcome. Archives of Gynecology and Obstetrics2010;281(4):741‐6. ">Karimzadeh 2010</a>; <a href="./references#CD001750-bbs2-0044" title="LainasTG , PetsasGK , ZorovilisIZ , LliadisGS , LainasGT , GazlarisHE , et al. Initiation of GnRH antagonist on day 1 of stimulation as compared to the long agonist protocol in PCOS patients: a randomised controlled trial: effect on hormonal levels and follicular development. Human Reproduction2007;22(6):1540‐6. ">Lainas 2007</a>; <a href="./references#CD001750-bbs2-0051" title="MartínezF , CluaE , PareraN , RodríguezI , BoadaM , CoroleuB . Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle‐stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients. Gynecological Endocrinology2008;24(4):188‐93. ">Martinez 2008</a>; <a href="./references#CD001750-bbs2-0057" title="PrapasY , PetousisS , DagklisT , PanagiotidisY , PapatheodorouA , AssuntaI , et al. GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2013;166(1):43‐6. ">Prapas 2013</a>; <a href="./references#CD001750-bbs2-0058" title="QiaoJ , LuG , ZhangHW , ChenH , MaC , OlofssonJI , et al. A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates. Gynecological Endocrinology2012;28(10):800‐4. ">Qiao 2012</a>; <a href="./references#CD001750-bbs2-0062" title="RombautsL , HealyD , NormanRJ . A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction (Oxford, England)2006;21(1):95‐103. ">Rombauts 2006</a>; <a href="./references#CD001750-bbs2-0066" title="StenbaekDS , ToftagerM , HjordtLV , JensenPS , HolstKK , BryndorfT , et al. Mental distress and personality in women undergoing GnRH agonist versus GnRH antagonist protocols for assisted reproductive technology. Human Reproduction2015;30(1):103‐10. ">Stenbaek 2015</a>). Three trials used both cetrorelix and ganirelix (<a href="./references#CD001750-bbs2-0013" title="ChoiMH , KimHO , ChaSW , KoongMKK , KimJY , ParkCW . IVF comparison of ART outcomes in infertile PCOS women; in vitro maturation (IVM) vs. GnRH agonist vs. GnRH antagonist cycles. Clinical Experimental Reproductive MedicineDecember 2012;39(4):S210. ChoiMH , LeeSH , KimHO , ChaSH , KimJY , YangKM , et al. Comparison of assisted reproductive technology outcomes in infertile women with polycystic ovary syndrome: In vitro maturation, GnRH agonist, and GnRH antagonist cycles. Clinical &amp; Experimental Reproductive Medicine2012;39(4):166‐71. ">Choi 2012</a>; <a href="./references#CD001750-bbs2-0056" title="PapanikolaouEG , PadosG , GrimbizisG , BiliE , KyriaziL , PolyzosNP , et al. GnRH‐agonist versus GnRH‐antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study. Human Reproduction2012;27(6):1822‐8. ">Papanikolaou 2012</a>; <a href="./references#CD001750-bbs2-0068" title="TazegülA , GörkemliH , OzdemirS , AktanTM . Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial. Archives of Gynecology and Obstetrics2008;278(5):467‐72. ">Tazegul 2008</a>) and in seven included trials the type of antagonist used was unclear (<a href="./references#CD001750-bbs2-0003" title="AndersonS , PereiraNE , BrasileDR , OrrisJJ , DaviesEB , GlassnerMJ . Comparison of antagonist to agonist in controlled ovarian stimulation (COS) cycles using human‐derived gonadotropin on in vitro fertilization (IVF) outcomes. A prospective randomized controlled study. Fertility and sterility. 2014; Vol. 102 (3; Suppl 1):e224. ">Anderson 2014</a>; <a href="./references#CD001750-bbs2-0004" title="AwataS , TanakaA , NagayoshiM . Selection of an optimal controlled ovarian hyperstimulation method in relation to the number of antral follicles in patients less than 40 years old. Fertility and Sterility2010;94 suppl 1(4):S164 Abstract no. P‐244. ">Awata 2010</a>; <a href="./references#CD001750-bbs2-0010" title="CelikN , CelikO , AktanE , OzerolE , CelikE , BozkurtK , et al. Plasma urocortin levels in women undergoing long agonist and antagonist protocols for IVF. Human Reproduction2011;26(1):i203. ">Celik 2011</a>; <a href="./references#CD001750-bbs2-0025" title="FriedlerS , GilboaS , SchachterM , RazielR , StrassburgerD , KastersteinE , et al. Luteal phase characteristics following GnRH antagonist or agonist treatment: a randomized comparative study. Human Reproduction (Oxford, England)2003;18 Suppl 1:26. ">Friedler 2003</a>; <a href="./references#CD001750-bbs2-0028" title="HeijnenEM , EijkemansMJ , DeKlerkC , PolinderS , BeckersNG , KlinkertER , et al. A mild treatment strategy for in‐vitro fertilisation: a randomised non‐inferiority trial. The Lancet2007;369:743‐9. ">Heijnen 2007</a>; <a href="./references#CD001750-bbs2-0036" title="InzaR , VanThilloG , LombardiE , BisioliC , DiradourianM , KennyA . Reproductive performance in second IVF cycles treated with the use of either GnRH antagonists (‐antag) vs GnRH agonists (‐ag) after failure with long protocols with GnRH agonists: a prospective randomized trial. Fertility and Sterility2004;82 Suppl:233‐4. ">Inza 2004</a>; <a href="./references#CD001750-bbs2-0071" title="ToltagerM , BogstadJ , Lossl , K , et al. Pregnancy rates and risk of ovarian hyperstimulation syndrome (OHSS) in a fixed GnRH‐antagonist versus GnRH‐agonist protocol: randomised controlled trial including 1099 first IVF/ICSI CYCLES. Abstract of the 31st annual meeting of ESHRE I Lisbon, Portigal. 2015:i94. ">Toltager 2015</a>). </p> </li> <li> <p>Oral contraceptive pill pre‐treatment was used in 18 studies (<a href="./references#CD001750-bbs2-0008" title="BarmatLI , ChantilisSJ , HurstBS , DickeyRP . A randomized prospective trial comparing gonadotropin‐releasing hormone (GnRH) antagonist/recombinant follicle‐stimulating hormone (r FSH) versus GnRH‐agonist/r FSH in women pretreated with oral contraceptives before in vitro fertilization. Fertility and Sterility2005;83(2):321‐30. [MEDLINE: 15705369] ">Barmat 2005</a>; <a href="./references#CD001750-bbs2-0012" title="CheungLP , LamPM , LokIH , ChiuTT , YeungSY , TjerCC , et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Human Reproduction (Oxford, England)2005;20(3):616‐21. [MEDLINE: 15608037] ">Cheung 2005</a>; <a href="./references#CD001750-bbs2-0017" title="EngmannL , DiLuigiA , SchmidtD , NulsenD , NulsenJ , BenadivaC . The use of gonadotropin‐releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high‐risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospsective randomised controlled study. Fertility and Sterility2008;89(1):84‐91. ">Engmann 2008a</a>; <a href="./references#CD001750-bbs2-0027" title="HaydardedeogluB , KilicdagEB , ParlakgumusAH , ZeynelogluHB . IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial. Archives of Gynecology and ObstetricsSeptember 2012;286(3):763‐769. ">Haydardedeoglu 2012</a>; <a href="./references#CD001750-bbs2-0029" title="Hershko KlementA , BerkovitzA , WiserA , GonenO , AmichayK , CohenI , et al. GnRH‐antagonist programming versus GnRH agonist protocol: a randomized trial. European Journal of Obstetrics Gynecology and Reproductive Biology2015;185:170‐3. Hershko KlementA , BerkovitzA , WiserA , GonenO , AmichayK , ShulmanA . Follicular estrogen for GnRH‐antagonist protocol programming: a prospective randomized clinical trial. Fertility and Sterility. 2013; Vol. 1:S523. ">Hershko Klement 2015</a>; <a href="./references#CD001750-bbs2-0032" title="HosseiniMA , AleyasinA , SaeediH , MahdaviA . Comparison of gonadotropin‐releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients. Journal of Obstetrics &amp; Gynaecology Research2010;36(3):605‐10. ">Hosseini 2010</a>; <a href="./references#CD001750-bbs2-0034" title="HuirneJA , VanLoenenAC , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. ">Huirne 2006</a>; <a href="./references#CD001750-bbs2-0039" title="KimC‐H , LeeY‐J , HongS‐H , NahH‐Y , KimS‐H , ChaeH‐D , et al. Efficacy of a GnRH antagonist during early and late controlled ovarian hyperstimulation period in women with polycystic ovary syndrome undergoing IVF‐ET. Human Reproduction (Oxford, England)2004;19:i104‐5. ">Kim 2004</a>; <a href="./references#CD001750-bbs2-0040" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐K , AhnJ‐W , JeonI , LeeJ‐W , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Abstracts of the 21st Annual Meeting of the ESHRE. Copenhagen, Denmark, 2005. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD001750-bbs2-0041" title="KimC‐H , MoonJ‐W , KangH‐J , AhnJ‐W , KimS‐H , ChaeH‐D , et al. Effectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase compared with GnRH agonist long protocol in non‐obese and obese patients with polycystic ovary syndrome undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2012;39(1):22‐7. ">Kim 2012</a>; <a href="./references#CD001750-bbs2-0042" title="KurzawaR , CiepielaP , BaczkowskiT , SafranowK , BrelikP . Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non‐obese patients. A prospective randomized study. Journal for Assisted Reproduction and Genetics2008;25(8):365‐74. ">Kurzawa 2008</a>; <a href="./references#CD001750-bbs2-0043" title="KyonoK , FuchinoueK , NakajoY , YagiA , SasakiK . A prospective randomized study of three ovulation induction protocols for IVF: GnRH agonist versus antagonist with and without low dose hCG. Fertility and Sterility2004;82 Suppl:31. KyonoK , NakajoY , SasakiS , KumagaiS , SuzukiS . A prospective randomized study of three different controlled ovarian hyperstimulation (COH) protocols. Fertility and Sterility2005;84 Suppl 1:299. ">Kyono 2005</a>; <a href="./references#CD001750-bbs2-0044" title="LainasTG , PetsasGK , ZorovilisIZ , LliadisGS , LainasGT , GazlarisHE , et al. Initiation of GnRH antagonist on day 1 of stimulation as compared to the long agonist protocol in PCOS patients: a randomised controlled trial: effect on hormonal levels and follicular development. Human Reproduction2007;22(6):1540‐6. ">Lainas 2007</a>; <a href="./references#CD001750-bbs2-0045" title="BaslyM , AchourR , Ben JemaaS , ChnitirM , MessaoudiL , ChibaniM , et al. Flexible Gnrh antagonist protocol versus Gnrh agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Internet Journal of Gynecology &amp; Obstetrics2012;16(3):1. LainasTG , SfontourisIA , ZorzovilisIZ , PetsasGK , LainasGT , AlexopoulouE , et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Human Reproduction2010;25(3):683‐9. ">Lainas 2010</a>; <a href="./references#CD001750-bbs2-0053" title="MoralogluO , KilicS , KarayalçinR , YukselB , TasdemirN , UgurM . Comparison of GnRH agonists and antagonists in normo‐responder IVF/ICSI in Turkish female patients. Advances in Therapy2008;25(3):266‐73. ">Moraloglu 2008</a>; <a href="./references#CD001750-bbs2-0062" title="RombautsL , HealyD , NormanRJ . A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction (Oxford, England)2006;21(1):95‐103. ">Rombauts 2006</a>; <a href="./references#CD001750-bbs2-0063" title="SauerMV , ThorntonMH , SchoolcraftW , FrishmanGN . Comparative efficacy and safety of cetrorelix with or without mid‐cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reproductive Biomedicine Online2004;9(5):487‐93. ">Sauer 2004</a>; <a href="./references#CD001750-bbs2-0069" title="TehraninejadES , NasiriR , RashidiB , HaghollahiF , AtaieM . Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients. Archives of Gynecology and Obstetrics2010;282(3):319‐25. ">Tehraninejad 2010</a>). Further single trials used Diane (<a href="./references#CD001750-bbs2-0035" title="HwangJL , SeowK , LinY , HuangL , HsiehB , TsaiY , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. ">Hwang 2004</a>), estradiol in the luteal phase (<a href="./references#CD001750-bbs2-0024" title="Franco JrJG , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH After 2nd phase protocols with GnRH Analogs (I‐estradiol + ganirelix versus II‐nafarelin) [Comparacao da estimulacao ovariana com FSH recombinante apos protocolo de 2A fase com analogos do GNRH (I ‐estradiol + ganirelix versus II‐nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco 2003</a>), and vaginal Nuvaring (<a href="./references#CD001750-bbs2-0051" title="MartínezF , CluaE , PareraN , RodríguezI , BoadaM , CoroleuB . Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle‐stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients. Gynecological Endocrinology2008;24(4):188‐93. ">Martinez 2008</a>). </p> </li> <li> <p>Women randomised to treatment with GnRH antagonist started ovarian stimulation on day two to three of the menstrual cycle. The GnRH antagonist was started on stimulation day six, by daily subcutaneous administration up to and including the day of human chorionic gonadotrophin (hCG) administration in the fixed protocol or depending on the dominant follicle size in the flexible protocol.The GnRH long agonist reference treatment was started in the mid‐luteal phase (cycle day 21 to 24) by either daily intranasal or subcutaneous administration. </p> </li> <li> <p>Ovarian stimulation was started after two weeks if pituitary down‐regulation was established (serum estradiol level &lt; 50 pg/ml). In both treatment groups, ovarian stimulation was started with a fixed daily dose of 150 IU or 225 IU recombinant follicle stimulating hormone (rFSH) or human menopausal gonadotrophin (hMG) for the first five stimulation days. Thereafter, the dose of FSH was adapted depending on the ovarian response, as monitored via ultrasonography (US). Triggering of ovulation was induced with hCG (10,000 IU) if at least three follicles that were more than 17 mm in diameter were observed by US. </p> </li> <li> <p>Trigger used: the majority of the included studies used hCG trigger or did not state which trigger was used; one of the included studies used a combination of both hCG and GnRH agonist as trigger agents (<a href="./references#CD001750-bbs2-0017" title="EngmannL , DiLuigiA , SchmidtD , NulsenD , NulsenJ , BenadivaC . The use of gonadotropin‐releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high‐risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospsective randomised controlled study. Fertility and Sterility2008;89(1):84‐91. ">Engmann 2008a</a>). </p> </li> </ul> </p> </section> <section id="CD001750-sec-0060"> <h5 class="title">Outcomes</h5> <p> <ul id="CD001750-list-0014"> <li> <p>Study participant follow up: the optimum follow up would be to report on the number of single, healthy babies going home with their parents (for example single, live, take‐home baby rate). If unavailable, other follow ups were assessed including the live birth rate (LBR) and ongoing pregnancy rate (OPR). None of the included trials described the single, live, take‐home baby rate or the take‐home baby rate. Twelve studies reported on the LBR (<a href="./references#CD001750-bbs2-0001" title="AlbanoC , FelberbaumR , SmitzJ , Riethmuller‐WinzenH , EngelJ , DiedrichK , et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone‐releasing hormone (LHRH)‐antagonist cetrorelix and the LHRH‐agonist buserlin. Human Reproduction2000;15(3):526‐31. LudwigM , FelberbaumRE , DevroeyP , AlbanoC , Riethmuller‐WinzenH , SchulerA , et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Archives of Gynecology and Obstetrics2000;264(1):29‐32. ">Albano 2000</a>; <a href="./references#CD001750-bbs2-0005" title="BaartEB , MartiniE , EijkemansMJ , VanOpstalD , BeckersNGM , VerhoeffA , et al. Milder ovarian stimulation for in‐vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Human Reproduction2007;22(4):980‐8. ">Baart 2007</a>; <a href="./references#CD001750-bbs2-0008" title="BarmatLI , ChantilisSJ , HurstBS , DickeyRP . A randomized prospective trial comparing gonadotropin‐releasing hormone (GnRH) antagonist/recombinant follicle‐stimulating hormone (r FSH) versus GnRH‐agonist/r FSH in women pretreated with oral contraceptives before in vitro fertilization. Fertility and Sterility2005;83(2):321‐30. [MEDLINE: 15705369] ">Barmat 2005</a>; <a href="./references#CD001750-bbs2-0028" title="HeijnenEM , EijkemansMJ , DeKlerkC , PolinderS , BeckersNG , KlinkertER , et al. A mild treatment strategy for in‐vitro fertilisation: a randomised non‐inferiority trial. The Lancet2007;369:743‐9. ">Heijnen 2007</a>; <a href="./references#CD001750-bbs2-0040" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐K , AhnJ‐W , JeonI , LeeJ‐W , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Abstracts of the 21st Annual Meeting of the ESHRE. Copenhagen, Denmark, 2005. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD001750-bbs2-0041" title="KimC‐H , MoonJ‐W , KangH‐J , AhnJ‐W , KimS‐H , ChaeH‐D , et al. Effectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase compared with GnRH agonist long protocol in non‐obese and obese patients with polycystic ovary syndrome undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2012;39(1):22‐7. ">Kim 2012</a>; <a href="./references#CD001750-bbs2-0042" title="KurzawaR , CiepielaP , BaczkowskiT , SafranowK , BrelikP . Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non‐obese patients. A prospective randomized study. Journal for Assisted Reproduction and Genetics2008;25(8):365‐74. ">Kurzawa 2008</a>; <a href="./references#CD001750-bbs2-0048" title="LinYH , HwangJL , SeowKM , HuangLW , HsiehBC , TzengCR . Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol ‐ a randomized study. Gynecological Endocrinology2006;22(6):297‐302. ">Lin 2006</a>; <a href="./references#CD001750-bbs2-0050" title="MarciR , CasertaD , DoloV , TatoneC , PavanA , MoscariniM . GnRH antagonist in IVF poor‐responder patients: results of a randomized trial. Reproductive Biomedicine Online2005;11(2):189‐93. MarciR , CasertaD , FarinaM , DessoleS , GermondM , TatoneC , et al. The use of GnRH antagonist in ovarian stimulation for IVF cycles can achieve good pregnancy rates in poor responder patients. Human Reproduction (Oxford, England)2002;17:115‐6. ">Marci 2005</a>; <a href="./references#CD001750-bbs2-0056" title="PapanikolaouEG , PadosG , GrimbizisG , BiliE , KyriaziL , PolyzosNP , et al. GnRH‐agonist versus GnRH‐antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study. Human Reproduction2012;27(6):1822‐8. ">Papanikolaou 2012</a>; <a href="./references#CD001750-bbs2-0061" title="RinaldiL , LisiF , SelmanH . Mild/minimal stimulation protocol for ovarian stimulation of patients at high risk of developing ovarian hyperstimulation syndrome. Journal of Endocrinological Investigation2014;37:65‐70. ">Rinaldi 2014</a>; <a href="./references#CD001750-bbs2-0073" title="YeH , HuangG , ZengP , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;2(3):105‐11. ">Ye 2009</a>). Further, 36 trials reported the OPR and 55 studies reported the clinical pregnancy rate (CPR). </p> </li> <li> <p>Thirty‐six studies reported OHSS incidence (<a href="./references#CD001750-bbs2-0001" title="AlbanoC , FelberbaumR , SmitzJ , Riethmuller‐WinzenH , EngelJ , DiedrichK , et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone‐releasing hormone (LHRH)‐antagonist cetrorelix and the LHRH‐agonist buserlin. Human Reproduction2000;15(3):526‐31. LudwigM , FelberbaumRE , DevroeyP , AlbanoC , Riethmuller‐WinzenH , SchulerA , et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Archives of Gynecology and Obstetrics2000;264(1):29‐32. ">Albano 2000</a>; <a href="./references#CD001750-bbs2-0006" title="BadrawiA , Al‐InanyH , HusseinM , ZakiS , RamzyAM . Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis. Middle East Fertility Society Journal2005;10(1):49‐54. ">Badrawi 2005</a>; <a href="./references#CD001750-bbs2-0007" title="BahceciM , UlugU , Ben‐ShlomoI , ErdenHF , AkmanMA . Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. Journal of Reproductive Medicine2005;50(2):84‐90. [MEDLINE: 15755044] ">Bahceci 2005</a>; <a href="./references#CD001750-bbs2-0008" title="BarmatLI , ChantilisSJ , HurstBS , DickeyRP . A randomized prospective trial comparing gonadotropin‐releasing hormone (GnRH) antagonist/recombinant follicle‐stimulating hormone (r FSH) versus GnRH‐agonist/r FSH in women pretreated with oral contraceptives before in vitro fertilization. Fertility and Sterility2005;83(2):321‐30. [MEDLINE: 15705369] ">Barmat 2005</a>; <a href="./references#CD001750-bbs2-0017" title="EngmannL , DiLuigiA , SchmidtD , NulsenD , NulsenJ , BenadivaC . The use of gonadotropin‐releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high‐risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospsective randomised controlled study. Fertility and Sterility2008;89(1):84‐91. ">Engmann 2008a</a>; <a href="./references#CD001750-bbs2-0018" title="European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction (Oxford, England)2001;16(4):644‐51. [MEDLINE: 11278211] SonntagB , KieselL , NieschlagE , BehreHM . Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing GnRH agonist versus antagonist protocols for ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics2004;21(7):249‐55. ">Euro Middle East 2001</a>; <a href="./references#CD001750-bbs2-0019" title="The European Orgalutran Study Group, BormG , MannaertsB . Treatment with the gonadotrophin‐releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction (Oxford, England) 15;7:1490‐8. ">Euro Orgalutran 2000</a>; <a href="./references#CD001750-bbs2-0022" title="FirouzabadiRD , AhmadiS , OskouianH , DavarR . Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART. Archives of Gynecology and Obstetrics2010;281(1):81‐5. [PUBMED: PMID: 19357861 ] ">Firouzabadi 2010</a>; <a href="./references#CD001750-bbs2-0023" title="FlukerM , GrifoJ , LeaderA , LevyM , MeldrumD , MuasherSJ , et al. for The North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility2001;75(1):38‐45. ">Fluker 2001</a>; <a href="./references#CD001750-bbs2-0027" title="HaydardedeogluB , KilicdagEB , ParlakgumusAH , ZeynelogluHB . IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial. Archives of Gynecology and ObstetricsSeptember 2012;286(3):763‐769. ">Haydardedeoglu 2012</a>; <a href="./references#CD001750-bbs2-0028" title="HeijnenEM , EijkemansMJ , DeKlerkC , PolinderS , BeckersNG , KlinkertER , et al. A mild treatment strategy for in‐vitro fertilisation: a randomised non‐inferiority trial. The Lancet2007;369:743‐9. ">Heijnen 2007</a>; <a href="./references#CD001750-bbs2-0030" title="HohmannFP , MacklonNS , FauserBC . A randomized comparison of two ovarian stimulation protocols with gonadotropin‐releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle‐stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. The Journal of Clinical Endocrinology and Metabolism2003;88(1):166‐73. ">Hohmann 2003</a>; <a href="./references#CD001750-bbs2-0032" title="HosseiniMA , AleyasinA , SaeediH , MahdaviA . Comparison of gonadotropin‐releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients. Journal of Obstetrics &amp; Gynaecology Research2010;36(3):605‐10. ">Hosseini 2010</a>; <a href="./references#CD001750-bbs2-0033" title="HsiehYY , ChangCC , TsaiHD . Comparisons of different dosages of gonadotropin‐releasing hormone (GnRH) antagonist, short‐acting form and single, half‐dose, long‐acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. Taiwan Journal of Obstetrics and Gynecology2008;47:66‐74. ">Hsieh 2008</a>; <a href="./references#CD001750-bbs2-0034" title="HuirneJA , VanLoenenAC , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. ">Huirne 2006</a>; <a href="./references#CD001750-bbs2-0035" title="HwangJL , SeowK , LinY , HuangL , HsiehB , TsaiY , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. ">Hwang 2004</a>; <a href="./references#CD001750-bbs2-0037" title="KarimzadehMA , AhmadiS , OskouianH , RahmaniE . Comparison of mild stimulation and conventional stimulation in ART outcome. Archives of Gynecology and Obstetrics2010;281(4):741‐6. ">Karimzadeh 2010</a>; <a href="./references#CD001750-bbs2-0041" title="KimC‐H , MoonJ‐W , KangH‐J , AhnJ‐W , KimS‐H , ChaeH‐D , et al. Effectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase compared with GnRH agonist long protocol in non‐obese and obese patients with polycystic ovary syndrome undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2012;39(1):22‐7. ">Kim 2012</a>; <a href="./references#CD001750-bbs2-0042" title="KurzawaR , CiepielaP , BaczkowskiT , SafranowK , BrelikP . Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non‐obese patients. A prospective randomized study. Journal for Assisted Reproduction and Genetics2008;25(8):365‐74. ">Kurzawa 2008</a>; <a href="./references#CD001750-bbs2-0043" title="KyonoK , FuchinoueK , NakajoY , YagiA , SasakiK . A prospective randomized study of three ovulation induction protocols for IVF: GnRH agonist versus antagonist with and without low dose hCG. Fertility and Sterility2004;82 Suppl:31. KyonoK , NakajoY , SasakiS , KumagaiS , SuzukiS . A prospective randomized study of three different controlled ovarian hyperstimulation (COH) protocols. Fertility and Sterility2005;84 Suppl 1:299. ">Kyono 2005</a>; <a href="./references#CD001750-bbs2-0044" title="LainasTG , PetsasGK , ZorovilisIZ , LliadisGS , LainasGT , GazlarisHE , et al. Initiation of GnRH antagonist on day 1 of stimulation as compared to the long agonist protocol in PCOS patients: a randomised controlled trial: effect on hormonal levels and follicular development. Human Reproduction2007;22(6):1540‐6. ">Lainas 2007</a>; <a href="./references#CD001750-bbs2-0045" title="BaslyM , AchourR , Ben JemaaS , ChnitirM , MessaoudiL , ChibaniM , et al. Flexible Gnrh antagonist protocol versus Gnrh agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Internet Journal of Gynecology &amp; Obstetrics2012;16(3):1. LainasTG , SfontourisIA , ZorzovilisIZ , PetsasGK , LainasGT , AlexopoulouE , et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Human Reproduction2010;25(3):683‐9. ">Lainas 2010</a>; <a href="./references#CD001750-bbs2-0047" title="LeeTH , WuMH , ChenHF , ChenMJ , HoHN , YangYS . Ovarian response and follicular development for single‐dose and multiple‐dose protocols for gonadotropin‐releasing hormone antagonist administration. Fertility and Sterility2005;83(6):1700‐7. ">Lee 2005</a>; <a href="./references#CD001750-bbs2-0048" title="LinYH , HwangJL , SeowKM , HuangLW , HsiehBC , TzengCR . Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol ‐ a randomized study. Gynecological Endocrinology2006;22(6):297‐302. ">Lin 2006</a>; <a href="./references#CD001750-bbs2-0053" title="MoralogluO , KilicS , KarayalçinR , YukselB , TasdemirN , UgurM . Comparison of GnRH agonists and antagonists in normo‐responder IVF/ICSI in Turkish female patients. Advances in Therapy2008;25(3):266‐73. ">Moraloglu 2008</a>; <a href="./references#CD001750-bbs2-0054" title="MoshinV , CroitorM , HotineanuA . GnRH antagonist versus long GnRH agonists protocol in PCOS patients undergoing IVF treatment. Abstracts of the 23rd Annual Meeting of the ESHRE, Lyon, France2007;22 Suppl 1:i121. ">Moshin 2007</a>; <a href="./references#CD001750-bbs2-0055" title="OlivennesF , Belaisch‐Allart , EmperareJ , DechaudH , S Alvarez S , MoreauL . Prospective randomized, controlled study of in vitro fertilization‐embryo transfer with a single dose of a luteinizing hormone‐releasing hormone (LH‐RH) antagonist (cetrorelix) or a depot formula of an LH‐RH agonist (triptorelin). Fertility and Sterility2000;73(2):314‐20. ">Olivennes 2000</a>; <a href="./references#CD001750-bbs2-0056" title="PapanikolaouEG , PadosG , GrimbizisG , BiliE , KyriaziL , PolyzosNP , et al. GnRH‐agonist versus GnRH‐antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study. Human Reproduction2012;27(6):1822‐8. ">Papanikolaou 2012</a>; <a href="./references#CD001750-bbs2-0058" title="QiaoJ , LuG , ZhangHW , ChenH , MaC , OlofssonJI , et al. A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates. Gynecological Endocrinology2012;28(10):800‐4. ">Qiao 2012</a>; <a href="./references#CD001750-bbs2-0059" title="RabatiBK , ZeidiSN . Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin‐releasing hormone protocol. Journal of Research in Medical Sciences2012;17(11):1063‐6. ">Rabati 2012</a>; <a href="./references#CD001750-bbs2-0062" title="RombautsL , HealyD , NormanRJ . A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction (Oxford, England)2006;21(1):95‐103. ">Rombauts 2006</a>; <a href="./references#CD001750-bbs2-0065" title="SerafiniP , YadidI , AlegrettiJ , PanzanM , CosloversuskyM , MottaE . A prospective, randomized trial of three ovulation induction protocols for IVF including a novel approach with low‐dose HCG and GnRH antagonist in the mid‐late follicular phase. Human Reproduction (Oxford, England)2003;18:1. SerafiniP , YadidI , MottaELA , AlegrettiJR , FioavantiJ , CoslovskyM . Ovarian stimulation with daily late follicular phase administration of low dose human chorionic gonadotropin for in vitro fertilization: a prospective randomized trial. Fertility and Sterility2006;86(4):830‐8. ">Serafini 2008</a>; <a href="./references#CD001750-bbs2-0069" title="TehraninejadES , NasiriR , RashidiB , HaghollahiF , AtaieM . Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients. Archives of Gynecology and Obstetrics2010;282(3):319‐25. ">Tehraninejad 2010</a>; <a href="./references#CD001750-bbs2-0071" title="ToltagerM , BogstadJ , Lossl , K , et al. Pregnancy rates and risk of ovarian hyperstimulation syndrome (OHSS) in a fixed GnRH‐antagonist versus GnRH‐agonist protocol: randomised controlled trial including 1099 first IVF/ICSI CYCLES. Abstract of the 31st annual meeting of ESHRE I Lisbon, Portigal. 2015:i94. ">Toltager 2015</a>; <a href="./references#CD001750-bbs2-0072" title="XavierP , GamboaC , CalejoL , SilvaJ , StevensonD , NunesA , et al. A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy. Eurpean Journal of Obstetrics, Gynecology, and Reproductive Biology2005;120(2):185‐9. [MEDLINE: 15925049] ">Xavier 2005</a>; <a href="./references#CD001750-bbs2-0073" title="YeH , HuangG , ZengP , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;2(3):105‐11. ">Ye 2009</a>). </p> </li> <li> <p>Ten studies did not present data in a form that could be included in meta‐analysis (<a href="./references#CD001750-bbs2-0003" title="AndersonS , PereiraNE , BrasileDR , OrrisJJ , DaviesEB , GlassnerMJ . Comparison of antagonist to agonist in controlled ovarian stimulation (COS) cycles using human‐derived gonadotropin on in vitro fertilization (IVF) outcomes. A prospective randomized controlled study. Fertility and sterility. 2014; Vol. 102 (3; Suppl 1):e224. ">Anderson 2014</a>; <a href="./references#CD001750-bbs2-0004" title="AwataS , TanakaA , NagayoshiM . Selection of an optimal controlled ovarian hyperstimulation method in relation to the number of antral follicles in patients less than 40 years old. Fertility and Sterility2010;94 suppl 1(4):S164 Abstract no. P‐244. ">Awata 2010</a>; <a href="./references#CD001750-bbs2-0010" title="CelikN , CelikO , AktanE , OzerolE , CelikE , BozkurtK , et al. Plasma urocortin levels in women undergoing long agonist and antagonist protocols for IVF. Human Reproduction2011;26(1):i203. ">Celik 2011</a>; <a href="./references#CD001750-bbs2-0013" title="ChoiMH , KimHO , ChaSW , KoongMKK , KimJY , ParkCW . IVF comparison of ART outcomes in infertile PCOS women; in vitro maturation (IVM) vs. GnRH agonist vs. GnRH antagonist cycles. Clinical Experimental Reproductive MedicineDecember 2012;39(4):S210. ChoiMH , LeeSH , KimHO , ChaSH , KimJY , YangKM , et al. Comparison of assisted reproductive technology outcomes in infertile women with polycystic ovary syndrome: In vitro maturation, GnRH agonist, and GnRH antagonist cycles. Clinical &amp; Experimental Reproductive Medicine2012;39(4):166‐71. ">Choi 2012</a>; <a href="./references#CD001750-bbs2-0014" title="CotaAM , OliveiraJB , PetersenCG , MauriAL , MassaroFC , SilvaLF , et al. GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology. Reproductive Biology and Endocrinology2012;10:33. LavoratoHL , OliveiraJB , PetersenCG , VagniniL , MauriAL , CavagnaM , et al. GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA fragmentation and apoptosis granulosa cells. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165:61‐5. ">Cota 2012</a>; <a href="./references#CD001750-bbs2-0021" title="FerreroS , AbbamonteL H , PrivameraMR , LeviS , VenturiniPL , AnseriniP . Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients at high risk of ovarian hyperstimulation syndrome: A prospective randomized controlled trial. Fertility and Sterility2010;94 suppl 1(4):S28 Abstract no. O‐92. ">Ferrero 2010</a>; <a href="./references#CD001750-bbs2-0031" title="HoseiniFS , MugahiSM , Akbari‐AsbaghF , Eftekhari‐YazdiP , AflatoonianB , Aghaee‐BakhtiariSH , et al. A randomized controlled trial of gonadotropin‐releasing hormone antagonist in Iranian infertile couples: oocyte gene expression. Journal of Pharmaceutical Sciences2014;22:67. ">Hoseini 2014</a>; <a href="./references#CD001750-bbs2-0038" title="KhalafM , MittreH , LevalletJ , HanouxV , DenoualC , HerlicoviezM , et al. GnRH agonist and GnRH antagonist protocols in ovarian stimulation: differential regulation pathway of aromatase expression in human granulosa cells. Reproductive Biomedicine Online2010;21(1):56‐65. ">Khalaf 2010</a>; <a href="./references#CD001750-bbs2-0046" title="LavoratoHL , OliveiraJB , PetersenCG , VagniniL , MaurAL , CavagnaM , et al. GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA fragmentation and apoptosis in granulosa cells. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(1):61‐5. ">Lavorato 2012</a>; <a href="./references#CD001750-bbs2-0066" title="StenbaekDS , ToftagerM , HjordtLV , JensenPS , HolstKK , BryndorfT , et al. Mental distress and personality in women undergoing GnRH agonist versus GnRH antagonist protocols for assisted reproductive technology. Human Reproduction2015;30(1):103‐10. ">Stenbaek 2015</a>). </p> </li> </ul> </p> </section> </section> <section id="CD001750-sec-0061"> <h4 class="title">Excluded studies</h4> <p>Forty seven studies were excluded for various reasons (see table <a href="./references#CD001750-sec-0120" title="">Characteristics of excluded studies</a>) </p> </section> </section> <section id="CD001750-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>For the risk of bias (ROB) of the included trials, please see <a href="#CD001750-fig-0002">Figure 2</a> and <a href="#CD001750-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD001750-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001750-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD001750-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001750-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001750-sec-0063"> <h4 class="title">Allocation</h4> <p> <ul id="CD001750-list-0015"> <li> <p>Randomisation was done at the time of recruitment of participants.</p> </li> <li> <p>All trials had a parallel design and proper randomisation was carried out by 39 studies by using: interactive voice response systems (<a href="./references#CD001750-bbs2-0001" title="AlbanoC , FelberbaumR , SmitzJ , Riethmuller‐WinzenH , EngelJ , DiedrichK , et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone‐releasing hormone (LHRH)‐antagonist cetrorelix and the LHRH‐agonist buserlin. Human Reproduction2000;15(3):526‐31. LudwigM , FelberbaumRE , DevroeyP , AlbanoC , Riethmuller‐WinzenH , SchulerA , et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Archives of Gynecology and Obstetrics2000;264(1):29‐32. ">Albano 2000</a>; <a href="./references#CD001750-bbs2-0018" title="European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction (Oxford, England)2001;16(4):644‐51. [MEDLINE: 11278211] SonntagB , KieselL , NieschlagE , BehreHM . Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing GnRH agonist versus antagonist protocols for ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics2004;21(7):249‐55. ">Euro Middle East 2001</a>; <a href="./references#CD001750-bbs2-0019" title="The European Orgalutran Study Group, BormG , MannaertsB . Treatment with the gonadotrophin‐releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction (Oxford, England) 15;7:1490‐8. ">Euro Orgalutran 2000</a>; <a href="./references#CD001750-bbs2-0062" title="RombautsL , HealyD , NormanRJ . A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction (Oxford, England)2006;21(1):95‐103. ">Rombauts 2006</a>); stratified randomisation (<a href="./references#CD001750-bbs2-0023" title="FlukerM , GrifoJ , LeaderA , LevyM , MeldrumD , MuasherSJ , et al. for The North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility2001;75(1):38‐45. ">Fluker 2001</a>); computer‐generated random number tables with or without sealed envelopes for allocation concealment (<a href="./references#CD001750-bbs2-0005" title="BaartEB , MartiniE , EijkemansMJ , VanOpstalD , BeckersNGM , VerhoeffA , et al. Milder ovarian stimulation for in‐vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Human Reproduction2007;22(4):980‐8. ">Baart 2007</a>; <a href="./references#CD001750-bbs2-0006" title="BadrawiA , Al‐InanyH , HusseinM , ZakiS , RamzyAM . Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis. Middle East Fertility Society Journal2005;10(1):49‐54. ">Badrawi 2005</a>; <a href="./references#CD001750-bbs2-0008" title="BarmatLI , ChantilisSJ , HurstBS , DickeyRP . A randomized prospective trial comparing gonadotropin‐releasing hormone (GnRH) antagonist/recombinant follicle‐stimulating hormone (r FSH) versus GnRH‐agonist/r FSH in women pretreated with oral contraceptives before in vitro fertilization. Fertility and Sterility2005;83(2):321‐30. [MEDLINE: 15705369] ">Barmat 2005</a>; <a href="./references#CD001750-bbs2-0014" title="CotaAM , OliveiraJB , PetersenCG , MauriAL , MassaroFC , SilvaLF , et al. GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology. Reproductive Biology and Endocrinology2012;10:33. LavoratoHL , OliveiraJB , PetersenCG , VagniniL , MauriAL , CavagnaM , et al. GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA fragmentation and apoptosis granulosa cells. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165:61‐5. ">Cota 2012</a>; <a href="./references#CD001750-bbs2-0015" title="DepaloR , LorussoF , PalmisanoM , BassiE , TotaroI , VaccaM , et al. Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols for in vitro fertilisation and embryo transfer. Gynecological Endocrinology2009;25(5):328‐34. ">Depalo 2009</a>; <a href="./references#CD001750-bbs2-0017" title="EngmannL , DiLuigiA , SchmidtD , NulsenD , NulsenJ , BenadivaC . The use of gonadotropin‐releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high‐risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospsective randomised controlled study. Fertility and Sterility2008;89(1):84‐91. ">Engmann 2008a</a>; <a href="./references#CD001750-bbs2-0020" title="FerrariB , PezzutoA , BarusiL , CoppolaF . Follicular fluid vascular endothelial growth factor concentrations are increased during GnRH antagonist/FSH ovarian stimulation cycles. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2006;124(1):70‐6. FerrariB , PezzutoA , BarusiL , CoppolaF . Gonadotrophin‐releasing hormone antagonists increase follicular fluid insulin‐like growth factor‐I and vascular endothelial growth factor during ovarian stimulation cycles. Gynecological EndocrinologyJune 2006;22(6):289‐96. [DOI: 10.1080/09513590600777602] ">Ferrari 2006</a>; <a href="./references#CD001750-bbs2-0022" title="FirouzabadiRD , AhmadiS , OskouianH , DavarR . Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART. Archives of Gynecology and Obstetrics2010;281(1):81‐5. [PUBMED: PMID: 19357861 ] ">Firouzabadi 2010</a>; <a href="./references#CD001750-bbs2-0024" title="Franco JrJG , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH After 2nd phase protocols with GnRH Analogs (I‐estradiol + ganirelix versus II‐nafarelin) [Comparacao da estimulacao ovariana com FSH recombinante apos protocolo de 2A fase com analogos do GNRH (I ‐estradiol + ganirelix versus II‐nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco 2003</a>; <a href="./references#CD001750-bbs2-0070" title="NezamabadiAG , TehraninejadES , RashidiB . GnRH Antagonist versus Agonist in Normoresponders Undergoing ICSI: A Randomized Clinical Trial in Iran. International Journal of Fertility and Sterility2013;7(1):106. TehraninejadE , NezamabadiAG , RashidiB , SohrabiM , BagheriM , HaghollahiF , et al. GnRH antagonist versus agonist in normoresponders undergoing ICSI: a randomized clinical trial in Iran. Iranian Journal of Reproductive Medicine2011;9(3):171‐6. [IRCT138902283950N1]] ">Tehraninejad 2011</a>; <a href="./references#CD001750-bbs2-0028" title="HeijnenEM , EijkemansMJ , DeKlerkC , PolinderS , BeckersNG , KlinkertER , et al. A mild treatment strategy for in‐vitro fertilisation: a randomised non‐inferiority trial. The Lancet2007;369:743‐9. ">Heijnen 2007</a>; <a href="./references#CD001750-bbs2-0030" title="HohmannFP , MacklonNS , FauserBC . A randomized comparison of two ovarian stimulation protocols with gonadotropin‐releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle‐stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. The Journal of Clinical Endocrinology and Metabolism2003;88(1):166‐73. ">Hohmann 2003</a>; <a href="./references#CD001750-bbs2-0034" title="HuirneJA , VanLoenenAC , DonnezJ , PirardC , HomburgR , SchatsR , et al. Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reproductive Biomedicine Online2006;13(2):235‐45. ">Huirne 2006</a>; <a href="./references#CD001750-bbs2-0035" title="HwangJL , SeowK , LinY , HuangL , HsiehB , TsaiY , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. ">Hwang 2004</a>; <a href="./references#CD001750-bbs2-0037" title="KarimzadehMA , AhmadiS , OskouianH , RahmaniE . Comparison of mild stimulation and conventional stimulation in ART outcome. Archives of Gynecology and Obstetrics2010;281(4):741‐6. ">Karimzadeh 2010</a>; <a href="./references#CD001750-bbs2-0040" title="KimC‐H , JeonG‐H , CheonY‐P , JeonI , KimS‐H , ChaeH‐D , et al. Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low‐dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertility and Sterility2009;92(5):1758‐60. KimC‐H , YouR‐M , KangH‐K , AhnJ‐W , JeonI , LeeJ‐W , et al. GnRH antagonist multiple dose protocol with oral contraceptive pill pre‐treatment in poor responders undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2011;38(4):228‐33. KimCH , LeeHA , LeeJW , LeeYJ , NahHY , HongSH , et al. The efficacy of oral contraceptive pretreatment in controlled ovarian hyperstimulation using a GnRH antagonist for low responders [poster]. Abstracts of the 21st Annual Meeting of the ESHRE. Copenhagen, Denmark, 2005. Human Reproduction. 2005; Vol. 20 Suppl 1:i105‐6. ">Kim 2011</a>; <a href="./references#CD001750-bbs2-0041" title="KimC‐H , MoonJ‐W , KangH‐J , AhnJ‐W , KimS‐H , ChaeH‐D , et al. Effectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase compared with GnRH agonist long protocol in non‐obese and obese patients with polycystic ovary syndrome undergoing IVF/ICSI. Clinical and Experimental Reproductive Medicine2012;39(1):22‐7. ">Kim 2012</a>; <a href="./references#CD001750-bbs2-0042" title="KurzawaR , CiepielaP , BaczkowskiT , SafranowK , BrelikP . Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non‐obese patients. A prospective randomized study. Journal for Assisted Reproduction and Genetics2008;25(8):365‐74. ">Kurzawa 2008</a>; <a href="./references#CD001750-bbs2-0044" title="LainasTG , PetsasGK , ZorovilisIZ , LliadisGS , LainasGT , GazlarisHE , et al. Initiation of GnRH antagonist on day 1 of stimulation as compared to the long agonist protocol in PCOS patients: a randomised controlled trial: effect on hormonal levels and follicular development. Human Reproduction2007;22(6):1540‐6. ">Lainas 2007</a>; <a href="./references#CD001750-bbs2-0045" title="BaslyM , AchourR , Ben JemaaS , ChnitirM , MessaoudiL , ChibaniM , et al. Flexible Gnrh antagonist protocol versus Gnrh agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Internet Journal of Gynecology &amp; Obstetrics2012;16(3):1. LainasTG , SfontourisIA , ZorzovilisIZ , PetsasGK , LainasGT , AlexopoulouE , et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Human Reproduction2010;25(3):683‐9. ">Lainas 2010</a>; <a href="./references#CD001750-bbs2-0046" title="LavoratoHL , OliveiraJB , PetersenCG , VagniniL , MaurAL , CavagnaM , et al. GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA fragmentation and apoptosis in granulosa cells. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165(1):61‐5. ">Lavorato 2012</a>; <a href="./references#CD001750-bbs2-0049" title="LoutradisD , StefanidisK , DrakakisP , MilingosS , AntsaklisA , MichalasS . A modified gonadotropin‐releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol. Fertility and Sterility2004;82(5):1446‐8. [MEDLINE: 15533377] ">Loutradis 2004</a>; <a href="./references#CD001750-bbs2-0051" title="MartínezF , CluaE , PareraN , RodríguezI , BoadaM , CoroleuB . Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle‐stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients. Gynecological Endocrinology2008;24(4):188‐93. ">Martinez 2008</a>; <a href="./references#CD001750-bbs2-0053" title="MoralogluO , KilicS , KarayalçinR , YukselB , TasdemirN , UgurM . Comparison of GnRH agonists and antagonists in normo‐responder IVF/ICSI in Turkish female patients. Advances in Therapy2008;25(3):266‐73. ">Moraloglu 2008</a>; <a href="./references#CD001750-bbs2-0056" title="PapanikolaouEG , PadosG , GrimbizisG , BiliE , KyriaziL , PolyzosNP , et al. GnRH‐agonist versus GnRH‐antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study. Human Reproduction2012;27(6):1822‐8. ">Papanikolaou 2012</a>; <a href="./references#CD001750-bbs2-0061" title="RinaldiL , LisiF , SelmanH . Mild/minimal stimulation protocol for ovarian stimulation of patients at high risk of developing ovarian hyperstimulation syndrome. Journal of Endocrinological Investigation2014;37:65‐70. ">Rinaldi 2014</a>; <a href="./references#CD001750-bbs2-0063" title="SauerMV , ThorntonMH , SchoolcraftW , FrishmanGN . Comparative efficacy and safety of cetrorelix with or without mid‐cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reproductive Biomedicine Online2004;9(5):487‐93. ">Sauer 2004</a>; <a href="./references#CD001750-bbs2-0064" title="SbraciaM , ColabianchiJ , GiallonardoA , GianniniP , PiscitelliC , MorgiaF , et al. Cetrorelix protocol versus gonadotropin‐releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40. Fertility and Sterility2009;91(5):1842‐7. ">Sbracia 2009</a>; <a href="./references#CD001750-bbs2-0068" title="TazegülA , GörkemliH , OzdemirS , AktanTM . Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial. Archives of Gynecology and Obstetrics2008;278(5):467‐72. ">Tazegul 2008</a>; <a href="./references#CD001750-bbs2-0069" title="TehraninejadES , NasiriR , RashidiB , HaghollahiF , AtaieM . Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients. Archives of Gynecology and Obstetrics2010;282(3):319‐25. ">Tehraninejad 2010</a>; <a href="./references#CD001750-bbs2-0073" title="YeH , HuangG , ZengP , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;2(3):105‐11. ">Ye 2009</a>; <a href="./references#CD001750-bbs2-0072" title="XavierP , GamboaC , CalejoL , SilvaJ , StevensonD , NunesA , et al. A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy. Eurpean Journal of Obstetrics, Gynecology, and Reproductive Biology2005;120(2):185‐9. [MEDLINE: 15925049] ">Xavier 2005</a>); or random number table (<a href="./references#CD001750-bbs2-0007" title="BahceciM , UlugU , Ben‐ShlomoI , ErdenHF , AkmanMA . Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. Journal of Reproductive Medicine2005;50(2):84‐90. [MEDLINE: 15755044] ">Bahceci 2005</a>; <a href="./references#CD001750-bbs2-0012" title="CheungLP , LamPM , LokIH , ChiuTT , YeungSY , TjerCC , et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Human Reproduction (Oxford, England)2005;20(3):616‐21. [MEDLINE: 15608037] ">Cheung 2005</a>; <a href="./references#CD001750-bbs2-0027" title="HaydardedeogluB , KilicdagEB , ParlakgumusAH , ZeynelogluHB . IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial. Archives of Gynecology and ObstetricsSeptember 2012;286(3):763‐769. ">Haydardedeoglu 2012</a> ). </p> </li> <li> <p>Allocation concealment was properly performed by a nurse (<a href="./references#CD001750-bbs2-0014" title="CotaAM , OliveiraJB , PetersenCG , MauriAL , MassaroFC , SilvaLF , et al. GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology. Reproductive Biology and Endocrinology2012;10:33. LavoratoHL , OliveiraJB , PetersenCG , VagniniL , MauriAL , CavagnaM , et al. GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA fragmentation and apoptosis granulosa cells. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2012;165:61‐5. ">Cota 2012</a>; <a href="./references#CD001750-bbs2-0044" title="LainasTG , PetsasGK , ZorovilisIZ , LliadisGS , LainasGT , GazlarisHE , et al. Initiation of GnRH antagonist on day 1 of stimulation as compared to the long agonist protocol in PCOS patients: a randomised controlled trial: effect on hormonal levels and follicular development. Human Reproduction2007;22(6):1540‐6. ">Lainas 2007</a>; <a href="./references#CD001750-bbs2-0056" title="PapanikolaouEG , PadosG , GrimbizisG , BiliE , KyriaziL , PolyzosNP , et al. GnRH‐agonist versus GnRH‐antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study. Human Reproduction2012;27(6):1822‐8. ">Papanikolaou 2012</a>), by an interactive telephone system (<a href="./references#CD001750-bbs2-0051" title="MartínezF , CluaE , PareraN , RodríguezI , BoadaM , CoroleuB . Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle‐stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients. Gynecological Endocrinology2008;24(4):188‐93. ">Martinez 2008</a>) or by a sealed opaque envelope (<a href="./references#CD001750-bbs2-0027" title="HaydardedeogluB , KilicdagEB , ParlakgumusAH , ZeynelogluHB . IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial. Archives of Gynecology and ObstetricsSeptember 2012;286(3):763‐769. ">Haydardedeoglu 2012</a>; <a href="./references#CD001750-bbs2-0029" title="Hershko KlementA , BerkovitzA , WiserA , GonenO , AmichayK , CohenI , et al. GnRH‐antagonist programming versus GnRH agonist protocol: a randomized trial. European Journal of Obstetrics Gynecology and Reproductive Biology2015;185:170‐3. Hershko KlementA , BerkovitzA , WiserA , GonenO , AmichayK , ShulmanA . Follicular estrogen for GnRH‐antagonist protocol programming: a prospective randomized clinical trial. Fertility and Sterility. 2013; Vol. 1:S523. ">Hershko Klement 2015</a>; <a href="./references#CD001750-bbs2-0057" title="PrapasY , PetousisS , DagklisT , PanagiotidisY , PapatheodorouA , AssuntaI , et al. GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2013;166(1):43‐6. ">Prapas 2013</a>; <a href="./references#CD001750-bbs2-0060" title="RevelliA , ChiadòA , DalmassoP , StabileV , EvangelistaF , BassoG , et al. “Mild” vs. “long” protocol for controlled ovarian hyperstimulation in patients with expected poor ovarian responsiveness undergoing in vitro fertilization (IVF): a large prospective randomized trial. Journal of Assisted Reproduction and GeneticsJuly 2014;31(7):809‐15. [DOI: 10.1007/s10815‐014‐0227‐y] ">Revelli 2014</a>; <a href="./references#CD001750-bbs2-0061" title="RinaldiL , LisiF , SelmanH . Mild/minimal stimulation protocol for ovarian stimulation of patients at high risk of developing ovarian hyperstimulation syndrome. Journal of Endocrinological Investigation2014;37:65‐70. ">Rinaldi 2014</a>). </p> </li> <li> <p>The remaining trials did not report the methods of sequence generation or allocation concealment, or both. </p> </li> </ul> </p> </section> <section id="CD001750-sec-0064"> <h4 class="title">Blinding</h4> <p> <ul id="CD001750-list-0016"> <li> <p>We examined blinding with regard to who was blinded in the trials. We looked for all levels of blinding and categorised them as follows: (i) double blind (neither the investigator nor the participants knew the allocation); (ii) single blind (only the investigator knew the allocation); (iii) no blinding (both the investigator and the participants knew the allocated treatment); (iv) unclear. </p> </li> </ul> <ul id="CD001750-list-0017"> <li> <p>Since it was impossible to administer the different medications (that is long agonist and antagonist) according to one standard protocol without the use of a double dummy, almost all the studies were open‐label (that is no blinding). One study (<a href="./references#CD001750-bbs2-0012" title="CheungLP , LamPM , LokIH , ChiuTT , YeungSY , TjerCC , et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Human Reproduction (Oxford, England)2005;20(3):616‐21. [MEDLINE: 15608037] ">Cheung 2005</a>) blinded the clinicians and embryologists from the treatment allocation by using a nurse practitioner to administer the medications. The embryologist scoring the embryos, or the researcher, was blinded to the study groups in five trials (<a href="./references#CD001750-bbs2-0005" title="BaartEB , MartiniE , EijkemansMJ , VanOpstalD , BeckersNGM , VerhoeffA , et al. Milder ovarian stimulation for in‐vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Human Reproduction2007;22(4):980‐8. ">Baart 2007</a>; <a href="./references#CD001750-bbs2-0015" title="DepaloR , LorussoF , PalmisanoM , BassiE , TotaroI , VaccaM , et al. Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols for in vitro fertilisation and embryo transfer. Gynecological Endocrinology2009;25(5):328‐34. ">Depalo 2009</a>; <a href="./references#CD001750-bbs2-0016" title="ElSahwiS . GnRH agonists versus GnRH antagonists in controlled ovarian stimulation in ICSI trials. Book of Abstracts, 8th International Symposium on GnRH Analogues in Cancer and Human Reproduction. Salzburg, Austria. 2005:A65. ">El Sahwi 2005</a>; <a href="./references#CD001750-bbs2-0035" title="HwangJL , SeowK , LinY , HuangL , HsiehB , TsaiY , et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane‐35 pre‐treatment for patients with polycystic ovary syndrome: a prospective randomized study. Human Reproduction2004;19(9):1993‐2000. ">Hwang 2004</a>; <a href="./references#CD001750-bbs2-0051" title="MartínezF , CluaE , PareraN , RodríguezI , BoadaM , CoroleuB . Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle‐stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients. Gynecological Endocrinology2008;24(4):188‐93. ">Martinez 2008</a>). </p> </li> </ul> <ul id="CD001750-list-0018"> <li> <p>Twenty‐seven trials reported no blinding and we assessed them as being at high risk of bias (<a href="./references#CD001750-bbs2-0001" title="AlbanoC , FelberbaumR , SmitzJ , Riethmuller‐WinzenH , EngelJ , DiedrichK , et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone‐releasing hormone (LHRH)‐antagonist cetrorelix and the LHRH‐agonist buserlin. Human Reproduction2000;15(3):526‐31. LudwigM , FelberbaumRE , DevroeyP , AlbanoC , Riethmuller‐WinzenH , SchulerA , et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Archives of Gynecology and Obstetrics2000;264(1):29‐32. ">Albano 2000</a>; <a href="./references#CD001750-bbs2-0006" title="BadrawiA , Al‐InanyH , HusseinM , ZakiS , RamzyAM . Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis. Middle East Fertility Society Journal2005;10(1):49‐54. ">Badrawi 2005</a>; <a href="./references#CD001750-bbs2-0007" title="BahceciM , UlugU , Ben‐ShlomoI , ErdenHF , AkmanMA . Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. Journal of Reproductive Medicine2005;50(2):84‐90. [MEDLINE: 15755044] ">Bahceci 2005</a>; <a href="./references#CD001750-bbs2-0008" title="BarmatLI , ChantilisSJ , HurstBS , DickeyRP . A randomized prospective trial comparing gonadotropin‐releasing hormone (GnRH) antagonist/recombinant follicle‐stimulating hormone (r FSH) versus GnRH‐agonist/r FSH in women pretreated with oral contraceptives before in vitro fertilization. Fertility and Sterility2005;83(2):321‐30. [MEDLINE: 15705369] ">Barmat 2005</a>; <a href="./references#CD001750-bbs2-0011" title="CheckML , CheckJH , ChoelJK , DaviesE , KieferD . Effect of antagonists vs agonists on in vitro fertilization outcome. Clinical and Experimental Obstetrics &amp; Gynecology2004;31(4):257‐9. [MEDLINE: 15672958] ">Check 2004</a>; <a href="./references#CD001750-bbs2-0017" title="EngmannL , DiLuigiA , SchmidtD , NulsenD , NulsenJ , BenadivaC . The use of gonadotropin‐releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high‐risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospsective randomised controlled study. Fertility and Sterility2008;89(1):84‐91. ">Engmann 2008a</a>; <a href="./references#CD001750-bbs2-0018" title="European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction (Oxford, England)2001;16(4):644‐51. [MEDLINE: 11278211] SonntagB , KieselL , NieschlagE , BehreHM . Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing GnRH agonist versus antagonist protocols for ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics2004;21(7):249‐55. ">Euro Middle East 2001</a>; <a href="./references#CD001750-bbs2-0019" title="The European Orgalutran Study Group, BormG , MannaertsB . Treatment with the gonadotrophin‐releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction (Oxford, England) 15;7:1490‐8. ">Euro Orgalutran 2000</a>; <a href="./references#CD001750-bbs2-0022" title="FirouzabadiRD , AhmadiS , OskouianH , DavarR . Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART. Archives of Gynecology and Obstetrics2010;281(1):81‐5. [PUBMED: PMID: 19357861 ] ">Firouzabadi 2010</a>; <a href="./references#CD001750-bbs2-0023" title="FlukerM , GrifoJ , LeaderA , LevyM , MeldrumD , MuasherSJ , et al. for The North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility2001;75(1):38‐45. ">Fluker 2001</a>; <a href="./references#CD001750-bbs2-0024" title="Franco JrJG , BaruffiRLR , PetersenCG , MauriAL , FelipeV , ContartP . Comparison of ovarian stimulation with recombinant FSH After 2nd phase protocols with GnRH Analogs (I‐estradiol + ganirelix versus II‐nafarelin) [Comparacao da estimulacao ovariana com FSH recombinante apos protocolo de 2A fase com analogos do GNRH (I ‐estradiol + ganirelix versus II‐nafarelin)]. Jornal Brasileiro de Reproducao Assistida2003;7(1):26‐32. ">Franco 2003</a>; <a href="./references#CD001750-bbs2-0025" title="FriedlerS , GilboaS , SchachterM , RazielR , StrassburgerD , KastersteinE , et al. Luteal phase characteristics following GnRH antagonist or agonist treatment: a randomized comparative study. Human Reproduction (Oxford, England)2003;18 Suppl 1:26. ">Friedler 2003</a>; <a href="./references#CD001750-bbs2-0028" title="HeijnenEM , EijkemansMJ , DeKlerkC , PolinderS , BeckersNG , KlinkertER , et al. A mild treatment strategy for in‐vitro fertilisation: a randomised non‐inferiority trial. The Lancet2007;369:743‐9. ">Heijnen 2007</a>; <a href="./references#CD001750-bbs2-0030" title="HohmannFP , MacklonNS , FauserBC . A randomized comparison of two ovarian stimulation protocols with gonadotropin‐releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle‐stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. The Journal of Clinical Endocrinology and Metabolism2003;88(1):166‐73. ">Hohmann 2003</a>; <a href="./references#CD001750-bbs2-0042" title="KurzawaR , CiepielaP , BaczkowskiT , SafranowK , BrelikP . Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non‐obese patients. A prospective randomized study. Journal for Assisted Reproduction and Genetics2008;25(8):365‐74. ">Kurzawa 2008</a>; <a href="./references#CD001750-bbs2-0043" title="KyonoK , FuchinoueK , NakajoY , YagiA , SasakiK . A prospective randomized study of three ovulation induction protocols for IVF: GnRH agonist versus antagonist with and without low dose hCG. Fertility and Sterility2004;82 Suppl:31. KyonoK , NakajoY , SasakiS , KumagaiS , SuzukiS . A prospective randomized study of three different controlled ovarian hyperstimulation (COH) protocols. Fertility and Sterility2005;84 Suppl 1:299. ">Kyono 2005</a>; <a href="./references#CD001750-bbs2-0044" title="LainasTG , PetsasGK , ZorovilisIZ , LliadisGS , LainasGT , GazlarisHE , et al. Initiation of GnRH antagonist on day 1 of stimulation as compared to the long agonist protocol in PCOS patients: a randomised controlled trial: effect on hormonal levels and follicular development. Human Reproduction2007;22(6):1540‐6. ">Lainas 2007</a>; <a href="./references#CD001750-bbs2-0045" title="BaslyM , AchourR , Ben JemaaS , ChnitirM , MessaoudiL , ChibaniM , et al. Flexible Gnrh antagonist protocol versus Gnrh agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Internet Journal of Gynecology &amp; Obstetrics2012;16(3):1. LainasTG , SfontourisIA , ZorzovilisIZ , PetsasGK , LainasGT , AlexopoulouE , et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Human Reproduction2010;25(3):683‐9. ">Lainas 2010</a>; <a href="./references#CD001750-bbs2-0049" title="LoutradisD , StefanidisK , DrakakisP , MilingosS , AntsaklisA , MichalasS . A modified gonadotropin‐releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol. Fertility and Sterility2004;82(5):1446‐8. [MEDLINE: 15533377] ">Loutradis 2004</a>; <a href="./references#CD001750-bbs2-0050" title="MarciR , CasertaD , DoloV , TatoneC , PavanA , MoscariniM . GnRH antagonist in IVF poor‐responder patients: results of a randomized trial. Reproductive Biomedicine Online2005;11(2):189‐93. MarciR , CasertaD , FarinaM , DessoleS , GermondM , TatoneC , et al. The use of GnRH antagonist in ovarian stimulation for IVF cycles can achieve good pregnancy rates in poor responder patients. Human Reproduction (Oxford, England)2002;17:115‐6. ">Marci 2005</a>; <a href="./references#CD001750-bbs2-0055" title="OlivennesF , Belaisch‐Allart , EmperareJ , DechaudH , S Alvarez S , MoreauL . Prospective randomized, controlled study of in vitro fertilization‐embryo transfer with a single dose of a luteinizing hormone‐releasing hormone (LH‐RH) antagonist (cetrorelix) or a depot formula of an LH‐RH agonist (triptorelin). Fertility and Sterility2000;73(2):314‐20. ">Olivennes 2000</a>; <a href="./references#CD001750-bbs2-0062" title="RombautsL , HealyD , NormanRJ . A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist‐treated patients. Human Reproduction (Oxford, England)2006;21(1):95‐103. ">Rombauts 2006</a>; <a href="./references#CD001750-bbs2-0063" title="SauerMV , ThorntonMH , SchoolcraftW , FrishmanGN . Comparative efficacy and safety of cetrorelix with or without mid‐cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reproductive Biomedicine Online2004;9(5):487‐93. ">Sauer 2004</a>; <a href="./references#CD001750-bbs2-0068" title="TazegülA , GörkemliH , OzdemirS , AktanTM . Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial. Archives of Gynecology and Obstetrics2008;278(5):467‐72. ">Tazegul 2008</a>; <a href="./references#CD001750-bbs2-0069" title="TehraninejadES , NasiriR , RashidiB , HaghollahiF , AtaieM . Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients. Archives of Gynecology and Obstetrics2010;282(3):319‐25. ">Tehraninejad 2010</a>; <a href="./references#CD001750-bbs2-0072" title="XavierP , GamboaC , CalejoL , SilvaJ , StevensonD , NunesA , et al. A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy. Eurpean Journal of Obstetrics, Gynecology, and Reproductive Biology2005;120(2):185‐9. [MEDLINE: 15925049] ">Xavier 2005</a>; <a href="./references#CD001750-bbs2-0073" title="YeH , HuangG , ZengP , PeiL . IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre‐treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. Journal of Assisted Reproduction and Genetics2009;2(3):105‐11. ">Ye 2009</a>). The remaining trials did not clearly report if blinding was performed and we therefore assessed them as being at unclear risk of bias. </p> </li> </ul> </p> <p>However, some of the outcome measures such as live birth were objectively assessed and non‐blinding of study outcome assessors was not likely to have affected their measurement. </p> </section> <section id="CD001750-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>We judged thirty‐seven of the included studies as being at low risk of bias in this domain, because they reported that there were no losses to follow up, proportions of withdrawals and reasons for withdrawals were balanced in both treatment groups, or women were analysed on the basis of intention‐to‐treat, where all women randomised were included in the final analysis whether or not they completed treatment. We judged the remaining studies either as unclear (where studies reported insufficient information with regard to attrition) or high risk of bias (where proportions of and reasons for withdrawals were not balanced between the two treatment groups and not all participants were included in the final analysis). </p> </section> <section id="CD001750-sec-0066"> <h4 class="title">Selective reporting</h4> <p>Although the protocols of the included studies were not available for assessment, we scrutinised the methods section for pre‐specified outcome measures. Most of the included studies were rated as low risk of bias in this domain as they pre‐specified the outcomes on which data were reported in the methods section. The remaining studies were judged to be either at unclear risk, where there was insufficient information to make conclusive judgements, or low risk, where it was clear that they engaged in selective outcome reporting. </p> </section> <section id="CD001750-sec-0067"> <h4 class="title">Other potential sources of bias</h4> <p>We found no potential sources of within‐study bias in most of the included studies as the baseline characteristics were similar between the treatment groups and were, therefore, rated to be at low risk of bias. The remaining studies were rated either as unclear risk, where there was insufficient information to arrive at a judgement, or high risk where there was evidence of significant differences in demographic characteristics between the treatment groups. </p> </section> </section> <section id="CD001750-sec-0068"> <h3 class="title" id="CD001750-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD001750-tbl-0001"><b>Summary of findings for the main comparison</b> GnRH antagonist compared to long‐course GnRH agonist for assisted reproductive technology (ART)</a> </p> <p>The included studies enrolled a total of 12,212 randomised participants, although the sample size varied across the trials. We performed the analyses on the number of women randomised and not on the number of participants treated. </p> <section id="CD001750-sec-0069"> <h4 class="title">GnRH antagonist versus long course GnRH agonist</h4> <section id="CD001750-sec-0070"> <h5 class="title">Primary outcomes</h5> <section id="CD001750-sec-0071"> <h6 class="title">1.1 Live birth rate per woman randomised</h6> <p>(<a href="./references#CD001750-fig-0010" title="">Analysis 1.1</a>; <a href="#CD001750-fig-0004">Figure 4</a>) </p> <div class="figure" id="CD001750-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.1 Live birth rate per woman randomised." data-id="CD001750-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.1 Live birth rate per woman randomised. </p> </div> </div> </div> <p>Twelve trials reported live birth rates in 2303 women. There was no evidence of a difference following GnRH antagonist compared with GnRH agonist (OR 1.02, 95% CI 0.85 to 1.23; I<sup>2</sup> = 27%, moderate quality evidence). The evidence suggested that if the chance of live birth following treatment with GnRH agonist is assumed to be 29%, the chance following treatment with GnRH antagonist would be between 25% and 33%. On sensitivity analysis, there was no change in the above conclusion using a random‐effects model (OR 1.01, 95% CI 0.80 to 1.27) or using risk ratio (RR) as a measure of effect estimate (RR 1.02, 95% CI 0.89 to 1.15). A funnel plot to explore the possibility of small study effect showed a tendency for estimates of the intervention effect to be more beneficial in smaller studies in the GnRH antagonist group (see <a href="#CD001750-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD001750-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.1 Live birth rate per woman randomised." data-id="CD001750-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.1 Live birth rate per woman randomised. </p> </div> </div> </div> </section> <section id="CD001750-sec-0072"> <h6 class="title">1.2 Live birth rate per woman randomised ‐ Subgroup analysis: Minimal stimulation</h6> <p><i>(</i><a href="./references#CD001750-fig-0011" title="">Analysis 1.2</a>; <a href="#CD001750-fig-0006">Figure 6</a>) </p> <div class="figure" id="CD001750-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.2 Live birth rate per woman randomised ‐ minimal stimulation." data-id="CD001750-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.2 Live birth rate per woman randomised ‐ minimal stimulation. </p> </div> </div> </div> <p>Two trials reported live birth rates in 524 women undergoing minimal stimulation IVF. There was no evidence of a difference following GnRH antagonist treatment compared with GnRH agonist treatment (OR 0.89, 95% CI 0.62 to 1.26; I<sup>2</sup> = 0%). </p> </section> <section id="CD001750-sec-0073"> <h6 class="title">1.3 Live birth rate per woman randomised ‐ Subgroup analysis: Grouped by trigger</h6> <p><i>(</i><a href="./references#CD001750-fig-0012" title="">Analysis 1.3</a>; <a href="#CD001750-fig-0007">Figure 7</a>) </p> <div class="figure" id="CD001750-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 GnRH antagonist versus long‐course GnRH agonist, outcome: 1.3 Live birth rate per woman randomised ‐ grouped by trigger." data-id="CD001750-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 GnRH antagonist versus long‐course GnRH agonist, outcome: 1.3 Live birth rate per woman randomised ‐ grouped by trigger. </p> </div> </div> </div> <section id="CD001750-sec-0074"> <p><b>1.3.1 hCG trigger</b></p> <p>In a subgroup analysis, 11 trials reported live birth rates in 1899 women receiving hCG for ovarian maturation. There was no evidence of a difference following GnRH antagonist treatment compared with GnRH agonist treatment (OR 1.09, 95% CI 0.89 to 1.34; I<sup>2</sup> = 26%). </p> </section> <section id="CD001750-sec-0075"> <p><b>1.3.2 Unknown trigger</b></p> <p>One trial did not report the triggering agent used for ovarian maturation in 404 women. There was no evidence of a difference in live birth rate between GnRH antagonist and GnRH agonist treatment groups (OR 0.80, 95% CI 0.54 to 1.21). </p> </section> </section> <section id="CD001750-sec-0076"> <h6 class="title">1.4 Ovarian hyperstimulation per woman randomised</h6> <p><i>(</i><a href="./references#CD001750-fig-0013" title="">Analysis 1.4</a>; <a href="#CD001750-fig-0008">Figure 8</a>) </p> <div class="figure" id="CD001750-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.4 Ovarian hyperstimulation per woman randomised ‐ all women." data-id="CD001750-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.4 Ovarian hyperstimulation per woman randomised ‐ all women. </p> </div> </div> </div> <p>Thirty‐six trials reported ovarian hyperstimulation rates in 7944 women. There was evidence of a lower OHSS rate in women who received GnRH antagonist compared with those were treated with GnRH agonist: 290/4474 (6%) versus 396/3470 (11%) (OR 0.61, 95% CI 0.51 to 0.72; I<sup>2</sup> = 31%, moderate quality evidence). The evidence suggested that if the risk of OHSS following GnRH agonist is assumed to be 11%, the risk following GnRH antagonist would be between 6% and 9%. </p> </section> <section id="CD001750-sec-0077"> <h6 class="title">1.5 Ovarian hyperstimulation per woman randomised ‐ Subgroup analysis: Moderate or severe OHSS </h6> <p><i>(</i><a href="./references#CD001750-fig-0014" title="">Analysis 1.5</a>; <a href="#CD001750-fig-0009">Figure 9</a>) </p> <div class="figure" id="CD001750-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.5 Ovarian hyperstimulation per woman randomised ‐ moderate or severe." data-id="CD001750-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.5 Ovarian hyperstimulation per woman randomised ‐ moderate or severe. </p> </div> </div> </div> <p>Twenty trials reported moderate or severe ovarian hyperstimulation rates in 5141 women. There was evidence of a lower rate of moderate or severe OHSS in GnRH antagonist compared with GnRH agonist groups: 97/2971 (3%) versus 155/2170 (7%) (OR 0.53, 95% CI 0.40 to 0.69; I<sup>2</sup> = 17%). </p> </section> </section> <section id="CD001750-sec-0078"> <h5 class="title">Secondary outcomes</h5> <section id="CD001750-sec-0079"> <h6 class="title">1.6 Ongoing pregnancy rate per woman randomised</h6> <p><i>(</i><a href="./references#CD001750-fig-0015" title="">Analysis 1.6</a>) </p> <p>Thirty‐seven trials reported ongoing pregnancy rates in 8311 women. There was no evidence of a difference in ongoing pregnancy rate following treatment with GnRH antagonist compared with GnRH agonist (OR 0.92, 95% CI 0.83 to 1.01; I<sup>2</sup> = 0%; moderate quality evidence). The evidence suggested that if the chance of ongoing pregnancy following GnRH agonist treatment is assumed to be 29%, the chance following GnRH antagonist treatment would be between 26% and 30%. There was no change in the conclusion on sensitivity analysis using either a random‐effects model (OR 0.91, 95% CI 0.83 to 1.01) or RR as a measure of treatment effect (RR 0.94, 95% CI 0.88 to 1.01). </p> </section> <section id="CD001750-sec-0080"> <h6 class="title">1.7 Ongoing pregnancy rate per woman randomised ‐ Subgroup analysis: Minimal stimulation</h6> <p><i>(</i><a href="./references#CD001750-fig-0016" title="">Analysis 1.7</a>) </p> <p>Seven trials reported ongoing pregnancy rates in 1456 women undergoing minimal stimulation IVF. There was no evidence of a difference following GnRH antagonist treatment compared with GnRH agonist treatment (OR 0.94, 95% CI 0.75 to 1.18; I<sup>2</sup> = 0%). </p> </section> <section id="CD001750-sec-0081"> <h6 class="title">1.8 Ongoing pregnancy rate per woman randomised ‐ Subgroup analysis: Grouped by trigger</h6> <p><i>(</i><a href="./references#CD001750-fig-0017" title="">Analysis 1.8</a>) </p> <section id="CD001750-sec-0082"> <p><b>1.8.1 hCG trigger</b></p> <p>In a subgroup analysis, 29 studies reported ongoing pregnancy rate in 5170 women in whom hCG was used to trigger oocyte maturation. There was no evidence of a difference in ongoing pregnancy rate between the two treatment groups (OR 0.95, 95% CI 0.84 to 1.08; I<sup>2</sup> = 0%). </p> </section> <section id="CD001750-sec-0083"> <p><b>1.8.2 Mixed trigger </b></p> <p>One study used hCG and GnRH agonist in GnRH antagonist and GnRH agonist groups respectively to trigger oocyte maturation in 66 women. There was no evidence of a difference in ongoing pregnancy rate between GnRH antagonist and GnRH agonist groups (OR 0.61, 95% CI 0.23 to 1.61). </p> </section> <section id="CD001750-sec-0084"> <p><b>1.8.3 Unknown trigger</b></p> <p>In a subgroup analysis, seven trials reported ongoing pregnancy rates in 3075 women in whom the agent used in triggering oocyte maturation was unknown. There was no evidence of a difference following treatment with GnRH antagonist compared with GnRH agonist (OR 0.87, 95% CI 0.74 to 1.03; I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD001750-sec-0085"> <h6 class="title">1.9 Clinical pregnancy rate per woman randomised</h6> <p><i>(</i><a href="./references#CD001750-fig-0018" title="">Analysis 1.9</a>) </p> <p>Fifty‐four trials reported clinical pregnancy rates in 9959 women . There was evidence of a difference following GnRH antagonist treatment compared with GnRH agonist treatment with a smaller proportion of women reporting clinical pregnancies in the GnRH antagonist group: 1510/5431 (28%) versus 1365/4528 (30%) (OR 0.91, 95% CI 0.83 to 1.00; I<sup>2</sup> = 1%, moderate quality evidence). The evidence suggested that if the chance of clinical pregnancy following GnRH agonist treatment is assumed to be 30%, the chance following GnRH antagonist treatment would be between 27% and 30%. </p> </section> <section id="CD001750-sec-0086"> <h6 class="title">1.10 Clinical pregnancy rate per woman randomised ‐ Subgroup analysis: Minimal stimulation</h6> <p><i>(</i><a href="./references#CD001750-fig-0019" title="">Analysis 1.10</a>) </p> <p>Six studies reported clinical pregnancy rate in 1102 women receiving minimal ovarian stimulation. There was evidence of a higher clinical pregnancy rate in the GnRH antagonist group compared to the GnRH agonist group: 179/552 (32%) versus 137/550 (25%) (OR 1.50, 95% CI 1.15 to 1.96; I<sup>2</sup> = 50%). </p> </section> <section id="CD001750-sec-0087"> <h6 class="title">1.11 Miscarriage rate per woman randomised</h6> <p>(<a href="./references#CD001750-fig-0020" title="">Analysis 1.11</a>) </p> <p>Thirty‐four trials reported miscarriage rates in 7082 women. There was no evidence of a difference following GnRH antagonist treatment compared with GnRH agonist treatment (OR 1.03, 95% CI 0.82 to 1.29; I<sup>2</sup> = 0%; moderate quality evidence). The evidence suggested that if the risk of miscarriage following GnRH agonist treatment is assumed to be 5%, the risk following GnRH antagonist treatment would be between 4% and 6%. </p> </section> <section id="CD001750-sec-0088"> <h6 class="title"> 1.12 Miscarriage rate per clinical pregnancy rate</h6> <p><i>(</i><a href="./references#CD001750-fig-0021" title="">Analysis 1.12</a>) </p> <p>Thirty‐four trials reported miscarriage rates per clinical pregnancy rates in 2308 women. There was no evidence of a difference following treatment with GnRH antagonist compared with GnRH agonist (OR 1.08, 95% CI 0.84 to 1.37; I<sup>2</sup> = 0%).. </p> </section> <section id="CD001750-sec-0089"> <h6 class="title"> 1.13 Cycle cancellation rate per woman randomised</h6> <p>(<a href="./references#CD001750-fig-0022" title="">Analysis 1.13</a>) </p> <section id="CD001750-sec-0090"> <p><b>1.13.1 Cancelled due to high risk of OHSS</b></p> <p>Nineteen trials reported rates of cycle cancellation due to high risk of OHSS in 4256 women. There was evidence of a difference in cancellation rates with fewer cycles cancelled in the GnRH antagonist groups compared with the GnRH agonist groups (OR 0.47, 95% CI 0.32 to 0.69; I<sup>2</sup> = 0%). </p> </section> <section id="CD001750-sec-0091"> <p><b>1.13.2 Cancellation due to poor ovarian response</b></p> <p>Twenty‐five trials reported rates of cancellation due to poor ovarian response in 5230 women. There was evidence of a difference in cycle cancellation rates with more cycles cancelled in GnRH antagonist groups compared with GnRH agonist groups (OR 1.32, 95% CI 1.06 to 1.65; I<sup>2</sup> = 68%, moderate quality evidence). The evidence suggested that if the risk of cycle cancellation following GnRH agonist treatment is assumed to be 6%, the risk following GnRH antagonist treatment would be between 7% and 10%. There was evidence of statistical heterogeneity among the trials that contributed data to the pooled effect estimate, with variations in the direction of effect estimates of individual trials. On sensitivity analysis using a random‐effects model, there was no evidence of a difference in cancellation rate between the two treatment groups (OR 1.38, 95% CI 0.82 to 2.31). Thus there is some degree of uncertainty with respect to this outcome, as it is sensitive to the choice of statistical model. </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001750-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001750-sec-0092"></div> <section id="CD001750-sec-0093"> <h3 class="title" id="CD001750-sec-0093">Summary of main results</h3> <p>The previous version of this systematic review included 45 studies, while this updated version includes 73 RCTs and 12,212 randomised women. To our knowledge this systematic review and meta‐analysis represents the most recent and largest amount of evidence comparing the use of GnRH antagonist with long‐course GnRH agonist protocols in IVF or ICSI treatment cycles. </p> <p>In this updated version of the review we focused on the effectiveness and safety of GnRH antagonist compared to GnRH agonist cycles in ART. Regarding effectiveness, there was no  evidence of differences in live birth rate and ongoing pregnancy rate between GnRH agonist and GnRH antagonist LH peak suppression protocols. </p> <p>With regard to safety, GnRH antagonists substantially reduced the incidence of OHSS. For the overall population from assembled studies, the evidence suggested that, if the risk of OHSS following GnRH agonist is assumed to be 11%, the risk following GnRH antagonist would be between 6% and 9%. In addition, there was evidence of a lower rate of moderate or severe OHSS in women who received the GnRH antagonist protocol compared with those who were treated with the GnRH agonist long protocol. However there was no evidence of a difference in miscarriage rates per woman randomised between the two treatment protocols. There was no clear picture with respect to cycle cancellation between the two treatment groups. While fewer cycles were cancelled in the GnRH antagonist group due to high risk of OHSS, there is some degree of uncertainty with cancellation due to poor ovarian response, as this outcome was sensitive to the choice of statistical model. In summary, there is moderate quality evidence that the use of GnRH antagonist compared with long‐course GnRH agonist protocols is associated with a substantial reduction in OHSS without reducing the likelihood of achieving live birth or ongoing pregnancy. </p> <p>Previous versions of this systematic review showed substantially lower clinical and ongoing pregnancy rates for the GnRH antagonist protocol. Two earlier meta‐analyses of studies, comparing fixed and flexible GnRH antagonist protocols directly, demonstrated a trend towards higher pregnancy rates when using the fixed protocol, possibly explained by better LH control (<a href="./references#CD001750-bbs2-0122" title="Al‐InanyH , AboulgharMA , MansourRT , SerourGI . Optimizing GnRH antagonist administration: meta‐analysis of fixed versus flexible protocol. Reproductive biomedicine online2005;10(5):567‐70. [PUBMED: 15949209] ">Al‐Inany 2005</a>; <a href="./references#CD001750-bbs2-0143" title="KolibianakisEM , CollinsJ , TarlatzisBC , DevroeyP , DiedrichK , GriesingerG . Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta‐analysis. Human reproduction update2006;12(6):651‐71. [PUBMED: 16920869] ">Kolibianakis 2006</a>). The improved performance of antagonist cycles in the present update cannot be explained by the relative use of fixed protocols however, as relatively few new fixed protocols were included. </p> <p>Several studies have suggested that LH instability decreases the probability of pregnancy in antagonist cycles (<a href="./references#CD001750-bbs2-0124" title="BoschE , ValenciaI , EscuderoE , CrespoJ , SimonC , RemohiJ , et al. Premature luteinization during gonadotropin‐releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertility and Sterility2003;80(6):1444‐9. ">Bosch 2003</a>; <a href="./references#CD001750-bbs2-0141" title="KolibianakisEM , AlbanoC , CamusM , TournayeH , VanSteirteghemAC , DevroeyP . Initiation of gonadotropin‐releasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles.. Journal of Clinical Endocrinology &amp; Metabolism2003;88:5632‐7. ">Kolibianakis 2003</a>; <a href="./references#CD001750-bbs2-0156" title="SeowKM , LinYH , HsiehBC , HuangLW , HuangSC , ChenCY , et al. Characteristics of progesterone changes in women with subtle progesterone rise in recombinant follicle‐stimulating hormone and gonadotropin‐releasing hormone antagonist cycle. Gynecologic and Obstetric Investigation2010;70:64–8. ">Seow 2010</a>; <a href="./references#CD001750-bbs2-0157" title="ShohamZ . The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertility and Sterility2002;77:1170‐7. ">Shoham 2002</a>). LH instability is defined as any fluctuation in LH level, either a LH surge or rise in LH concentration, in the course of ovarian hyperstimulation. A decrease in the relative incidence of LH instability in the current review can possibly have improved pregnancy outcomes in antagonist cycles, although the mechanism for such change is still unclear. Further studies are needed to investigate the possible role of LH‐instability in the improvement of pregnancy outcomes of GnRH antagonist cycles. </p> <p>Increased favourable pregnancy outcomes with GnRH antagonist treatment may also be the result of an improved learning curve with the relatively new GnRH antagonist over the last 15 years. Extensive experience with GnRH antagonist protocols in large studies, leading to more favourable study outcomes, may have positively influenced pregnancy outcomes of GnRH antagonist cycles. Finally, changes in the use of OCP pretreatment (<a href="./references#CD001750-bbs2-0135" title="GriesingerG , VenetisCA , MarxT , DiedrichK , TarlatzisBC , KolibianakisEM . Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta‐analysis. Fertility and Sterility2008;90(4):1055. ">Griesinger 2008</a>), scheduling of hCG for final oocyte maturation (<a href="./references#CD001750-bbs2-0142" title="KolibianakisEM , ZikopoulosK , SmitzJ , CamusM , TournayeH , VanSteirteghemandAC , et al. Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists. Human Reproduction2004;19(7):1525‐9. ">Kolibianakis 2004</a>; <a href="./references#CD001750-bbs2-0158" title="TremellenKP , LaneM . Avoidance of weekend oocyte retrievals during GnRH antagonist treatment by simple advancement or delay of hCG administration does not adversely affect IVF live birth outcomes. Humanan Reproduction2010;25(5):1219‐24. ">Tremellen 2010</a>; <a href="./references#CD001750-bbs2-0105" title="OrvietoR , MeltzerS , RabinsonJ . GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity. Fertility and Sterility2008;90(4):1294‐6. ">Orvieto 2008</a>) or patient selection (<a href="./references#CD001750-bbs2-0064" title="SbraciaM , ColabianchiJ , GiallonardoA , GianniniP , PiscitelliC , MorgiaF , et al. Cetrorelix protocol versus gonadotropin‐releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40. Fertility and Sterility2009;91(5):1842‐7. ">Sbracia 2009</a>) may all have contributed to the optimisation of the use of antagonist cycles in ART. However, the improvement in pregnancy outcomes could also be due to the effects of potential bias in the included studies. For example, the forest plot (<a href="#CD001750-fig-0005">Figure 5</a>) suggests a tendency for publication of studies with more favourable outcomes with the possibility of existence of unpublished studies with less favourable outcomes. </p> <p>Previous work on the role of OCP pretreatment in direct comparison studies has indicated that OCP pretreatment leads to a longer duration of stimulation, higher oocyte yield, but reduced ongoing pregnancy rate (<a href="http://archie.cochrane.org/sections/documents/view?version=48477926069055880290110606143734%26format=REVMAN#REF-Smulders-2010#REF-Smulders-2010" target="_blank">Smulders 2010</a>). Also a trend towards lower pregnancy rates when using OCP pretreatment has been observed in a separate meta‐analysis (<a href="http://archie.cochrane.org/sections/documents/view?version=48477926069055880290110606143734%26format=REVMAN#REF-Griesinger-2008#REF-Griesinger-2008" target="_blank">Griesinger 2008</a>). As such, it has been recommended that OCP pretreatment does not seem to be the regimen of choice for GnRH antagonist cycles. In the previous versions of this review, however, a subgroup analysis of studies that used OCP pretreatment revealed no substantial difference between the agonist and antagonist groups for ongoing or clinical pregnancy rates. The percentage of women receiving OCP pretreatment in the 2011 update was comparable with the preceding version in 2006. </p> </section> <section id="CD001750-sec-0094"> <h3 class="title" id="CD001750-sec-0094">Overall completeness and applicability of evidence</h3> <p>Overall, the data demonstrate that GnRH antagonist is useful in women undergoing IVF or ICSI because it substantially reduces the occurrence of OHSS without reducing the chances of achieving live a live birth. </p> <p>A long‐course GnRH agonist protocol with maximum ovarian stimulation has been the standard protocol for many decades. However, it is relatively complex and expensive, requires long treatment cycles and intensive monitoring, and leads to an abnormal hormonal environment in women. There is now an eager desire to shift to more patient‐friendly, mild ovarian‐stimulation regimens in which GnRH antagonist may be a suitable solution because there is evidence to suggest that its use is associated with comparable pregnancy outcomes. </p> <p>A good number of the included studies did not report live birth and OHSS: 12 of the included studies reported data on live birth while only 36 reported data on OHSS. One study used single embryo transfer in the antagonist arm and double embryo transfer in the agonist arm. Some of the outcomes of interest were reported by some of the included studies in such a way that they could not be included in meta‐analyses. For example, some of the denominators were reported as 'per oocyte' or 'per embryo' transferred, where the numbers of oocytes or embryos transferred were not equal to the number of women randomised. In some of the included studies, some outcomes were not properly defined making it difficult to categorise such outcomes, for example, 'pregnancy rate' which could either be 'ongoing' or 'clinical' pregnancy. We included a small number of studies because they met the inclusion criteria, although they did not report data on any of the outcomes of interest. With respect to the triggering agent used for oocyte maturation, the majority of the studies either used hCG or did not report the triggering agent used. Thus no comparison could be made between the triggering agents such as hCG versus GnRH agonist. </p> </section> <section id="CD001750-sec-0095"> <h3 class="title" id="CD001750-sec-0095">Quality of the evidence</h3> <p>The evidence was of moderate quality using GRADE ratings for live birth, OHSS, ongoing pregnancy, clinical pregnancy, miscarriage and cycle cancellation due to poor ovarian response. The main limitations in the evidence were poor reporting of study methods. For example, a majority of the included studies either did not report the processes involved in random sequence generation and allocation concealment or reported vague and insufficient information on the processes, thereby making it difficult to make conclusive judgements on these domains of risk of bias. Poor reporting also affected the assessment of other domains of risk of bias with most of them being rated as 'unclear'. For live birth, there was evidence suggestive of the possibility of reporting (publication) bias with small studies more likely to report favourable outcomes for GnRH antagonist. </p> </section> <section id="CD001750-sec-0096"> <h3 class="title" id="CD001750-sec-0096">Potential biases in the review process</h3> <p>Although comprehensive searches were undertaken to ensure that all eligible studies were identified, it is not impossible that some potentially eligible studies could have been left out. </p> </section> <section id="CD001750-sec-0097"> <h3 class="title" id="CD001750-sec-0097">Agreements and disagreements with other studies or reviews</h3> <p> <ul id="CD001750-list-0019"> <li> <p>A systematic review and meta‐analysis, <a href="./references#CD001750-bbs2-0159" title="YoussefM , AboulfoutouhL , Van DerVeenF , VanWelyM . Could mild/minimal ovarian stimulation‐IVF displace conventional IVF in poor responder women undergoing IVF/ICSI treatment cycles: systematic review &amp; meta‐analysis. Human Reproduction2012;27. ">Youssef 2012</a>, compared the effectiveness and safety of various protocols including GnRH antagonist versus long‐course GnRH agonist protocol. There was no evidence of a difference between women who received GnRH antagonist and those who were treated with long‐course GnRH agonist protocol in three RCTs, either in clinical pregnancy rate (OR 0.72, 95% CI 0.49 to 1.05, five RCTs) or cycle cancellation rate (OR 1.25, 95% CI 0.76 to 2.05). </p> </li> </ul> <ul id="CD001750-list-0020"> <li> <p>There is a systematic review and meta‐analysis that included 22 RCTs (n = 3176) to compare GnRH antagonists and GnRH agonists (<a href="http://archie.cochrane.org/sections/documents/view?version=48477926069055880290110606143734%26format=REVMAN#REF-Kolibianakis--2006#REF-Kolibianakis--2006" target="_blank">Kolibianakis 2006</a>). The reported outcome measure, clinical pregnancy or ongoing pregnancy, was converted to live births in 12 studies using the published data. No evidence of a difference was detected in the probability of a live birth between the two GnRH analogues (OR 0.86, 95% CI 0.72 to 1.02). The result remained stable in a subgroup analysis that ordered the studies by type of population studied, gonadotrophin type used for stimulation, type of agonist protocol used, type of agonist used, type of antagonist protocol used, type of antagonist used, presence of allocation concealment, presence of co‐intervention and the way the information on live births was retrieved. </p> </li> <li> <p>A systematic review and meta‐analysis, <a href="http://archie.cochrane.org/sections/documents/view?version=48477926069055880290110606143734%26format=REVMAN#REF-Franco-2006#REF-Franco-2006" target="_blank">Franco 2006</a>, evaluated the efficacy of gonadotrophin antagonist versus GnRH agonist in poor ovarian responders in IVF and ICSI cycles. The review included six RCTs that compared GnRH antagonist to long or short GnRH agonist. There was no difference between GnRH antagonist and GnRH agonist (long and flare‐up protocols) with respect to cycle cancellation rate, number of mature oocytes and clinical pregnancy rate per cycle initiated, per oocyte retrieval and per embryo transfer. When the meta‐analysis was applied to the two trials that had used GnRH antagonist versus long protocols of GnRH agonist, a significantly higher number of retrieved oocytes was observed in the GnRH antagonist protocols (MD 1.12, 95% CI 0.18 to 2.05; P = 0.018). </p> </li> <li> <p>In another systematic review and meta‐analysis of four RCTs (n = 874) ongoing pregnancy rate was the main outcome (<a href="http://archie.cochrane.org/sections/documents/view?version=48477926069055880290110606143734%26format=REVMAN#REF-Griesinger-2008#REF-Griesinger-2008" target="_blank">Griesinger 2008</a>). There was no evidence of a statistically significant difference between women with and without OCP pre‐treatment (OR 0.74, 95% CI 0.53 to 1.03). Duration of gonadotrophin stimulation (1.41 days, 95% CI 1.13 to 1.68) and gonadotrophin consumption (542 IU, 95% CI 127 to 956) were significantly increased after OCP pre‐treatment. No significant differences were observed regarding the number of retrieved oocytes. </p> </li> </ul> </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001750-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001750-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001750-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001750-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.1 Live birth rate per woman randomised." data-id="CD001750-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.1 Live birth rate per woman randomised. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.1 Live birth rate per woman randomised." data-id="CD001750-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.1 Live birth rate per woman randomised. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.2 Live birth rate per woman randomised ‐ minimal stimulation." data-id="CD001750-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.2 Live birth rate per woman randomised ‐ minimal stimulation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 GnRH antagonist versus long‐course GnRH agonist, outcome: 1.3 Live birth rate per woman randomised ‐ grouped by trigger." data-id="CD001750-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 GnRH antagonist versus long‐course GnRH agonist, outcome: 1.3 Live birth rate per woman randomised ‐ grouped by trigger. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.4 Ovarian hyperstimulation per woman randomised ‐ all women." data-id="CD001750-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.4 Ovarian hyperstimulation per woman randomised ‐ all women. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.5 Ovarian hyperstimulation per woman randomised ‐ moderate or severe." data-id="CD001750-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 GnRH antagonist versus long course GnRH agonist, outcome: 1.5 Ovarian hyperstimulation per woman randomised ‐ moderate or severe. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 1 Live birth rate per woman randomised." data-id="CD001750-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 1 Live birth rate per woman randomised. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#CD001750-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 2 Live birth rate per woman randomised ‐ minimal stimulation." data-id="CD001750-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 2 Live birth rate per woman randomised ‐ minimal stimulation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#CD001750-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 3 Live birth rate per woman randomised ‐ grouped by trigger." data-id="CD001750-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 3 Live birth rate per woman randomised ‐ grouped by trigger. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#CD001750-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 4 Ovarian hyperstimulation per woman randomised ‐ all women." data-id="CD001750-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 4 Ovarian hyperstimulation per woman randomised ‐ all women. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#CD001750-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-CMP-001-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 5 Ovarian hyperstimulation per woman randomised ‐ moderate or severe." data-id="CD001750-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 5 Ovarian hyperstimulation per woman randomised ‐ moderate or severe. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#CD001750-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 6 Ongoing pregnancy rate per woman randomised ‐ all women." data-id="CD001750-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 6 Ongoing pregnancy rate per woman randomised ‐ all women. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#CD001750-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 7 Ongoing pregnancy rate per woman randomised ‐ minimal stimulation." data-id="CD001750-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 7 Ongoing pregnancy rate per woman randomised ‐ minimal stimulation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#CD001750-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 8 Ongoing pregnancy rate per women randomised ‐ grouped by trigger." data-id="CD001750-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 8 Ongoing pregnancy rate per women randomised ‐ grouped by trigger. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#CD001750-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 9 Clinical pregnancy rate per woman randomised ‐ all women." data-id="CD001750-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 9 Clinical pregnancy rate per woman randomised ‐ all women. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#CD001750-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 10 Clinical pregnancy rate per woman randomised ‐ minimal stimulation." data-id="CD001750-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 10 Clinical pregnancy rate per woman randomised ‐ minimal stimulation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#CD001750-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 11 Miscarriage rate per woman randomised." data-id="CD001750-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 11 Miscarriage rate per woman randomised. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#CD001750-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 12 Miscarriage rate per clinical pregnancy." data-id="CD001750-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 12 Miscarriage rate per clinical pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#CD001750-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001750-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/urn:x-wiley:14651858:media:CD001750:CD001750-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_t/tCD001750-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 13 Cycle cancellation rate per woman randomised." data-id="CD001750-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 GnRH antagonist versus long‐course GnRH agonist, Outcome 13 Cycle cancellation rate per woman randomised. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#CD001750-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/media/CDSR/CD001750/image_n/nCD001750-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001750-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">GnRH antagonist compared to long‐course GnRH agonist for assisted reproductive technology (ART)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GnRH antagonist compared to long‐course GnRH agonist for assisted reproductive technology (ART)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women undergoing assisted reproductive technology (ART)<br/> <b>Settings:</b> clinic for ART<br/> <b>Intervention:</b> GnRH antagonist<br/> <b>Comparison:</b> long‐course GnRH agonist </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Long course GnRH agonist</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> GnRH antagonist</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman randomised</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>290 per 1000</b> <br/> (254 to 330) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.02</b> <br/> (0.85 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2303<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OHSS per woman randomised (any grade)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b> <br/> (62 to 85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.61</b> <br/> (0.51 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7944<br/> (36 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ongoing pregnancy rate per woman randomised</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>293 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>276 per 1000</b> <br/> (256 to 295) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.92</b> <br/> (0.83 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8311<br/> (37 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman randomised</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>303 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>283 per 1000</b> <br/> (267 to 303) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.91</b> <br/> (0.83 to 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9959<br/> (54 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman randomised</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>48 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> <br/> (40 to 61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.03</b> <br/> (0.82 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7082<br/> (34 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cycle cancellation due to poor ovarian response</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> <br/> (68 to 101) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.32</b> <br/> (1.06 to 1.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5230<br/> (25 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>moderate</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Asymmetry of the funnel plot with small study effects in favour of GnRH antagonist<br/> <sup>2</sup> Most domains of the risk of bias were assessed as either 'unclear' or 'high'<br/> <sup>3</sup> Presence of significant heterogeneity among studies with inconsistency in the directions of effect estimates<br/> <sup>4</sup> Effect estimate with wide confidence interval </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">GnRH antagonist compared to long‐course GnRH agonist for assisted reproductive technology (ART)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/full#CD001750-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001750-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">GnRH antagonist versus long‐course GnRH agonist</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth rate per woman randomised <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.85, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Live birth rate per woman randomised ‐ minimal stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.62, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Live birth rate per woman randomised ‐ grouped by trigger <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.85, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 hCG trigger</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.89, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Unknown trigger</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.54, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Ovarian hyperstimulation per woman randomised ‐ all women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7944</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.51, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Ovarian hyperstimulation per woman randomised ‐ moderate or severe <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.40, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Ongoing pregnancy rate per woman randomised ‐ all women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.83, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Ongoing pregnancy rate per woman randomised ‐ minimal stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.75, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Ongoing pregnancy rate per women randomised ‐ grouped by trigger <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 hCG trigger</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Mixed trigger (hCG/GnRH agonist)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.23, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Unknown trigger</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3075</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.74, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Clinical pregnancy rate per woman randomised ‐ all women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.83, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Clinical pregnancy rate per woman randomised ‐ minimal stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.15, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Miscarriage rate per woman randomised <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.82, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Miscarriage rate per clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.84, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Cycle cancellation rate per woman randomised <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Cancellation due to high risk of OHSS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.32, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Cancellation due to poor ovarian response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.06, 1.65]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">GnRH antagonist versus long‐course GnRH agonist</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001750.pub4/references#CD001750-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001750.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001750-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001750-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD001750-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD001750-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001750-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001750-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001750\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001750\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001750\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001750\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001750\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001750.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001750.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001750.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001750.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001750.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729047492"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001750.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729047496"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001750.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed3472d74f56f',t:'MTc0MDcyOTA0Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 